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Abstract 
The alarming increase in the occurrence of antimicrobial resistance has 
led to a situation whereby some strains are untreatable by known 
antimicrobials. The Trojan horse strategy is one methodology with the 
potential to overcome the rising tide of resistance. 
Work was undertaken to synthesise two different Trojan horses. One 
based on an analogue of the Bacillus siderophore petrobactin, the other a 
novel compound prepared using the Ugi four component condensation. Both 
contained a fluoroquinolone antimicrobial; ciprofloxacin. Additionally a series 
of bis-catecholate ligands were prepared for use as iron chelating 
antimicrobial agents.  
 The Trojan horse based on the Ugi four component condensation was 
screened against wild type E. coli and was found to have antibacterial 
activity, but at a lower level than the parent drug ciprofloxacin. The 
mechanism of action was determined by performing a DNA gyrase assay, 
which confirmed the conjugate was inhibiting E. coli DNA gyrase activity.  
A set of three glycosylated fluoroquinolones was screened, to assess 
the extent to which they were actively transported. Experiments were 
performed using glucose and galactose as carbon sources, with E. coli 
strains deficient in galactose transport. Further experiments with outer 
membrane porins (OMPs) mutants were also performed. The results 
suggested that the conjugates were not actively transported, but were 
gaining access to the cells via the OMPs. Studies were undertaken on the 
bis-catecholate ligands to assess their suitability as potential antimicrobial 
agents. However, stability studies showed that one set of ligands was highly 
unstable due to hydrolysis and oxidation, and therefore not viable for use. 
The asymmetric ligand showed promising activity in vitro however 
electrochemical studies indicated it was susceptible to oxidation. 
Consequently, the active species could not be reliably determined. Further 
study is required to establish its identity. 
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1. Introduction 
1.1. Antibiotic resistance 
1.1.1. Overview 
The increasing occurrence of antibiotic resistance was described in 
2013 as a very real threat, which could potentially make otherwise routine 
medical procedures high risk operations[1]. It is conceivable that unless the 
situation improves rapidly there will come a point where common infections 
cannot be prevented or effectively treated[2]. While cases of the well known 
pathogen methicillin resistant Staphylococcus aureus (S. aureus) (MRSA), a 
bacterial strain first reported in the 1960s[3], have reduced in the UK and 
Europe in the past decade[4], MRSA is still endemic in a number of places 
such as Romania, Malta Argentina where more than 50% of clinical S. 
aureus isolates are methicillin resistant[5]. Additionally, S. aureus strains have 
been found that display resistance to a broad spectrum of antimicrobial 
agents in addition to methicillin. Clinically resistant bacterial strains are 
known for the majority of antimicrobial agents currently in clinical use[6]. 
Furthermore, in 2011 a bacterial strain was isolated in India which carried a 
new gene for carbapenem resistance[7-8], a class of antimicrobials that was 
thought to be reliable in treating most antimicrobial resistant infections. While  
resistance is most commonly observed where there is a high level of 
antimicrobial use, particularly where antimicrobials are self-prescribed and 
administered. Failure to complete a course of antibiotics presents the 
opportunity for bacteria to develop resistance and subsequently survive and 
reproduce. The overuse of antimicrobials in both human and veterinary 
medicine has also contributed to the rise of resistance[9]. There is a 
comprehensive online database which extensively details antibiotic 
resistance including data on resistant strains, mechanisms of the resistance 
and the genes encoding the resistance[10].  
Chapter 1: Introduction 
 
The evolution of antimicrobial resistance at the cellular level has 
occurred largely due to two key factors. The first is intrinsic resistance, micro-
organisms which produce antimicrobial agents also carry a corresponding 
resistance gene, and this gives them a selective advantage over competing 
microorganisms. The second factor is acquired resistance via horizontal gene 
transfer. This process is the exchange of DNA between a bacteria and its 
immediate extracellular environment. Horizontal transfer occurs through 
several mechanisms: transduction, where new genetic material is delivered 
into the cell from a virus; transformation, whereby a bacterium takes in 
genetic material from its extracellular environment; and conjugation whereby 
transfer of genetic material is initiated by cellular contact[6]. The described 
mechanisms allow acquired resistance to evolve and spread. These 
phenomena, coupled with the overuse of antibiotics have resulted in an 
increase in the number and variety of multi-drug resistant bacterial strains[6]. 
The evolution of acquired resistance has also occurred due to accumulation 
of mutations in bacteria[9]. Additionally it has been postulated by Zhang et al. 
that humans are born with antimicrobial resistant bacteria present within their 
gut flora[11]. Their experiments analysed samples from infants and found that 
there were high populations of microbes resistant to several antimicrobials 
present. This was observed with subjects just 1 week of age, even without 
exposure to antimicrobial agents. They suggest that both environmental and 
maternal microbes have a significant impact on the development of antibiotic 
resistance in the gut flora. 
The manner of evolution can also vary; Toprak et al. studied Escherichia 
coli, culturing the bacterium in real time, using dynamically regulated drug 
concentrations[12]. Using chloramphenicol, doxycycline and trimethoprim they 
observed key mutations in target systems for all three antimicrobials. 
Curiously, they also observed that while the bacteria displayed a “smooth” 
evolution of resistance to chloramphenicol and doxycycline, which was 
gradually increasing due to combined mutations, in the case of trimethoprim, 
the bacteria appeared to evolve in a stepwise fashion, with parallel 
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populations displaying similar mutations acquired in a similar order, rather 
than randomly[12]. This suggests that the evolution of antimicrobial resistance 
under selection pressure depends on the target of the antimicrobial used. In 
this case the protein synthesis inhibitors appeared to induce gradual random 
evolution within several genes, and the dehydrofolate reductase inhibitor an 
ordered stepwise evolution, within a specific gene. 
1.2. Mechanisms of resistance 
1.2.1. Overview 
In spite of the wide variety of genes which encode antimicrobial 
resistance, the range of basic mechanisms of resistance is surprisingly 
limited[6]. There are four primary mechanisms of resistance that are 
commonly observed (Figure 1.1). These mechanisms include reduced 
uptake, increased efflux, target alteration and drug alteration/deactivation. 
Mutations which reduce the uptake of drug molecules are the key focus of 
this project, although gyrase mutations are an alternative mechanism of 
resistance, which will be discussed later (Section1.4.3.)  
 
Figure 1.1: Schematic overview of antimicrobial resistance mechanisms (section 
1.2.2) based on Levy and Marshall  
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1.2.2. Deactivation of antimicrobial compounds 
1.2.2.1. Deactivation of the antimicrobial moiety. 
Drug deactivation is a comprehensively studied form of resistance, 
which involves either degrading or altering an antimicrobial to compromise its 
antimicrobial activity[13]. A key example of drug degradation is observed in β-
lactam resistance[14]. Antimicrobials such as penicillin 1-1 are rendered 
inactive by β-lactamases enzymatically cleaving open the β-lactam ring 
(Scheme 1.1). β-Lactam antibiotics function by binding to penicillin binding 
proteins (PBPs), blocking the active site and consequently inhibiting 
peptidoglycan synthesis. The inhibition of this process results in disruption of 
the bacterial cell wall integrity. The β-lactam ring is critical to the function of 
the antimicrobial. Without the ring structure the antimicrobials are unable to 
bind to the PBPs and consequently no longer exert a bactericidal effect[15]. 
 
Scheme 1.1: Cleavage of the β-lactam ring of penicillin 
 
β-Lactamase resistance is extremely wide-spread, to the extent that 
there are now bacterial strains of Enterobactericeae which are resistant to all 
currently available treatments for Gram-negative bacteria[8]. The situation has 
been exacerbated by the recent emergence of carbapenemases. 
Carbapenems were able to resist rapid hydrolysis by β-lactamases due to 
their trans stereochemistry across the lac tam ring and containing an α-
hydroxy ethyl group instead of a β-amide at carbon 6 (Figure 1.2)[13]. 
However, carbapenemase proteins have been identified with specific 
adaptations in their active site including a disulfide bridge and additional 
threonine and histidine residues. Klebsiella pneumoniae (K. pneumoniae) 
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carbapenemases (KBCs) are a serious problem as the genes conferring 
resistance are found on mobile genetic elements, allowing the spread of 
resistance to other bacteria[13]. 
 
Figure 1.2: Core structure of penicillins (left) and carbapenems (right)  
 
 Antimicrobials can also be deactivated by modification of the 
antimicrobial. Several examples have been observed including the 
modification of aminoglycosides and lincosamides by phosphorylation and 
ADP ribosylation of rifampin[13]. The number of different mechanisms of 
modifying antimicrobials highlights the variety found within the bacterial 
resistome.  
1.2.2.2. Reduction in intracellular drug concentration  
Bacteria utilise two different mechanisms to reduce the intracellular 
concentration of antimicrobial compounds. The first of these is a reduction in 
membrane permeability. Antimicrobials often gain access through the outer 
cell membrane via porins, trimeric β-barrel proteins. By down-regulating the 
expression of these proteins, bacteria can reduce the amount of antimicrobial 
that enters the cell[16]. A variation of this is the formation of biofilms. Biofilms 
are aggregates of bacterial cells that form on surfaces in response to 
environmental stresses[17]. As most antimicrobials are designed to attack 
planktonic cells, they are ineffective against biofilms as they are unable to 
penetrate beyond the first layer of cells. In addition, as biofilms are 
communities of cells, there may be several different resistance mechanisms 
at work within a biofilm[18]. Consequently biofilms are persistent, and a 
common feature in chronic infections.  
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The second method that bacteria have evolved to reduce intracellular 
drug concentration is the over-expression of active efflux pumps. There are 
several super-families of efflux pumps including ATP binding cassette (ABC), 
resistance nodulation-cell division (RND) and multidrug and toxic compound 
extrusion (MATE)[19]. There are examples of both specific and non-specific 
antimicrobial efflux pumps. The MacAB-TolC efflux pump specifically 
transports macrolide antibiotics, whereas ArcAB-TolC transports a broad 
spectrum of antimicrobials including chloramphenicol and tetracycline [20]. 
1.2.2.3. Modification and protection of the antimicrobial target 
An alternative form of resistance in bacteria is to alter or protect the 
intracellular target of an antimicrobial. This removes the need to reduce the 
active concentration or to break down an antimicrobial. Resistance has been 
observed to tetracyclines through the production of ribosomal protecting 
proteins[21]. Proteins have also been indentified in some P. aeruginosa strains 
that incorporate an additional methyl group into the 30S subunit of bacterial 
ribosomes, resulting in resistance to aminoglycosides. The proteins show a 
high degree of similarity to 16S rRNA methyl transferase proteins found in 
aminoglycoside producing acetomytes[22]. Occurrences like this are examples 
of the transfer of intrinsic resistance to a strain which would normally be 
susceptible to an antimicrobial. An additional mode of target protection is to 
over-express the antimicrobial target, or a protein mimic of the target. The 
consequence of over-expression is the antimicrobial being sequestered from 
the intracellular medium by the excess target, leaving additional target 
molecules uninhibited and able to carry out their function[20].  
1.3. Counteracting antimicrobial resistance 
1.3.1.1. Developing novel antimicrobial compounds 
The most obvious strategy for counteracting the growing number of 
antimicrobial resistant strains is to identify or develop novel antimicrobial 
compounds. A current challenge in this is a lack of funding in antimicrobial 
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research. A recent report found that; since 1997, from £2.6 billion of 
investment in infectious disease research in the UK, only 3.9% (£102 million) 
was spent on antimicrobial research[23]. In addition, there is a lack of interest 
from large pharmaceutical companies due to the low financial returns on offer 
in the antimicrobial market. Considering the rate at which resistance is 
increasing, this seems a worrying situation. In the last few decades only two 
new classes of antimicrobials have been developed. The first is a class of 
protein synthesis inhibitors which target bacterial ribosomes, the 
oxazolidinones (Figure 1.3)[24-26]. The second class is lipopeptides which 
disrupt bacterial membranes in Gram-positive bacteria 
 
Figure 1.3: Structures of oxazolidinones synthesised by Zurenko et al.  
 
In 2000, Tally and DeBruin reported the development of the lipopeptide 
Daptomycin 1-6 (Figure 1.4), New examples of lipopeptides have recently 
been found in both Citrobacter and Enterobacter species[27].  
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Figure 1.4: Structure of the lipopeptide antimicrobial Daptomycin  
 
 A more recent attempt at developing novel antimicrobial agents has 
been made by Wright et al., by analysing the genomes of bacterial species to 
identify strains which carry genes for inherent bacterial resistance. The logic 
behind this is that bacteria which naturally carry resistance genes are likely to 
be producers of antimicrobial compounds. Using this approach they 
discovered a glycopeptide antimicrobial, pekiskomycin 1-7, which had a 
novel peptide scaffold not previously observed in antimicrobials (Figure 
1.5)[28]. 
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Figure 1.5: Structure of the glycopeptide antimicrobial pekiskomycin 
 
 While identifying and developing novel pharmacophores is the ideal 
method of counteracting resistance, in 2011 there were 40 different drugs in 
clinical trials[29], it is a time consuming and highly costly process. The cost of 
developing an antimicrobial compound from initial lead to a marketable 
product is over £400 million. When coupled with the length of time required, i t 
is not perceived as a profitable process for pharmaceutical companies. 
Consequently there has been a significant decline in the amount of money 
invested in antimicrobial research. However, as the number of drugs in 
clinical trials indicates, work is still being undertaken, including on the 
synthetic fluoroquinolone drug class. 
1.3.1.2. Alternative approaches to combat bacterial resistance  
In situations where the mechanism of resistance to a specific 
antimicrobial is known, it is possible to utilise a secondary agent to 
counteract resistance. In the case of β-lactams, where the antibiotic is 
degraded by a β-lactamase enzyme, the solution is to co-administer a β-
lactamase inhibitor, such as tazobactam 1-8 (Figure 1.6) in addition to the 
antimicrobial[13]. Recently, research has been undertaken to achieve a similar 
result with aminoglycoside resistant bacteria. Aminoglycosides target 
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bacterial ribosomes, interfering with bacterial replication. They are 
deactivated by bacterial kinases, which phosphorylate the antimicrobial 
species, rendering it unable to bind its target[30]. Wright et al. have used 
structure-guided optimisation to develop new inhibitors of bacterial protein 
kinases, in an effort to counteract aminoglycoside resistance. They 
successfully managed to synthesise compounds based on a 
pyrazolopyrimidine scaffold 1-9 which restored antimicrobial susceptibility to 
an aminoglycoside resistant E. coli strain [31].  
 
Figure 1.6: Tazobactam 1-8, a β-lactamase inhibitor and PP2 1-9, an aminoglycoside 
phosphotransferase inhibitor 
 
A simpler version of combination therapy is to utilise two different 
classes of antimicrobial simultaneously. Combination therapy is already used 
to treat MRSA and vancomycin resistant S. aureus, using a combination of 
two streptogramins: dalfopristin 1-10 and quinupristin 1-11. (Figure 1.7). 
However, this method is flawed as it is costly, and doesn’t tackle the problem 
of bacteria developing resistance[14]. Buckling et al. have demonstrated that 
using a variation of combination therapy, sequential therapy, can be more 
effective. By administering antimicrobials in a specific order, the development 
of multidrug resistant strains can be attenuated[32]. If acquiring resistance to 
the first antimicrobial administered comes at a high cost to the bacteria, the 
chance of multidrug resistance occurring is minimised.  
Chapter 1: Introduction 
 
 
Figure 1.7: Structures of streptogramin drugs dalfopristin 1-10 and quinupristin 1-11 
 
Hybrid antimicrobials have also been developed. Two antimicrobials 
where resistance has been observed are combined in order to overcome 
resistance. Gordeev et al. synthesised oxazolidinone-quinolone hybrids 
(Figure 1.8). The compounds showed activity against both ciprofloxacin 1-18 
and linezolid 1-3 resistant bacterial strains[33].  
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Figure 1.8: Structures of two quinolone-oxazolidinone hybrids using linezolid 1-3 as 
the oxazolidinone component and ciprofloxacin, conjugate 1-12, and levofloxacin, 
conjugate 1-13, as the fluoroquinolone components. 
 
While combination therapy and hybrid antimicrobials have proven to be 
effective, they are only a short term solution as strains eventually evolve 
resistance to both drugs contained within a hybrid/combination. What is 
required is the development of novel, preferably synthetic antimicrobials, 
where innate resistance does not exist, or is at least absent from the bacterial 
resistome of pathogenic bacteria. The focus of the research in this thesis is 
on one such class of antimicrobials: the fluoroquinolones. 
1.4. Fluoroquinolones 
1.4.1. Introduction to fluoroquinolones 
The fluoroquinolones are a synthetic class of antimicrobials that have 
gone through several generations since they were first identified[10]. The first 
of the quinolone drugs, nalidixic acid 1-16, was discovered in 1962, when it 
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was isolated as a by-product of chloroquine 1-14 synthesis (Error! 
eference source not found.)[34]. 
 
Figure 1.9: Structures of chloroquine 1-14, the antibacterial by-product 1-15, and the 
first quinolone nalidixic acid 1-16.  
 
Lesher observed that a by-product 1-15 displayed antimicrobial activity 
against a series of Gram-negative pathogens including Escherichia coli and 
Staphylococcus aureus, but was largely ineffective against Gram-positive 
strains[34]. Initial attempts at broadening the spectrum of activity were largely 
unsuccessful, with nalidixic acid 1-16 having limited applications beyond 
treating urinary tract infections[35]. The next significant breakthrough in the 
development of the fluoroquinolones came in 1980, when Koga et al. 
reported a drug with an enhanced spectrum of Gram-negative activity, and 
increased Gram-positive activity[36]. 
 
Figure 1.10: The basic pharmacophore of the quinolones with substitution positions 
labelled 
 
This drug featured a fluorine atom at position 6 and a piperazinyl ring at 
position 7 (Figure 1.11), whilst maintaining the β-diketone system observed 
in nalidixic acid 1-16, and became known as norfloxacin 1-17. While 
norfloxacin 1-17 was an effective antimicrobial, it had poor bioavailability, 
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meaning higher doses were required for a clinically relevant bactericidal 
effect[35]. In an attempt to improve the efficacy of the fluoroquinolone 
pharmacophore, studies have analysed the effect of modifications to various 
points on the central skeleton of the molecule (Figure 1.10). A study by Koga 
et al. in 1980 found that fluorinating the quinolone pharmacophore at position 
6 appeared to reduce the rate at which resistance was acquired, and that a 
piperazinyl moiety at position 7 produced an increase in activity[36]. 
A study by Murphy et al. built on this research and produced a series of 
nitrile containing fluoroquinolones. They found that adding a nitrile to the 
piperazinyl ring on position 7 enhanced activity. They also found that 
modifications at 5, 6 and 8 did not compromise activity[37]. Modifications at 
positions 3 and 4 are not possible, as these disrupt the planar β -diketone 
system, which is critical to quinolone function. Modifications at position 2 
would also be unfavourable, as any additional steric bulk could have a 
detrimental effect on binding to the target protein[35]. Subsequently, in 1983, a 
new fluoroquinolone was produced: Bay09867[38]. Bay09867 retained the 
piperazinyl ring and fluorine atom present in norfloxacin 1-17, but exhibited a 
cyclopropyl ring at N1. This compound was ciprofloxacin 1-18 , and is still in 
clinical use today[35]. More recent developments include antimicrobials such 
as levofloxacin 1-19 and moxifloxacin 1-20 (Figure 1.11)[39], with variations in 
specific positions around the pharmacophore. These variations effect key 
antimicrobial properties including bioavailability, spectrum of activity and half 
life.  
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Figure 1.11: Structures of second and third generation fluoroquinolones and the 
recently developed fluoroquinolone delafloxacin 1-21  
  
In 2006 Barnes et al. reported the synthesis of a new fluoroquinolone 
antimicrobial, ABT-492[40]. The structure was unusual for a fluoroquinolone 
due to chlorination at C8 and a substituted pyridine ring at N1 (Figure 1.10, 
Figure 1.11). A key feature is that delafloxacin 1-21 is anionic, allowing it to 
exert an antimicrobial effect at acidic pHs which zwitterionic fluoroquinolones 
are incapable of[41]. Lemair et al. examined the properties of delafloxacin 
under acidic conditions, using moxifloxacin 1-20 as a control. Their findings 
suggested that the uptake of delafloxacin 1-21 increased significantly under 
acidic conditions[41]. Furthermore Lemair postulated that the nature of 
delafloxacin 1-21 would allow it to diffuse more readily than a zwitterionic 
fluoroquinolone under acidic conditions, but once inside the cell the increase 
in pH would de-protonate the drug, reducing the likelihood of passive 
diffusion back into the extracellular environment[41]. The drug also displayed 
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good levels of activity against fluoroquinolone resistant strains and at the 
time of writing has been granted status as a qualified infectious disease 
product (QIDP) by the food and drug administration (FDA). 
1.4.2. Mechanism of action 
The fluoroquinolone drugs function by targeting the DNA replication 
pathway in bacteria, specifically the two stabilising proteins DNA gyrase (in 
Gram-negative strains) and topoisomerase IV (in Gram-positive strains)[35, 42].  
These proteins are both type II topoisomerases, so called because they 
introduce temporary strand breaks in double stranded DNA as opposed to 
type I topoisomerases which make temporary strand breaks in single 
stranded DNA. DNA gyrase catalytically introduces negative supercoils in 
bacterial DNA to relieve torsional strain during DNA replication[43]. 
Topoisomerase IV is a homologue of DNA gyrase, both are tetrameric 
proteins, which use double stranded passage as a mode of action[42]. During 
the process two strands cross over, and as the top strand moves along the 
amount of strain increases. The topoisomerase catalyses a double strand 
break in the lower strand, allowing the top strand to pass through the gap 
made. The break is then ligated to repair the broken strand, resulting in a 
stable supercoil[35].  
The mode of binding of the fluoroquinolones is via a ternary complex. 
The earliest theory was of a “Viking helmet” conformation postulated by 
Mitscher et al. Their hypothesis focused on a cooperative binding model 
involving four quinolone molecules[44] (Figure 1.12). A more recent study by 
Laponogov et al. agrees that the model is cooperative. However, they 
successfully co-crystallised DNA gyrase with moxifloxacin 1-20 and 
demonstrated that the complex only involves two fluoroquinolone 
molecules[45]. There is also evidence that magnesium ions play a key role in 
stabilising the ternary complex[46]. Each fluoroquinolone molecule binds to 
one strand of DNA, in a sequence dependent manner. The presence of 
magnesium ions encourages tighter binding[47]. The binding of 
Chapter 1: Introduction 
 
fluoroquinolones to the DNA-gyrase complex blocks the ligation of the double 
strand break. This stabilises the DNA in a supercoiled state. Consequently 
the release of DNA from the complex is blocked, triggering the apoptosis 
pathway and resulting in cell death[35]. 
 
Figure 1.12: Proposed binding modes of fluoroquinolone antimicrobials detailing the 
initial four molecule “Viking helmet” configuration 
[44]
 and the recently identified 2 
fluoroquinolone binding mode
[45]
. 
1.4.3. Mechanism of resistance 
Bacterial resistance to the quinolones and fluoroquinolones manifests 
itself using several mechanisms of resistance: reduced accumulation, target 
alteration, target protection, and drug modification/degradation[48].  
1.4.3.1. Reduction of intracellular fluoroquinolone concentration 
As the main uptake pathway of fluoroquinolone drugs is through the 
porins situated on the outer membrane of bacteria, reduced accumulation is 
a key resistance mechanism[35]. In Gram negative bacteria, studies have 
shown that a reduction in the expression of outer membrane porins (OMPs) 
in a bacteria’s plasma membrane drastically reduces its susceptibility to the 
fluoroquinolones[48-49]. Furthermore, genes have been identified in bacteria 
which down regulate the expression of outer membrane porins. These strains 
exhibit resistance to both ciprofloxacin 1-18 and norfloxacin 1-17[50].This 
reduction in the number of porins can also result in resistance to other drug 
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classes including tetracyclines[51]. A second method of reducing accumulation 
is the over-expression of efflux pumps, which is observed in both Gram-
positive and negative strains. Over-expression of efflux pumps increases the 
export of drug molecules back into the extracellular environment, preventing 
the intracellular concentration of the antimicrobial reaching toxic levels [51]. 
Efflux pump mediated resistance to quinolones has been reviewed in 
detail[52-53]. There have been several examples of specific fluoroquinolone 
exporting pumps identified in several species including both E. coli and S. 
aureus. The transporters QepA1 and QacBIII are both proton dependent 
efflux pumps from the major facilitator superfamily (MFS). These two pumps 
transport hydrophilic fluoroquinolones, QacBIII having a high specificity for 
norfloxacin and ciprofloxacin[52]. The best characterised efflux pump is the 
NorA pump from S. aureus. NorA is also targeted to transporting hydrophilic 
fluoroquinolones, however it can also transport other antimicrobials such as 
chloramphenicol[48]. While efflux pumps are a useful tool for bacteria in 
evolving resistance to fluoroquinolones, they do not confer total resistance. 
As with other transferable mechanisms of quinolone resistance (TMQRs), 
they have an additive effect. The consequence of the additive effect is that 
initial over-expression of efflux pumps can raise the MIC of a fluoroquinolone 
against the bacterial strain in question, facilitating the development of further 
resistance mechanisms[52]. 
1.4.3.2. Mutation and protection of fluoroquinolone targets 
There are examples of mutations in DNA gyrase and topoisomerase IV 
resulting in resistance in bacteria. One recent study indicated that amino acid 
substitutions at positions 87 and 91 of DNA gyrase A in Helicobacter pylori 
confer antibiotic resistance[54]. A further study by Yokoyama et al. found that 
substitutions at position 95 of DNA gyrase A conferred resistance in 
Mycobacterium leprae[55]. Proteins have also been identified that shield the 
DNA-gyrase complex, these have been dubbed quinolone resistance 
proteins (Qnr)[56]. The structure of one of these proteins, QnrB1 was recently 
elucidated. It is a penta-peptide repeat protein (PRP) with a quadrilateral β-
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helix structure. The dimer is asymmetric, and confers a degree of quinolone 
resistance[57]. 
1.4.3.3. Modification and degradation of fluoroquinolones 
While modification and degradation of fluoroquinolones isn’t common, 
there is some evidence of organisms producing chemicals that are capable of 
modifying and degrading fluoroquinolones. Degradation has been observed 
in wood rotting fungi[58]. An enzyme has also been observed that can 
acetylate the piperazinyl nitrogen of ciprofloxacin 1-18, it is a variant of an 
aminoglycoside acetyl transferase. The modification results in a small 
reduction in activity[59]. While this modification does not disrupt the β-diketo 
system, and consequently does not confer significant resistance, if this type 
of resistance was acquired by a bacterial strain which also possessed genes 
to express Qnr proteins, a significant clinically resistant strain could arise.  
1.5. Siderophores 
1.5.1. Iron bioavailability and introduction to siderophores 
Iron is a vital element in biology. It is required by most life forms for 
survival, due to its key role in metalloproteins and their functions within an 
organism[60]. Consequently, it is crucial that organisms evolve ways of 
sequestering the iron they require. In theory this should not be too 
problematic as iron is the fourth most abundant element in the earth’s crust. 
However, in the environment, ferric iron (Fe(III)) exists mainly as insoluble 
iron hydroxides and oxides, such as haematite (Fe2O3)
[61]. Under 
physiological conditions, the concentration of free Fe(III) ranges from 10 -9- 
10-18 M[62]. In a mammalian system, proteins such as transferrin remove iron 
from the bloodstream meaning the in vivo concentration of ferric iron is 
reduced to approximately 10-24 M. This is an important defence mechanism 
as it further reduces the amount of iron available to invading pathogens [62]. 
To counteract this lack of iron, bacteria have evolved to synthesise low 
molecular weight iron chelators known as siderophores. These iron chelators 
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allow bacteria to compete with the mammalian host for iron, in some cases 
removing bound iron from transferrin[63]. There are several classes of 
siderophore (Figure 1.13) produced by a wide variety of bacteria, as well as 
some fungi and plants[64]. The main classes of siderophore are catecholate, 
carboxylate (α-hydroxycarboxylate) and hydroxamate, although there are 
three less common classes which are: hydroxyphenyloxazolone, α -amino 
carboxylate, α-hydroxyimidazole. 
 
Figure 1.13: Structure of six different classes of siderophore binding groups, including 
resonance forms, from Hider and Kong 2010 
 
The iron binding units outlined above are all bi-dentate, however in 
siderophores two or three of these binding groups are linked together via a 
backbone to form tetradentate and hexadentate ligands respectively[64]. The 
donor atoms in siderophores are generally hard donors such as oxygen. 
However, in some cases, such as the mycobactins and the Yersinia pestis 
siderophore yersiniabactin 1-40 (Figure 1.18)[61, 65]; heterocyclic nitrogen 
atoms are used in addition to carboxylate and alkoxide binding sites to 
sequester iron. The co-ordination geometry is influenced by both the denticity 
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and the nature of the binding groups in the siderophore. The preference for 
an octahedral geometry is a factor behind the high prevalence of 
hexadentate siderophores[61]. Hexadentate siderophore iron complexes are 
less dependent on the free ligand concentration (Equation 1), and have 
higher overall formation constants. 
There is also a correlation between formation constants and the 
Fe(II)/Fe(III) redox potential of the iron complexes siderophores. The higher 
the formation constant, the more negative the redox potential. The large 
negative redox potential prevents redox cycling of iron within the iron-
siderophore complex. For most siderophores and mammalian iron binding 
proteins, the Fe(II)/Fe(III) redox potential is below -0.2 V[66]. 
                             
      
           
      
                                 
       
         
       
                            
     
       
       
Equation 1: Equations of overall formation constants for bidentate (i), tetradentate (ii) 
and hexadentate (iii) siderophore complexes (charges omitted for clarity). β2 = K1 × K2, 
β3 = K1 × K2 × K3, where K1, K2, and K3 are the stepwise equilibrium constants for the 
sequential addition of multiple ligands for bidentate and tetradentate ligands.   
 
The siderophore that gives rise to the lowest Fe(II)/Fe(III) redox potential 
is the hexadentate (tris-didentate) catecholate siderophore enterobactin 1-
34[64]. Complex formation by siderophores is also promoted by the chelate 
effect, which lowers the entropic cost of forming 1:1 complexes with Fe( III) 
and consequently makes such complexes more thermodynamically 
favourable.  
It should be noted that formation constants of iron-siderophore complexes 
are conditional and vary depending on the pH of their environment. At pHs 
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above the pKa value of the donating oxygen atoms, the pFe3+ values are very 
high, as the deprotonated oxygen carries a high charge density, and 
consequently a high affinity for cations. As the pH is lowered, the oxygen 
donor atoms become protonated, reducing the charge density on the donor 
atoms and consequently lowering their affinity for cations in solution. 
Consequently siderophores with donor atoms that have low pKa values are 
more effective at acidic pHs, whereas those with high pHs, like the 
catecholate siderophores are far more effective at alkaline pHs[67]. 
1.5.2. Hydroxamate siderophores 
Hydroxamate siderophores are commonly produced by fungi, for example 
ferrichrome 1-24 (Figure 1.14) and coprogen are both known to be produced 
by the fungus Suillus granulatus (S. granulatus), as well as streptomycetes[61, 
64, 68]. There are a number of examples of hydroxamates known in the 
literature. The best known are the ferrichromes and ferrioxamines, which 
differ in the nature of their backbone while utilising the same chelating 
groups. Ferrichromes exhibit cyclic backbones, whereas ferrioxamines have 
linear backbones[64]. Hydroxamate siderophores have also been identified in 
marine bacteria, putrebactin 1-23 is a cyclic hydroxamate isolated from a 
Gram-negative pathogen; Shewanella putrefaciens (S. putrefaciens). There 
are also examples of mixed ligand, hydroxamate-containing siderophores, 
such as arthrobactin 1-25. 
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Figure 1.14: Some examples of known hydroxamate siderophores: desferrioxamine B 
1-22, putrebactin 1-23, ferrichrome 1-24 and arthrobactin 1-25  
 
The hydroxamate siderophore desferrioxamine B 1-22 is also versatile, 
it can also coordinate to Mn(II) and Mn(III) as well as Fe(III)[70]. It has been 
found that some hydroxamate siderophores, specifically the albomycins 
(Figure 1.23), display innate antimicrobial activity, these are a natural 
example of a “Trojan horse” and will be discussed later in this chapter[61]. 
1.5.3. Carboxylate siderophores 
Carboxylate siderophores are more recently documented phenomena [61]. 
Siderophores in this class tend to be bis-tridentate ligands containing citrate 
moieties. However, there are exceptions to this rule such as rhizobactin 1-28, 
which uses individual carboxylic acids as ligand groups[71]. Citric acid 1-26 
can also act as an exogeneous siderophore which can bind iron and is 
actively transported by certain species of enteric bacteria. However, citrate is 
not secreted by bacteria for this purpose[72]. Carboxylates also appear in 
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mixed ligand siderophores, like the previously shown arthrobactin 1-25 and 
petrobactin 1-30[73-74]. 
While carboxylate siderophores are common, they are relatively weak 
chelators when compared with the hydroxamate and catecholate 
siderophores. This is despite the high pKa of the hydroxyl component giving 
them a high affinity for Fe(III)[75]. Siderophore affinities can be compared 
using pFe values. Rhizoferrin 1-29 has a pFe(III) of 20.0, compared with a 
value of 35 for enterobactin 1-34. A siderophore’s pFe is defined as the 
negative log of the concentration of free Fe(III) under a fixed set of conditions 
(10 µM of ligand and 1 µM of Fe(III) at pH 7.4). 
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Figure 1.15: Examples of carboxylate siderophores including carboxylate only and 
mixed ligand siderophores. 
 
Citrate siderophores are less effective compared to the catecholate and 
hydroxamate siderophores at physiological pH but become more competitive 
at acidic pHs. As citrate siderophores remain deprotonated at lower pHs than 
hydroxamate or catecholate siderophores, they have been shown to show 
optimum iron binding and transport at pH 4.5[75]. This is a logical situation, as 
citrate siderophores desferrioxamine B 1-22 and rhizoferrin 1-29 are both 
fungal siderophores. The optimum pH for the growth of the Rhizobium fungi 
that produce rhizoferrin is pH 4.0, significantly lower than physiological pH 
and consequently siderophores that are effective at lower pHs are well suited 
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to a fungal environment. A more recently discovered citrate siderophore is 
vibrioferrin 1-31 (Figure 1.16). Vibrioferrin has a more intriguing structure 
than the previously described citrate based siderophores, as it contains a 
cyclic amide and only has five chelating groups. Vibrioferrin 1-31 sti ll forms 
1:1 complexes with Fe(III), the complex is stabilised by a co-ordinating H2O 
completing the co-ordination sphere. However vibrioferrin 1-31 is also a 
weaker iron chelator than other citrate siderophores.  
 
Figure 1.16: Structures of vibrioferrin 1-31, proposed vibrioferrin photoproduct 1-32 
and the vibrioferrin-Fe(III) complex 1-33 
 
The studies on the siderophore also suggest that like a number of 
marine siderophores, it is photoreactive, which may aid it’s iron delivery as 
iron can be released by photoreduction[76]. 
1.5.4. Catecholate siderophores 
The catecholate class of siderophores, which also includes the 
phenolates, is the main focus of the research described in this thesis. The 
catecholate class contains one of the strongest binding siderophores, 
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enterobactin 1-34, with a pFe(III) value of 35.5[64].  The formation constant 
has been reported as 1052 dm
3 mol-1[60]. Part of the reason for this high affinity 
is the chelate effect. A second reason is linked to its structure (Figure 1.17). 
The catechol amides allow each of enterobactin’s three binding groups to 
bind iron in a salicylate type configuration, before rotating and bringing the 
iron into the centre of the siderophore where it is chelated by the remaining 
ligand groups[77]. Enterobactin 1-34 was the first catecholate siderophore to 
be identified, by Pollack and Neilands in 1970.  
 
Figure 1.17: Structures of five catecholate siderophores; enterobactin 1-34  
parabactin 1-35, agrobactin 1-36, rhodobactin 1-37 and vibriobactin 1-38.  
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As a representative of the catecholate class, enterobactin 1-34 is rather 
atypical. It is one of only two characterised catecholate siderophores with a 
cyclic backbone. The other cyclic catecholate siderophore is the Bacillus 
siderophore bacillibactin 2-3 (Figure 2.1). The majority of catecholate 
siderophores have linear backbones. It is also apparent that this class of 
siderophores generally contains tris-bidentate (hexadentate) ligands, as well 
as very similar backbones. Parabactin 1-35 and agrobactin 1-36 differ only in 
that one of the ligand groups in parabactin is a phenolate rather than a 
catecholate binding group[79]. Vibriobactin 1-38 is also similar, with the two 
differences being a shorter backbone, and an additional oxazoline ring [80]. 
The best known phenolate examples within this class of siderophores exhibit 
a different kind of structure. They still exhibit linear backbones; however their 
denticity is not the usual tris-bidentate configuration (Figure 1.17). The 
mycobactins 1-41, a series of siderophores from Mycobacterium tuberculosis 
exhibit hydroxyphenyloxazolone ligands. Pyochelin 1-39 and yersiniabactin 
1-40 exhibit a similar structure, but with thiazoline rings as opposed to 
oxazoline rings adjacent to the phenol. 
 
Figure 1.18: Examples of phenolate siderophores; pyochelin 1-39, yersiniabactin 1-40 
and mycobactin 1-41.  
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The phenolate groups allow iron binding in these siderophores. 
Examining the structures shows that this class of ligands display structural 
diversity. They have been isolated from a broad range of species including 
enteric bacteria, Mycobacteirum, Yersinia, and Pseudomonas species, as 
well as some marine organisms. It is this diversity of species that produce 
and recognise the siderophores that makes them an ideal siderophore for 
use in a “Trojan horse” strategy. 
1.5.5. Siderophore uptake mechanisms 
Whilst the ligand geometry and backbone structure of siderophores can 
vary substantially, the general mechanisms for uptake into bacterial cells are 
relatively uniform. In Gram-negative bacteria, the siderophore-iron complex is 
recognised by a binding protein on the outer cell membrane, once in the 
periplasm it binds to a periplasmic binding protein (PerBP), which hands it 
over to the inner membrane transporter complex, which carries it across the 
inner membrane into the cytoplasm[81]. E.coli is capable of transporting a 
multitude of different siderophores from its environment in order to obtain the 
iron it requires. 
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Figure 1.19: Schematic overview of siderophore uptake in E.coli redrawn from Liang 
et al.
[81]
 OM = outer membrane IM = inner membrane. Reproduced from X. Y. Liang, 
D. J. Campopiano and P. J. Sadler, Chem. Soc. Rev. 2007, 36, 968-992 with 
permission from The Royal Society of Chemistry. 
 
The energy for active siderophore-Fe(III) complex uptake is produced 
by ABC proteins. In this case, this is a protein complex comprised of three 
proteins: ExbB, ExbD and TonB. These proteins are in a 7:2:1 ratio (ExbB: 
ExbD: TonB). The Exb proteins are ATPases which generate the energy for 
transporting the siderophore complex across the inner membrane[62, 81]. TonB 
has a more important role in this process. It is TonB which interacts with the 
receptor proteins on the surface of the outer membrane[82]. This interaction 
occurs via an N-terminal region on the receptor proteins referred to as the 
TonB box, this is a highly conserved motif which always contains aspartic 
acid and valine residues[82]. The interaction between TonB and siderophore 
transporters has been demonstrated by Moeck et al, among others, by cross 
linking TonB to the ferric hydroxamate transporter FhuA [83]. The siderophore 
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transporters all have a broadly similar tertiary structure (Figure 1.20). This is 
composed of a 22 stranded β barrel, and an N-terminal chain (approximately 
150 residues) which folds inside the barrel as a plug domain[62, 81]. When 
TonB interacts with the “TonB box” it induces a conformational change which 
removes the plug domain from the barrel, allowing the siderophore iron 
complex to pass through the receptor and into the periplasm[81]. 
 
Figure 1.20: Crystal structures of FhuA (left), FepA (centre) and FecA (right) all with 
bound ligands 
[84-86]
. Structures from the Protein Data Bank: FhuA image came from 
RCSB PDB (www.RCSB.org) of PBD ID 2FCP (Ferguson, A.D. Hoffman, E. Coulton, 
J.W. Diederichs, K. Welte, W.(1998) Siderophore-mediate iron transport: crystal 
structure of FhuA with bound liposaccharide Science. 282:2215-2220). FepA image 
came from RCSB PDB (www.RCSB.org) of PBD ID 1FEP (Buchanan, S.K. Smith, 
B.S. Venkatramani, L. Xia, D. Esser, L. Palnitkar, M. Chakraborty, R. van der Helm, D. 
Deisenhofer, J.(1999) Crystal structure of the outer membrane active transporter FepA 
Nat. Struct. Biol. 6: 56-63). FecA image came from RCSB PDB (www.RCSB.org) of 
PBD ID 1PNZ (Yue, W.W. Grizot, S. Buchanan, S.K.(2003) Structural evidence for 
iron free and ferric citrate binding to the TonB-dependent outer membrane transporter 
FecA J. Mol. Biol. 332: 353-368). 
 
It should be noted however, that not all siderophore transporters rely on 
this interaction. LbtU, a receptor for the Legionella pneumophila siderophore 
legiobactin, was recently found to be TonB independent. This conclusion is 
based on the fact that while the bacterium produces siderophores, and 
siderophore transporters, there is no gene encoding TonB within its 
genome[87]. 
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1.5.6. Mammalian defence against siderophores 
While siderophores are a triumph of evolution from bacteria, in terms of 
allowing them to scavenge sufficient iron to survive from the minimal amount 
available in their host, mammals have evolved mechanisms of preventing 
siderophores from doing their job. Mammals have evolved proteins known as 
siderocalins, which bind siderophores and preclude them from scavenging 
iron. These proteins have a highly conserved structure with an 8 stranded β-
barrel, with α- and 310 helices. The β-barrel encloses a cup shaped binding 
site[88].  
Siderocalin is unlike most of the lipocalins (the family of proteins to 
which it belongs) due to the nature of its binding site. While the lipocalins 
possess hydrophobic binding pockets, siderocalin has a series of positively 
charged residues. The binding pocket contains arginine and lysine 
residues[88]. The nature of this binding pocket allows it to bind a range of 
catecholate siderophore complexes including those of enterobactin 1-34, 
bacillibactin and parabactin. Additionally, siderocalin was found to bind the 
siderophore-Fe(III) complex of the mixed catecholate/hydroxamate 
siderophore carboxymycobactins from Mycobacterium. The siderocalin 
protein binds catecholate siderophores and their Fe(III) complexes by 
positioning the positively charged arginine and lysine residues of the binding 
pocket between the three catecholate rings. The protein-siderophore 
complex is secured by a combination of ionic and cation-π interactions[89], 
resulting in strong binding of siderocalin’s siderophore targets. It has been 
found to bind ferric enterobactin 1-34 with a KD of 0.4 nM
[88]. 
The combination of ionic and cation-π interactions allows siderocalin to 
bind multiple types of siderophore. However, as in the long running arms 
race between bacteria and antibiotics, bacteria are also raising the stakes in 
the battle for iron. Siderophores are being identified that can evade 
sequestration by the siderocalin protein. Petrobactin 1-30 (Figure 1.15) has 
evolved with an alternative catechol configuration which alters the 
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conformation of its iron complex sufficiently to prevent it being bound by 
siderocalin[90]. Additionally it has been found that bacteria have evolved to 
glycosylate their siderophores[91].  
 
Figure 1.21: Salmochelin S4, a glycosylated analogue of enterobactin  
 
The glycosylation generates sufficient steric hindrance to have a 
negative effect on the binding by siderocalin[92]. In designing our siderophore-
antimicrobial conjugates, we need to bear in mind the presence of 
siderocalin, and amend the target structures accordingly. The methods 
employed by bacteria can be used to generate siderophore analogue-
antimicrobial conjugates, which siderocalin will not bind, but will bind iron and 
be recognised by bacteria. This ability to evade a host’s immune system is 
potentially useful in the design of siderophore based Trojan horses. If the 
siderophore component is not recognised by mammalian siderocalins, it 
minimises the risk of the Trojan horse being removed from the host before it 
can act on its target bacteria. 
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1.6. Trojan horse strategy 
1.6.1. The basic concept 
In biological terms the aim is to mask a drug or other toxic moiety as 
harmless or preferably essential to a bacterial species. In this project, the 
essential component is iron, which as previously described is essential for 
bacteria to function and grow. By exploiting bacterial iron uptake, it could be 
possible to bypass drug access related resistance mechanisms (Figure 
1.22), specifically the mechanisms by which bacteria reduce the intracellular 
concentration of antimicrobials: reduced uptake and efflux pumps [48]. 
Research on outer membrane porin (OMP) mutants has shown that a 
reduction in the number of OMPs can convey resistance by decreasing 
accumulation[49]. A study on Acinetobacter showed an emphasis on the efflux 
of antimicrobials in its resistance profile[93], whilst Speciale et al. observed 
that P. aeruginosa develops resistance by modifying its outer membrane [94]. 
Consequently, reduced accumulation is a significant mechanism to target 
when attempting to eliminate antimicrobial resistance. By exploiting the 
uptake of a key nutrient, in the case of this research iron, it makes the 
development of resistance by reduced uptake or active efflux evolutionarily 
unfavourable. If a bacterium evolves to reduce the uptake of a conjugate, or 
actively removes it from the cell, it will also reduce its ability to obtain iron 
from its extracellular environment. Such mutations would reduce the 
likelihood of bacteria to survive and would ultimately result in attenuated 
growth or cell death.  
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Figure 1.22: Schematic overview of bacterial iron transport (top) and the concept of 
the Trojan horse strategy (bottom) 
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1.6.2. Natural examples of Trojan horses  
The idea of “Trojan horses” for antibiotics is based on a natural precedent, 
as bacteria evolved their own Trojan horses, the sideromycins. These are 
based on a number of siderophores including enterobactin 1-34 and 
microcins[6]. The two best known are salmycin 1-46 and the albomycins 1-
43−1-45 (Figure 1.23). Natural Trojan horses are structurally diverse, but 
their overall composition is the same. They contain a siderophore component 
to chelate and transport iron, and an antimicrobial component to induce cell 
death. The albomycins comprise of a nucleotide analogue and a thioribosyl 
pyrimidine component, conjugated to a tripeptide siderophore [95]. A third 
example Ferrimycin A 1-47 is based on the siderophore ferrioxamine B, with 
an antimicrobial moiety conjugated via its terminal hydroxamate [96]. The 
salmycins use danoxamine as their siderophore component. The 
antimicrobial component is an aminoglycoside[97]. 
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Figure 1.23: Examples of naturally occurring Trojan horses; albomycin 1-43−1-45
[95]
 , 
salmycin 1-46
[97]
, and Ferrimycin A 1-47
[98]
 
 
 There are other naturally occurring examples including the 
nannochelins and myxochelin, identified by Kunze et al[99-100]. There is also a 
more recent example published by Nolan et al., a microcin based on 
enterobactin 1-34. The microcin is an 84 amino acid ribosomal protein linked 
to enterobactin by a sugar residue[101]. Siderophore mimicking Trojan horses 
are not the only natural form produced by bacteria. An alternative Trojan 
horse strategy is the production of bacteriocins, which target competing 
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bacteria, and gain access by exploiting the TonB and TolB active uptake 
systems[102].  
1.6.3. Synthetic examples of Trojan horses 
There have been two main approaches to preparing synthetic “Trojan 
Horses”, either through conjugation of a known antimicrobial agent to a 
natural siderophore, or conjugation of a known antimicrobial agent to a novel 
iron chelator[103-104]. The earliest work began in the 1970s and focused on 
antimicrobials whose chemistry was well established, namely; sulfonamides, 
cephalosporins and β-lactams[62]. The second advantage of these particular 
antimicrobials is that they have periplasmic targets, and consequently the 
“Trojan horse” only needed to penetrate the outer membrane and not the 
cytoplasmic membrane. 
The first example of a synthetic “Trojan horse” was published by Zähner 
et al. in 1977. The work utilised sulfonamide antimicrobials, and prepared two 
conjugates using two hydroxamate siderophores: ferrichrome 1-23 (1-48)   
and ferrioxamine 1-21 (1-49) (Figure 1.24)[105]. The compounds were 
prepared by conjugating the antimicrobial to the siderophores via a nicotinic 
acid linker, in the case of ferrichrome the conjugation was via the hydroxyl 
group of a serine residue in the backbone. For the ferrioxamine conjugate 1-
49, a primary amine was used as the point of attachment[105]. Antimicrobial 
screening showed the ferrichrome conjugate 1-48 to have similar levels of 
activity against S. aureus to the parent sulfonamide. The ferrioxamine 
conjugate 1-49 showed no activity, this raised the question of whether the 
antimicrobials needed to be released once inside the cell, or whether longer 
linkers were needed to ensure activity was retained[105]. 
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Figure 1.24: Sulfonamide Trojan horses utilising ferrichrome 1-24 (1-48) and 
ferrioxamine 1-22 (1-49)
[105]
 
 
1.6.3.1. Catecholate siderophore Trojan horses 
A significant proportion of the work undertaken on Trojan horses has 
focused on utilising catecholate siderophores and novel catechol based 
ligands as the iron binding component. Throughout the 80’s and 90’s several 
groups reported catechol based Trojan horses, with a variety of β-lactam 
antibiotics including aminopenicillins and cephalosporins. Watanabe 
produced a conjugate designated E0702, 1-50. This contained a phenolate 
binding group and a 6,7-dihydroxy-4-hydro-chromen-4-one moiety as the iron 
binding groups (1-50, Figure 1.25)[106], conjugated to the antimicrobial via an 
amide bond. This conjugate exhibited good levels of activity with MIC values 
that were significantly lower than well established antibiotics including 
ampicillin, tetracycline and several cephalosporins. This was observed 
across a series of E. coli strains. Curiously, when mutants with resistance 
were observed, the mutation wasn’t mapped to the target or a specific 
transporter, but to the TonB protein[106]. As TonB is essential for the iron 
transport system[81], it was clear that the conjugate was successfully working 
as a Trojan horse and exploiting the bacteria’s iron transport system. This 
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was further confirmed by its high level of efficacy against iron starved 
bacteria[106]. 
 
Figure 1.25: Structure of a cephalosporin based Trojan horse using 
phenolate/catecholate binding groups 1-50 
 
A disadvantage of the Trojan horse approach is that the additional steric 
bulk created by conjugating an antimicrobial molecule to a natural or 
synthetic siderophore, may reduce or completely prevent uptake of the 
complex by bacteria. This is not necessarily the case, as evidenced by a 
catechol siderophore conjugate containing the high molecular weight 
macrolide vancomycin, prepared by Ghosh and Miller (1-51, Figure 1.26)[107]. 
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Figure 1.26: Structure of a vancomycin-pyoverdin conjugate 1-51 produced by Ghosh 
and Miller
[107]
. This showed increased activity against Pseudomonas aeruginosa.  
 
The Pyoverdin component is a bis-catecholate/hydroxamate mixed 
ligand siderophore. The conjugate 1-51 displays a 4-8 fold increase in activity 
when compared to vancomycin when tested against bacteria in iron deficient 
conditions. As iron is tightly regulated in a mammalian host and is present 
only at yoctomolar concentrations[62], this conjugate could be highly effective 
in vivo. 
As the bacterial iron transport system is designed to bind and transport 
specific siderophores (e.g. FepA transporting enterobactin)[81], siderophore-
antimicrobial conjugates could also be targeted at specific transporters, using 
known siderophores, or analogues with similar structures. As there are 
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known natural siderophores with mixed ligands, Trojan Horses can be 
prepared using natural mixed ligand siderophores, or mixed ligand iron 
chelators. As long as the iron binding regions of the siderophores are not 
disrupted, this is a realistic possibility. Schobert et al. employed this theory to 
produce new synthetic Trojan horses (1-52, Figure 1.27), using β-lactams as 
the antimicrobial moiety[108]. 
 
Figure 1.27: A mixed ligand (catecholate/hydroxamate) siderophore-β-lactam 
conjugate synthesised by Schobert et al.
[108]
 
 
Schobert et al. used 6-aminopenicillanate as the antimicrobial moiety, 
and prepared a variety of conjugates including bis-catecholate hydroxamates 
and tris-catecholate conjugates. They established the conjugates were acting 
as siderophores by using antibiotic-free siderophores and analysing the 
promotion of growth in siderophore deficient E.coli. These experiments 
suggested that the synthetic siderophores 1-52 (Figure 1.27) and similar 
conjugates they prepared were being actively transported [108]. Additionally, 
Schobert et al. highlighted the importance of the iron binding ligands.  They 
observed that removing a single key atom from the iron binding groups 
removed the siderophore activity of the conjugates[108]. 
More recently Heinisch et al. and Wittmann et al. both reported catechol 
based Trojan horses. Like Schobert they utilised aminopenicillins as the 
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antimicrobial component, conjugated to via an amide bond (Figure 1.28)[109-
110].  
 
 
Figure 1.28: Structures of catecholate siderophore-β-lactam pro-drugs synthesised by 
Heinisch et al.
[110]
 
 
These conjugates 1-53 and 1-54 (Figure 1.28) proved to be successful 
in vitro with the amide coupled conjugates displaying MIC values as low as 1 
mg/L against wild type Pseudomonas aeruginosa. This value is one hundred 
fold lower than the MIC of ampicillin against the same strain. The ether linked 
compound 1-55 was substantially less active. It exhibited an MIC of 50 mg/L. 
However, when compared with the MIC of ampicillin this was still a significant 
improvement[109, 111]. This difference in activity suggests that the lability of the 
siderophore component is key to the success of the conjugate. This was 
further explored by Miller et al. with their desferrioxamine-ciprofloxacin 
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conjugates (section 1.6.3.2)[112]. Heinisch et al. also attempted to investigate 
the mechanism of uptake, and the efficacy of the conjugates as 
siderophores. The activity of the conjugates was diminished when they were 
tested against strains which were deficient in key catecholate transporters, 
suggesting that the conjugates were binding iron and being actively 
transported via the iron uptake system to reach their intracellular target as 
opposed to accessing the cell via a porin[109].  
1.6.3.2. Quinolone and fluoroquinolone based Trojan horses 
In recent years there have been several Trojan horses reported that use 
fluoroquinolones as the parent antimicrobial[104]. Miller et al. used nalidixic 
acid and prepared conjugates with desferrioxamine B 1-22. Their 
experiments found that the conjugates could perform DNA cleavage in vitro, 
but only in the presence of Fe(II) ascorbate and H2O2 as reducing agents. 
However the conjugate did show significant anti-malarial activity[113]. Mislin et 
al. did work using norfloxacin 1-17 and the Psuedomonas siderophore 
pyochelin (Figure 1.29). They focused not only on whether the conjugate 
would function as a siderophore, but whether the nature of the linker between 
siderophore and antimicrobial would influence the function o f the conjugate 
as an antibiotic[114]. They observed that the conjugate with a bio-labile linker 
retained the antimicrobial activity, but the conjugate with a non-labile linker 
had no activity. This suggests that either the presence of the siderophore 
prevents the antimicrobial binding to its target or that the antimicrobial 
prevents the siderophore from being recognised and subsequently 
transported into the cell[114]. A more recent study by Miller et al. examined 
salmycins and desferridanoxamine-antibiotic conjugates to elucidate the 
importance of drug release. After synthesising a series of conjugates with 
both labile and non-labile linkers, they found that the conjugates with labile 
linkers often displayed equal or greater activity than the free antimicrobial, 
but those with non-labile linkers had reduced activity[115].  
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Figure 1.29: A) Conjugate 1-56 synthesised by Miller et al. using desferrioxamine 1-
22/nalidixic acid 1-16. B) Conjugates 1-57 and 1-58 synthesised by Mislin et al. using 
pyochelin 1-39/norfloxacin 1-17. Fluoroquinolones are coloured, nalidixic acid 1-16: 
red, norfloxacin 1-17: blue 
 
In addition to these conjugates, there are also several recent examples 
of fluoroquinolone based Trojan horses using ciprofloxacin 1-18. Mislin et al. 
built on their earlier work with fluoroquinolone-pyochelin conjugates (Figure 
1.30B). In these conjugates, the fluoroquinolone was linked to an N3’ 
functionalised version of pyochelin rather than via the aromatic ring as in 
conjugates 1-57 and 1-58. However, the same stable and cleavable linkers 
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were used. Miller et al  bui lt on their work on Desferrioxamine B conjugates. 
Like Mislin they used ciprofloxacin as the fluoroquino lone component. Miller 
used “trimethyl-lock” based linkers, designed to release the antimicrobial 
agent via cleavage by an esterase or phosphatase[112].  
 
Figure 1.30: Structures of a pyochelin ciprofloxacin conjugate 1-58 and an esterase 
sensitive desferrioxamine-ciprofloxacin conjugate 1-59
[112]
. 
 
Mislin et al. found that their conjugates 1-57 and 1-58 displayed weaker 
activity than the free fluoroquinolones. However, they attributed this to low 
solubility and potential hydrolysis of the labile linkers in aqueous media, 
preventing the active uptake of the antibiotic[116]. Miller observed that the 
esterase sensitive conjugate 1-60 had good antimicrobial activity against 
desferrioxamine-utilising bacteria, however the conjugates designed to be 
phosphatise sensitive were inactive against the same panel of strains [112]. 
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 Two additional examples of Trojan horses using ciprofloxacin 1-18 
have been reported by the Duhme-Klair/Routledge research group[117-118]. 
They used α-carboxylate siderophores as the iron binding component 
(Figure 1.31). They reported two conjugates with a single citrate as the iron 
binding moiety 1-61 and 1-62[117], and subsequently reported a ciprofloxacin 
conjugate with the Staphylococcus aureus siderophore staphyloferrin A as 
the iron binding component 1-63 [118]. 
 
Figure 1.31: Structures of carboxylate siderophore-ciprofloxacin conjugates reported 
by the Duhme-Klair/Routledge group 
 
The carboxylate-ciprofloxacin conjugates (Figure 1.31) showed activity 
against a range of pathogenic bacteria, however the activity was significantly 
attenuated compared to that of the parent antimicrobial ciprofloxacin 1-18[117-
118]. The decrease in activity was determined to be due to reduced inhibitory 
activity against DNA gyrase.  
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1.6.3.3. Recent successes with Trojan horse antimicrobials 
There have been some significant discoveries in the field of Trojan 
horses in recent years. Miller et al. prepared artemisinin-mycobactin 
conjugates to target Mycobacterium tuberculosis as well as malaria. (Figure 
1.32)[119]. The antimicrobial component artemisinin has no anti-mycobacterial 
activity. However, it is known to be an effective antimalarial drug. 
 
Figure 1.32: Structure of an artemesinin-mycobactin conjugate 1-64 produced by 
Miller et al.
[119]
  
 
Miller et al. found that their conjugate 1-64 (Figure 1.32) possessed 
good activity and as expected was highly specific for Mycobacterium 
tuberculosis, including activity against multi-drug resistant strains[119]. 
Furthermore, artemisinin retained its activity against Plasmodium falciparum. 
The high affinity of the conjugate for one specific bacteria suggests that it 
may be possible to use the Trojan horse strategy to design bacteria specific 
delivery agents[103]. Recently, in our research group a ciprofloxacin 1-18 
based siderophore was produced using staphyloferrin A (1-63, Figure 1.31) 
as the siderophore component, which showed antimicrobial activity against a 
range of strains, albeit reduced when compared to the parent antimicrobial 
ciprofloxacin 1-18[118]. 
A significant success in the field of Trojan horses has recently been 
achieved at Basilea Pharmaceutica. The Trojan horse antimicrobial Bal30072 
is currently in phase 1 clinical trials (Figure 1.33)[104, 120]. The conjugate 
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contains a monosulfactam antimicrobial with a dihydropyridone as an iron 
binding group. Bal30072 1-65 shows a good spectrum of activity against 
gram negative bacteria, including several multi-drug resistant strains[120]. 
 
Figure 1.33: Structure of Bal 30072, a siderophore-monosulfactam drug currently in 
clinical trials  
 
The variety of conjugates that have been prepared using different 
siderophore and antimicrobial components demonstrates how powerful a tool 
the Trojan horse strategy could be against antimicrobial resistance. The 
versatility of the strategy allows the synthesis of a diverse range of 
compounds possess both iron chelating and antimicrobial activity. By 
investigating natural and synthetic iron chelators with existing antimicrobials it 
may be possible to overcome certain forms of resistance, specifically 
mechanisms linked to reduced uptake and efflux of antibiotics. 
1.7. Overall project aims 
This thesis details the development of novel catechol based Trojan 
horse antimicrobials, specifically the attempted synthesis and 
characterisation of a Trojan horse based on the Bacillus siderophore 
petrobactin and the fluoroquinolone antimicrobial ciprofloxacin. Furthermore, 
this thesis details the development of a novel Trojan horse antimicrobial 
using the Ugi four component condensation. The compounds produce will 
then undergo biological evaluation to determine if they possess similar 
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bactericidal activity to the parent antimicrobial. If this is not the case, further 
experimentation will be performed to elucidate the reason for any observed 
decrease or increase in activity. It is possible that catechol based Trojan 
horses may be able to target bacteria which rely on catecholate siderophores 
such as Bacillus species and E. coli. 
Additionally, the potential of catechol based ligands as metal delivery 
agents, and as antimicrobials in their own right, will be investigated. Simple 
ligands will be synthesised and subjected to biological evaluation to establish 
if they possess bactericidal activity, and the mechanism by which they may 
be acting. 
Additionally, experiments will be undertaken to probe the viability of 
using carbohydrate transport for the Trojan horse strategy. Several 
carbohydrate based Trojan horses will be screened under specific carbon 
limiting conditions to determine whether or not they are taken into bacterial 
cells via active transport or via a passive uptake mechanism. 
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2. Studies towards the synthesis of a 
siderophore-ciprofloxacin conjugate based on 
petrobactin 
2.1. Aims 
The aim of the research in this chapter was the synthesis of a Trojan 
horse conjugate, using ciprofloxacin 1-18 as the antimicrobial component, 
and an analogue of the Bacillus siderophore petrobactin 1-30 as the iron-
binding component. The conjugate was designed to incorporate the key iron 
binding groups of the native siderophore structure, with the ciprofloxacin 
moiety conjugated via the carboxylic acid of the central citrate. 
2.2. Introduction 
2.2.1. The stealth siderophore: Petrobactin 
Petrobactin 1-30 is a mixed ligand siderophore, containing two 
catechols and a central citrate. The siderophore was originally isolated from 
the marine bacteria Marinobacter hydrocarbonoclasticus by Butler et al. in 
2002[74]. Based on NMR analysis of the siderophore, they predicted a bis-
catecholate structure with 2,3-configuration around the aromatic ring, linked 
via a bis-spermidine backbone with a central citrate. They observed that the 
petrobactin-Fe(III) complex 2-1 can undergo a photolytic ligand to metal 
charge transfer, this results in decarboxylation of the ligand, followed by 
oxidation which resulted in the formation of a keto group (Scheme 2.1). 
Butler et al. had previously demonstrated that aquachelin, another marine 
siderophore, was important for iron cycling. They had found that photolysis of 
the aquachelin Fe(III) complex by UV light resulted in reduction of Fe(III) to 
Fe(II)[74, 121]. It is possible that bacterial uptake of iron via petrobactin 1-30 
utilises the same mechanism to release bound iron into the intracellular 
medium. The siderophore aerobactin, a siderophore produced by numerous 
bacterial species, has also been shown to be photoreactive.  
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Scheme 2.1: Schematic representation of the photolysis of the petrobactin-Fe(III) 
complex proposed by Butler et al.
[74]
 Based on the originally accepted structure of 
petrobactin.  
 
Butler et al. subsequently found that the structure they initially published 
for petrobactin 1-30 was incorrect. They synthesised petrobactin with both 
2,3-dihydroxy and 3,4-dihydroxybenzamide moieties, and found that the 
NMR data of the 3,4-configured petrobactin matched the previously 
published NMR data[122]. While the siderophore was initially isolated from a 
marine bacterium, in 2005 Ruggiero et al. identified it as a key siderophore of 
the anthrax pathogen Bacillus anthracis[123]. This was the first example of 
petrobactin 1-30 observed in a pathogenic species, although the presence of 
3,4-dihydroxybenzamide moieties had previously been observed in B. 
anthracis siderophores[124].  
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Figure 2.1: Structure of Bacillus siderophores bacillibactin 2-3 and petrobactin 1-30 
 
It was found that Bacillus cereus also produced petrobactin 1-30, but 
Bacillus thuringiensis did not[125]. They did however find that all Bacillus 
species they tested produced bacillibactin (Figure 2.1) Studies on the 
siderophores in B. anthracis have demonstrated that petrobactin is required 
for the virulence of the bacterium[126]. The study also found that in low iron 
media, petrobactin was secreted several hours before the bacterium started 
producing bacillibactin. A recent investigation into the impact of iron and O2 
concentration on petrobactin and bacillibactin production, demonstrated a 
repression of bacillibactin production in high iron concentrations [127]. 
However, they found petrobactin was still produced even at iron 
concentrations of 20 µM, suggesting that other factors were involved in the 
regulation of petrobactin biosynthesis. They went on to demonstrate that 
petrobactin biosynthesis was also regulated by the amount of oxygen 
available. They observed that accumulation of petrobactin in the extracellular 
medium was higher in an oxygen rich atmosphere than an atmosphere with 
low oxygen levels.[127] Additionally they found that high levels of oxygen 
delayed the repression of petrobactin biosynthesis by iron.  
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The iron binding properties of petrobactin have been investigated by 
Raymond et al. and Butler et al. Both groups observed a pM value of 
approximately 23 at physiological pH[63, 128]. Raymond determined that the 
photoproduct of petrobactin 2-2 had a higher affinity for iron, with a pM of 
24.1 at physiological pH. Byers had previously established that B. anthracis 
could scavenge iron that was bound by transferrin, as well as hemoproteins 
and heterologous siderophores[124]. Raymond investigated the rate at which 
petrobactin 1-30 could remove iron from transferrin. They found that the kmax 
for the process was 12.3x10-2 min-1, this was six times the published kmax for 
enterobactin 1-34 (2.1x10-2 min-1) by Harris et al. in 1979[63, 129]. The 
efficiency with which petrobactin 1-30 removes iron from transferrin suggests 
transferrin-bound iron is the primary iron source utilised by Bacillus species 
during initial stages of infection[63]. 
2.2.2. Biosynthesis of petrobactin 
The use of 3,4-dihydroxybenzoic acid in petrobactin 1-30, raised 
questions about the biosynthetic pathway of the siderophore. Hanna et al. 
first identified the importance of six genes to the  virulence of B. anthracis; 
AsbABCDEF[130]. Several studies have elucidated the individual roles of the 
proteins encoded by the gene cluster. Challis et al. demonstrated that the 
AsbA protein catalysed the ATP dependent condensation of spermidine to 
the central citrate of the siderophore[131]. They subsequently found that AsbB 
protein fulfilled a similar role, catalysing the condensation of a second 
spermidine moiety onto the central citrate (Scheme 2.2)[132].  
The AsbC, AsbD and AsbE proteins work in a pathway to catalyse the 
condensation of 3,4-dihydroxybenzoic acid moiety 2-7 onto the N8- N8- bis-
spermidyl citrate.  
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Scheme 2.2: Biosynthesis of petrobactin proposed by Challis et al. 
 
The AsbF protein is responsible for the formation of the 3,4-
dihydroxybenzoic acid moiety. The gene encoding AsbF had previously been 
observed in bacteria that produced 3,4-dihydroxybenzoic acid[124-125]. 
Koppisch et al. postulated that the 3,4-dihydroxybenzoic acid moiety was a 
by-product of the shikimate pathway[133]. Further research into the role of 
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AsbF by Koppisch et al. and Pfleger et al. determined that the protein is a 3-
dihydroshikimate dehydratase[134-135].  
 
Scheme 2.3: Proposed biosynthetic pathway to 3,4-dihydroxybenzoic acid from 
Koppisch et al., showing the roles of several enzymes including the proposed role of 
the key AsbF protein (3-dehydroshikimate dehydratase) 
 
2.2.3. Total synthesis of petrobactin 
The total synthesis has been achieved by several research groups [122, 
136-137]. The syntheses all used a fragment based approach, synthesising the 
individual building blocks before systematically coupling them together to 
form the complete siderophore.  
2.2.3.1. Synthesis of the catechol subunit  
To prepare the catechol groups, the hydroxyls were benzyl protected. 
Butler used the method of Rastetter et al. reacting 3,4-
dihydroxybenzaldehyde with benzyl chloride and K2CO3 in EtOH
[122, 138]. 
Phanstiel used a similar method, utilising benzyl bromide instead of benzyl 
chloride[137]. Low took an alternative approach, reacting 3,4-dihydroxybenzoic 
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acid with MeOH to generate a methyl ester, then performing the benzyl 
protection using benzyl bromide and K2CO3 in DMF
[136] 
2.2.3.2. Coupling and deprotection of the petrobactin backbone 
To generate the full siderophore backbone, several methods have been 
employed. The initial step in the published total syntheses is the formation of 
a tert-butyl protected citrate. All three reported total syntheses achieved this 
using a procedure published by Milewska et al., where 1,5-dimethyl citrate 
was trans-esterified using tert-butyl acetate[139]. The second step was to 
couple the catechol unit to the spermidine linker. Butler and Phanstiel both 
achieved this by activating the benzylated catechol. 3,4-
bis(benzyloxy)benzoic acid was reacted with oxalyl chloride to yield 3,4-
bis(benzyloxy)benzoyl chloride. The acid chloride was then reacted with the 
free amine of spermidine to generate the catechol-spermidine moiety. Low et 
al. used an alternative method, whereby the methyl ester of 3,4-
bis(benzyloxy)benzoic acid was reacted with the spermidine linker by ester-
amide exchange[136]. To assemble the back bone, the spermidine catechol 
moiety was coupled to the central citrate (Scheme 2.4). Phanstiel and Low 
both achieved this by generating a disuccinimidyl ester of the tert-butyl 
citrate, and reacting it with the catecholate-spermidine moiety in 
triethylamine, dioxane and DCM[136-137, 139].  Butler also used an activated 
form of the citrate moiety, utilising a method originally published by Miller et 
al. they generated a di-nitrophenol ester, which they subsequently reacted 
with the catecholate-spermidine moiety using DIPEA in MeCN[122, 140]. The 
final stage of the total synthesis was the removal of the tert-butyl and benzyl 
ether protecting groups. Butler and Low both removed the ester via TFA 
mediated hydrolysis in DCM, Phanstiel utilised an HCl mediated hydrolysis in 
acetone. All three published syntheses removed the benzyl ether protecting 
groups by hydrogenolysis with a Pd/C catalyst, with Butler and Low 
performing the deprotection in acetic acid, and Phanstiel using EtOH. In 
terms of reaction economy, the synthesis published by Butler et al. was the 
most efficient, with the highest overall yield (25%) and smallest number of 
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reaction steps (7 steps)[122]. While the synthesis by Phanstiel was less 
efficient, they were able to use it to generate several homologues of 
petrobactin in addition to the native structure[137]. 
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Scheme 2.4: Assembly of the petrobactin backbone by A) Butler et al. and B) 
Gardner et al./Low et al. 
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2.2.4. Transport of petrobactin 
The uptake mechanism for petrobactin 1-30 is similar to other 
siderophores, using TonB dependent uptake, with the energy provided by 
ATP hydrolysis[141]. The first receptors were identified and characterised by 
Raymond et al. in 2009. They identified two binding proteins in Bacillus 
cereus, named FatB and FpuA. FatB showed a broad range of binding, 
including to the 3,4-dihydroxybenzyl moiety and the petrobactin iron complex 
photoproduct. However, FpuA showed a high level of specificity, only binding 
to free petrobactin and the iron complex[142]. They also identified a further 
binding protein from Bacillus subtilis: YclQ, which has similar properties to 
FatB, in that it binds selectively to both iron free and ferric petrobactin, 3,4-
dihydroxybenzoic acid and the ferric complex photoproduct. The crystal 
structure demonstrated that YclQ was capable of binding for petrobactin[143]. 
YclQ was subsequently renamed FpiA after Oberthür et al. used synthetic 
petrobactin ligands to confirm the binding of the protein to petrobactin, and 
subsequently demonstrated that it was essential for petrobactin transport in 
Bacillus subtilis[144]. 
Recent research has examined transport of petrobactin in Bacillus 
anthracis, as it has been established that petrobactin is essential for 
virulence in the pathogen[92, 145-146]. Analysis of the FatB and FpuA proteins 
by Hanna et al. demonstrated that FatB was not required for petrobactin 
transport in B. anthracis[147], despite being able to bind petrobactin[142]. FpuA 
however was found to be essential for petrobactin uptake, as growth was 
attenuated in iron depleted conditions, even with purified petrobactin added. 
In a later study, they were able to elucidate more details about the overall 
uptake mechanism, describing two permeases and three ATPases that were 
required for petrobactin transport[141]. It was found that only one of the two 
permeases, FpuB or FatCD, was required. However if the ATPase 
corresponding to that permease was missing, attenuation of growth in iron 
limited conditions was observed. 
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2.3. Results and discussion 
2.3.1. Towards the synthesis of a ciprofloxacin-petrobactin 
analogue conjugate 
The analogue designed in this research will retain the key binding 
groups, the central citrate and two catechol units. The analogue will use a 
2,3-dihydroxybenzoic acid moiety for the catechol groups, and the length of 
the backbone will be decreased. Both modifications could influence the iron 
binding ability of the siderophore. The conjugation of ciprofloxacin may also 
influence iron binding and bacterial uptake, as conjugation will be to one of 
the chelating groups within the siderophore structure, the citrate unit. The 
synthesis of the 2,3-configured petrobactin analogue was chosen as the 
catechol chemistry is well established[148].  
2.3.1.1. Components of the target molecule 
In order to establish a synthetic route to the target molecule 2-17, it was 
disconnected to individual components (Figure 2.2) to give a fragment-based 
synthetic scheme, similar to that employed in total synthesis of the full 
petrobactin siderophore[122, 136-137]. The target molecule is composed of four 
key fragments: 2,3-dihydroxybenzaldehyde 2-14, 1,2-diaminoethane 2-15, 
citric acid 1-23 and the antimicrobial component: ciprofloxacin 1-18. The 
structure was subsequently revised to include a butyl linked backbone, as the 
chemistry to prepare the catechol-amine unit using 1,4-diamino butane and 
2,3-bis(benzyloxy)benzoic acid was already established. Additionally, a  
glycine spacer was added to ciprofloxacin 1-18 to generate a primary amine 
and allow a more efficient coupling to the analogue backbone (section 
2.3.2.8.).  
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Figure 2.2: Structure and initial components of the target petrobactin analogue-
ciprofloxacin conjugate 2-13 
 
The synthesis of homologues of petrobactin and the total synthesis of 
petrobactin 1-30 has also been achieved by several groups[122, 136-137]. The 
chemistry employed in these investigations was the basis of the synthesis  of  
the target molecule 2-17[122, 136-137]. 
2.3.1.2. Protection of ciprofloxacin 1-18 by esterification 
The first step in the synthesis of the proposed petrobactin analogue 2-
17 was the protection of the drug component, ciprofloxacin 1-18. 
Ciprofloxacin has zwitterionic character at neutral pH, consequently it has 
limited solubility in both aqueous and organic solvents; therefore protection of 
one of these groups was undertaken to increase the solubility of the 
compound in organic solvents. In addition, as the β-keto acid system is 
required for antimicrobial activity[35],  carboxylic acid protection was used to 
protect the β-keto acid from unwanted side reactions. To protect the 
carboxylic acid, the methyl ester of ciprofloxacin 1-18 was synthesised[117].  
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Scheme 2.5: Synthesis of the methyl ester of ciprofloxacin 2-16 using thionyl chloride 
 
The reaction was carried out as shown by refluxing ciprofloxacin 1-18 in 
MeOH with thionyl chloride (Scheme 2.5). After work up, 2-20 was isolated in 
60% yield. Formation of the product was supported by 1H NMR 
spectroscopy, with a singlet with a relative integration of three at 3.89 ppm 
corresponding to the methyl ester evident in the spectra. ESI mass 
spectrometric analysis gave a peak with m/z 346.16, corresponding to the 
[M+H]+ form of 2-20.  
2.3.1.3. Preparation of the central citrate moiety 
As the citric acid has three carboxylic acid groups, the central carboxylic 
acid required protection prior to being incorporated in the synthesis (Scheme 
2.6). This ensures that after the backbone is synthesised, the central 
carboxylic acid can be deprotected, so it is available for chemical conjugation 
to the methyl ester of ciprofloxacin 2-20. 
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Scheme 2.6: Protecting group strategy to give mono-protected citrate 
 
The synthesis of 1,5-dimethyl citrate 2-21 was achieved by refluxing 
citric acid 1-26 in MeOH with H2SO4 (Scheme 2.7)
[149-150]
. 
 
Scheme 2.7: Synthesis of 1,5-dimethyl citrate by acid catalysed esterification of citric 
acid 
 
To isolate 2-21 a hybrid purification process of two published 
procedures was used. The first stage of the purification used the method of 
Hirota et al.[149]. The solution was neutralised using Ca(OH)2, the resultant 
precipitate filtered off, and the filtrate concentrated in vacuo[149]. The 
remainder of the purification used the procedure of Guo et al.[150]. This 
involved sonicating the solid from concentration of the filtrate in H2O and the 
removal of insoluble material The filtrate was acidified to pH zero using conc. 
HCl and the precipitate isolated by filtration. The precipitate was the n 
redissolved using NaHCO3(aq) and extracted using CHCl3. The aqueous 
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phase was then reacidified to pH zero using conc. HCl, resulting in  
precipitation of the product as a white solid. After purification, 1,5 -dimethyl 
citrate 2-21 was isolated in 54% yield. The successful synthesis of the 
product was supported by 1H NMR spectroscopy with a singlet at 3.64 ppm 
with a relative integration of six due to the terminal methyl groups present in 
the spectrum. ESI mass spectrometric analysis showed peaks with m/z 
221.06 and 243.04, corresponding to the [M+H]+ and [M+Na]+ ions of the 
required product 2-21. A by-product of the reaction was 1,3,5-trimethyl 
citrate, which was isolated in 15% yield [151]. 
Protection of the secondary carboxylic acid group used the method of 
Deacon et al. reacting 1,5-dimethyl citrate with tert-butyl acetate in the 
presence of 70 % perchloric acid (Scheme 2.8)[150].  
 
Scheme 2.8: Synthesis of 3-tert-butyl-1,5-dimethyl citrate  2-23 using the method of 
Deacon et al.  
 
Initially a procedure by Phanstiel et al. was followed, this utilised a 10:1 
(t-butyl acetate: 1,5-dimethyl citrate) molar ratio[150], 1H NMR spectroscopy of 
2-23 showed a singlet resonance at 1.49 ppm with relative integration nine 
corresponding to the t-butyl group present in the spectra. ESI mass 
spectrometry gave a peak with m/z of 299.11, corresponding to the [M+Na]+ 
ion of the product 2-23. However, the ESI mass spectrometric analysis also 
gave a peak with m/z of 221.06, suggesting the presence of unreacted 1,5-
dimethyl citrate 2-21. Subsequently a method by Deacon et al. was 
attempted[152]. This method used a greater excess of tert-butyl acetate 
(~15:1, t-butyl acetate: 1,5-dimethyl citrate molar ratio). The product 2-23 
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was isolated as pale yellow oil, in 58% yield. 1H NMR and ESI mass 
spectrometric data was obtained. The peak with m/z of 299.11 corresponding 
to the [M+Na]+ of 2-23 was observed in the ESI mass spectrum, but no peak 
with mass corresponding to 2-21 was observed, suggesting a pure product. 
In the 1H NMR spectrum the ratio of the integrations of the t-butyl group and 
the methyl esters was 9:6, as expected for the product 2-23.   
To deprotect 1,5-dimethyl-3-tert-butyl citrate 2-23, the method by 
Phanstiel et al. was used (Scheme 2.9)[150]. 
 
Scheme 2.9: NaOH mediated deprotection of 3 -tert-butyl 1,5-dimethyl citrate 2-23 
 
The reaction gave 2-15 as a white solid in 75% yield. 1H NMR 
spectroscopic analysis supported successful formation that the product 2-15 
with the loss of a singlet at 3.64 ppm with relative integration of six 
corresponding to the two terminal methyl esters. In addition, ESI mass 
spectrometric analysis gave two peaks with m/z 249.10 and 271.08, 
corresponding to the [M+H]+ and [M+Na]+ ions of the product 2-15 
respectively. 
A drawback of this synthetic step was the five day reaction time 
required. Additionally the reaction was unreliable, giving variable yields and 
purity as unreacted 1,5-dimethyl citrate 2-21 was often observed. The  tert-
butyl ester was also found later to be an unsuitable protecting group (Section 
2.3.1.4), as the benzyl ethers used in the protection of the catechol units did 
not survive a HCl-mediated deprotection and consequently would be unlikely 
to survive the required TFA mediated deprotection of the t-butyl ester[122, 137].  
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An alternative strategy was adopted[149], 3-monomethyl citrate 2-24 was 
prepared (Scheme 2.10)[149]. The process involved taking the previously 
synthesised 1,5-dimethyl citrate 2-21 and performing an additional 
esterification to produce 1,3,5-trimethyl citrate 2-22. This was then 
deprotected to produce 3-monomethyl citrate 2-24. 
 
Scheme 2.10: Preparation of 3-monomethyl citrate 2-24 in two steps from 1,5-
dimethyl citrate. 
 
1,3,5-trimethyl citrate 2-22 was deprotected using a variation of the 
method published of Hirota et al.[149]. Commercially available 1,3,5-trimethyl 
citrate 2-22 (Fluka) was used, and the reaction gave 2-24 as a white 
crystalline solid in 53% yield. Presence of the product was supported by 1H 
NMR spectroscopic analysis with a singlet at 3.61 ppm with a relative 
integration of three for the central methyl ester present, and the loss of the 
six proton singlet corresponding to the terminal methyl esters. ESI mass 
spectrometric analysis gave two peaks with m/z 207.05 and 229.03 
corresponding to the [M+H]+ and [M+Na]+ ions of the required product 2-24. 
Due to the prohibitive cost of purchasing 1,3,5-trimethyl citrate 2-22 from a 
commercial source, it was necessary synthesise 1,3,5-trimethyl citrate 2-22 
from 1,5-dimethyl citrate 2-21. To produce the 1,3,5-trimethyl citrate 2-22, 
esterification of 1,5-dimethyl citrate was performed using an acid catalysed  
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esterification with 2,2-dimethoxypropane. After work up, the product 2-18 was 
isolated in 81% yield. This successful synthesis was supported by the 
presence of two singlets in the 1H NMR spectrum at 3.83 ppm, with a relative 
integration of three, and 3.69 ppm, with a relative integration of six, 
corresponding to the central and terminal methyl groups respectively. ESI 
mass spectrometric analysis gave two peaks with m/z 235.08 and 257.06 
corresponding to the [M+H]+ and [M+Na]+ ions of the required product 2-22 
respectively.  
2.3.1.4. Preparation of the catechol subunit 
The catechol subunit is an integral part of the target molecule and while 
petrobactin contains a 3,4-dihydroxybenzamide moiety, it was decided to 
initially synthesise analogues based upon 2,3-dihydroxybenzamide acid 
moieties as procedures for these reactions were well established (Scheme 
2.11)[138, 153-154]. Additionally, due to the salicylate binding mode, 2,3-
configured catechol amides have a higher iron affinity[77, 155-156]. Furthermore, 
due to intramolecular hydrogen bonding, 2,3-configured catechols are less 
susceptible to oxidation.  
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Scheme 2.11: The proposed synthetic route from 2,3-dihydroxybenzaldehyde to the 
activated ester of the protected benzoic acid  
 
The first step was to protect the hydroxyl groups at the 2- and 3- 
positions of the dihydroxybenzaldehyde (Scheme 2.12). This was required to 
protect the hydroxyl groups from unwanted side reactions, specifically 
oxidation of the catechols to the corresponding quinone. To protect 2,3-
dihydroxybenzaldehyde 2-18, it was refluxed in dry EtOH with benzyl 
chloride. After purification 2-25 was isolated in 92% yield. ESI mass 
spectrometric analysis gave three peaks with m/z 319.13 and 336.16 and 
341.12. These corresponded to the [M+H]+, [M+NH4]
+ and [M+Na]+ ions of 
the required product 2-25. 1H NMR spectroscopy also supported successful 
formation of 2-25.A 10 H multiplet in the aromatic region from 7.38-7.21 ppm 
due to additional benzyl rings was observed in addition to two singlets with 
relative integration two at 5.26 and 5.17ppm corresponding to the benzyl CH2 
groups observed.  
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Scheme 2.12: Protection of 2,3-dihydroxybenzaldehyde 
 
However, there was evidence of impurities in the 1H NMR spectrum 
suggesting that the initial method of purification by partitioning between 
EtOAc/H2O was insufficient. Consequently, the procedure was modified in 
subsequent reactions, the reaction solution was filtered, and the filtrate 
evaporated to dryness in vacuo. The resultant yellow solid was then 
recrystallised from hot methanol and isolated as a pale brown crystalline solid 
in 70% yield. 
The next step in the synthesis of the catechol unit was a sodium chlorite 
mediated oxidation of 2-25 to the corresponding carboxylic acid 2-26, a 
variation of the method used by Chimiak et al.[153] was used. 2,3-bis 
(benzyloxy)benzaldehyde 2-25 was reacted with alternating portions of 
sulfamic acid and sodium chlorite. (Scheme 2.13). After reaction 2-26 was 
isolated in 90% yield. 
ESI mass spectrometry confirmed the presence of a molecular ion with 
an m/z value of 335.12 corresponding to the [M+H]+ ion of the required 
product 2-26. 1H NMR spectrometry confirmed the identity of 2-26. 
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Scheme 2.13: Oxidation of the protected aldehyde to the corresponding carboxylic 
acid. 
 
2,3-bis(benzyloxy)benzoic acid 2-26 was then converted to a 
succinimidyl ester, to allow rapid coupling to the diamine when assembling 
the siderophore backbone. The reaction was performed using DCC as a 
coupling agent[153]. 2,3-bis(benzyloxy)benzoic acid was dissolved in 1,4-
dioxane with N-hydroxysuccinimide and DCC (Scheme 2.14) 
 
Scheme 2.14: Preparation of activated ester of the bis(benzyloxy)benzoic acid using 
the method of Chimiak et al. 
 
After workup 2-27 was isolated as a white crystalline solid in 86% yield. 
The presence of a broad singlet in the 1H NMR spectrum at 2.8 ppm with a 
relative integration of four indicated the presence of the succinimidyl CH2. A 
signal at 169.2 ppm in the 13C NMR spectrum confirmed the presence of the 
carbonyl (C=O) groups of the succinimidyl ring. ESI mass spectrometric 
analysis gave three peaks with m/z 432.14, 449.17 and 454.13 
corresponding to the [M+H]+, [M+NH4]
+ and [M+Na]+  ions of the required 
product 2-27. 
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2.3.1.5. Assembly of the siderophore backbone: 
With the central citrate 2-24 and terminal catecholate subunits 2-27 
prepared, the two catechol units were ready to link via the citrate using an 
alkyl diamine backbone. Rather than using the bis-spermidine linker found in 
native petrobactin[122], a shorter 1,2-diaminoethane linker 2-19 was used, to 
create a smaller, more compact siderophore (Scheme 2.15). The advantage 
of this is a reduction in molecular weight, which should aid uptake through 
outer membrane porins (OMPs) if the conjugate isn’t actively transported. 
Additionally, a shorter linker reduces the entropic cost of chelating Fe(III) in 
solution. One disadvantage is that a petrobactin analogue with a significantly 
shorter linker may not be recognised for active transport. 
 
Scheme 2.15: Route to petrobactin analogue with ethyl linked backbone  
 
To enable the coupling of the diamine component to the catechol 
moiety, it was necessary to protect one of the amine groups of the 1,2-
diaminoethane using a tert-butyloxycarbonyl (Boc) protecting group, to 
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prevent the formation of dimers. The method of Keillor et al. was followed for 
the synthesis[157]. A solution of Boc2O in DCM was added dropwise to an 
excess (10 equivalents) of 1,2–diaminoethane 2-19. 
 
Scheme 2.16: Boc protection of 1,2-diaminoethane using a combination of the 
methods published by Keillor et al. and Saari et al.  
 
The product 2-31 was purified using the method of Saari et al.[158] to 
give the product 2-31 in 81% yield. 1H NMR analysis showed a singlet at 1.5 
ppm with a relative integration of nine, indicating the presence of the tert-
butyl group. ESI mass spectrometric analysis gave a peak at m/z 161.13 
corresponding to the [M+H]+ ion of the required product 2-31. 
The protected diamine was then conjugated to the benzyl protected 
catechol unit (Scheme 2.17).  
 
Scheme 2.17: Coupling of the Boc protected 1,2-diaminoethane 2-32 to the activated 
ester of the catechol moiety 
 
To ensure full conversion of the activated ester 2-27, a slight excess of 
the Boc protected diamine 2-31 was used (1.1: 1 molar ratio) and the product 
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2-32 was isolated in quantitative yield. ESI mass spectrometry showed two 
peaks at m/z 477.24 and 499.22 corresponding to the [M+H]+ and [M+Na]+  
ions of the product 2-32. In addition 1H NMR analysis showed a triplet 
resonance at 7.99 ppm, corresponding to the amide proton adjacent to the 
catechol unit. 
The next stage of the synthesis was the removal of the Boc protecting 
group to allow conjugation of the catechol unit to the central citrate. The 
deprotection was first attempted by using a procedure by Han et al.[159].  
 
Scheme 2.18: Attempted deprotection of the Boc protected catechol amine using two 
methods of acid hydrolysis. 
 
After reaction with 4 M HCl in MeOH, 1H NMR spectroscopy showed 
that the resonance at 1.5 ppm of relative integration 9 was absent from the 
spectrum. However, the two singlet resonances of relative integration two at 
5.0 ppm and the multiplet with a relative integration of ten in the aromatic 
region were also absent from the spectrum. This indicated that the acidic 
conditions had removed both the Boc protecting group, and the benzyl 
ethers.  
The reaction was repeated using a reduced reaction time. ESI mass 
spectrometry indicated that the required product 2-28 was present with a 
peak of m/z 377.18. However, the main molecular ion appeared with an m/z 
of 287.14, consistent with one benzyl ether removed, 2-33 and 2-34. An m/z 
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of 197.09 consistent with a fully deprotected product was also present. This 
suggested a mixture of products had been formed (Figure 2.3). 
 
Figure 2.3: Compounds formed from the attempted acid-mediated removal of the Boc 
protecting group  
 
As the benzyl protecting groups on the catechol subunit were sensitive 
to 4 M HCl, a milder set of conditions by Li et al. was used[160]. This method 
used 85% H3PO4 for the deprotection (Scheme 2.18). After three hours, TLC 
analysis of the reaction mixture suggested successful deprotection of the 
amine. After workup ESI mass spectrometry showed formation of 2-28 as a 
peak with m/z 377.18 was observed in the spectrum. However, an m/z of 
499.22 consistent with the [M+Na]+ ion of the starting material was also 
present, 1H NMR analysis showed a singlet at 1.34 ppm with a relative 
integration of nine, confirming that the Boc protecting group was still present. 
The reaction was repeated, extending the reaction time to 24 h. However, the 
result of the reaction was the same.  
A procedure by Duhme et al.[161] coupled the 2,3-bis(benzyloxy)benzoic 
acid unit 2-26 directly to a diamine (Scheme 2.19). As this procedure utilised 
1,4-diaminobutane 2-39, the design of the target molecule was altered 
accordingly to incorporate this change (Figure 2.4). 
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Figure 2.4: Updated target structure incorporating 1,4-diamino butane linker 
 
N,N’-carbonyldiimidazole mediated coupling was used and after work 
up 2-40 was isolated as a white precipitate in 54% yield. Successful 
formation of the product was confirmed by the presence of a peak with m/z 
405.21 in the ESI mass spectrum corresponding to the [M+H]+ ion of 2-40. 
Further confirmation was provided by the presence of a triplet with a relative 
integration of one at chemical shift 8.25 ppm, corresponding to the amide 
proton in the 1H NMR spectrum. 
 
 
Scheme 2.19: Synthesis of benzyl protected aminochelin using the synthesis 
published by Duhme et al.
[161]
 
2.3.2. Synthesis of a protected petrobactin analogue 
2.3.2.1. Attempts at coupling using existing literature procedures 
To prepare the backbone of the analogue, it was decided to use the 
method published by Gardner et al. and Low et al., generating a 
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disuccinimidyl ester of the protected citrate and reacting this with benzyl 
protected aminochelin 2-40 (Scheme 2.4) The reaction was performed as 
described in the literature, on a larger scale[136-137]. 
The first stage of the reaction proceeded as described in the literature, 
with a precipitate of urea being observed. The second phase of the reaction 
was stirred for 24 hours. The reaction mixture was then worked up and 
purified according to the literature procedure[137]. However, analysis by ESI 
mass spectrometry showed that the molecular ion of the expected product at 
m/z = 979.4 was not present. 1H NMR analysis also showed a mixture of 
compounds as there were multiple resonances in the range 4.9 -5.2 ppm, 
where there should only have been two resonances, with relative integration 
four corresponding to the benzyl CH2 groups.  
2.3.2.2. Coupling with HBTU 
The use of HBTU as the coupling agent was investigated (Scheme 
2.20). Formation of 2-41 was confirmed by 1H NMR spectroscopy due to the 
presence of a triplet resonance at 6.84 ppm, with a relative integrations of 
two, corresponding to the amide protons adjacent to the central ci trate. The 
loss of a broad signal at 8.07 ppm corresponding to the NH2 group of 
aminochelin was also observed. In the ESI mass spectrometric analysis, 
peaks with m/z 979.44 and 1001.42 were identified, corresponding to the 
[M+H]+ and [M+Na]+ ions of 2-41. However, there was a problem with the 
synthesis. Although initially promising, close inspection of the 1H NMR 
spectrum showed there was also a singlet resonance at 2.80 ppm which did 
not correspond to anything in the structure of 2-41. Integration of this 
resonance gave a relative integration of twelve, which suggested the impurity 
was a by-product of HBTU, tetramethyl urea[162]. The suggested methods for 
removal of the impurity were washing with H2O or toluene
[163]. Unfortunately, 
the product was also toluene soluble, rendering this method unsuitable. It 
was also attempted to remove the impurity by sonicating the product in H2O, 
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however while this reduced the amount of tetramethyl urea present, it did not 
remove it entirely.  
 
 
Scheme 2.20: Formation of the protected petrobactin analogue 2-41 via a 1) HBTU 
mediated coupling, 2) EDC·HCl mediated coupling 
 
2.3.2.3. Coupling with EDC·HCl and HOBt·H2O 
Due to the difficulties in removing tetramethyl urea from 2-41, an 
alternative method using EDC·HCl/HOBt·H2O was investigated. After 
reaction and workup successful formation of the product 2-41 was confirmed 
by ESI mass spectrometry and 1H NMR spectroscopy. The disadvantage of 
using EDC·HCl and HOBt·H2O is a longer reaction time, and a lower yield of 
41%, however, a pure product was obtained (Scheme 2.20). 
2.3.2.4. NaOH mediated deprotection of 2-41 
The methyl ester of the analogue backbone 2-41 was deprotected using 
the method of Theodorou et al.[164]. The protected analogue 2-41 was 
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dissolved in a 9:1 mixture of DCM: MeOH and the solution adjusted to pH 12 
by the addition of 2 M methanolic NaOH (Scheme 2.21). 
 
Scheme 2.21: Deprotection of the methyl ester on the petrobactin analogue backbone 
using methanolic NaOH in 9:1 DCM: MeOH 
 
After reaction and workup ESI mass spectrometry confirmed successful 
formation of the product. Peaks with m/z 965.43 and 987.41 corresponding to 
the [M+H]+ and [M+Na]+ ions of 2-42 were observed in the spectrum. 
However, there was also a peak at m/z 947.42, which did not correspond to 
2-42. Analysis by 1H NMR spectroscopy showed that the signal with relative 
integration three corresponding to the methyl ester in the protected precursor 
was absent. However, the roofed doublets observed in the  protected 
analogue 2-41 at 2.8 ppm with a relative integration of four were no longer 
symmetrical. This suggested that the central citrate had cyclised via one of 
the amide bonds to form the cyclic succinimide 2-43. Phanstiel et al. and 
Butler et al. reported an imide by-product in their total syntheses of 
petrobactin[122, 137]. However, in the published syntheses, the deprotection of 
the central citrate was an acid catalysed (TFA or HCl) hydrolysis, as opposed 
to base catalysed; therefore it was unlikely the basic conditions (pH 12.0) 
used in the reaction induced the cyclization.  
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Figure 2.5: Structure of the succinimide by-product of the petrobactin analogue 
backbone deprotection.  
 
It is proposed that the cyclization took place during flash 
chromatography purification, due to the acidic nature of the silica and the use 
of formic acid in the solvent system. The reaction was repeated, without the 
use of flash chromatography for product purification. This produced 2-42 as a 
white solid in 83% yield. The 1H NMR spectrum showed successful formation 
of the product with no imide present, confirmed by the symmetrical doublet 
resonances at 2.7 ppm with relative integration four, corresponding to the 
enantiotopic citrate protons. ESI mass spectrometric analysis showed no 
peak with m/z 947.42 corresponding to the succinimide 2-43.  
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2.3.2.5. Hydrogenolysis of protected analogue backbone to give petrobactin 
the analogue 2-44 
 
Scheme 2.22: Hydrogenation of the petrobactin analogue backbone. 
 
The protected siderophore 2-42 was subjected to hydrogenolysis over 
Pd on carbon to remove the benzyl protecting groups. After 24 hours TLC 
analysis showed the reaction was only partially complete. A small amount of 
additional catalyst was added and the reaction was continued. After a further 
24 hours, TLC analysis showed the reaction had reached completion, as only 
one UV active spot was visible. The deprotected product 2-44 was isolated in 
20% yield. Successful formation of 2-44 was confirmed by ESI mass 
spectrometric analysis, where peaks with m/z of 605.24 and 627.22 were 
observed. These corresponded to the [M+H]+ and [M+Na]+ ions of the 
required product 2-44 respectively. 1H NMR spectroscopy showed the loss of 
two signals with relative integration 4 at 5.26 and 5.17 ppm and the loss of a 
multiplet in the aromatic region, confirming removal of the benzyl groups. The 
low yield for the deprotection is most likely due to adsorption of 2-44 onto the 
charcoal component of the catalyst. Charcoal has a high affinity for 
compounds containing aromatic rings[148].  
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2.3.2.6. Coupling of the methyl ester of ciprofloxacin to the analogue 
backbone 
The next stage of the synthesis was to couple the methyl ester of 
ciprofloxacin 2-20 to the benzyl protected analogue backbone 2-42. This was 
performed using an HBTU-mediated coupling (Scheme 2.23). In this case 
the required product 2-45 was recovered as an oil in 65% yield. The 
successful formation of 2-45 was supported by ESI mass spectrometry and 
1H NMR spectroscopy. In the mass spectrum a peak with m/z 1292.49 was 
observed, corresponding to the [M+H]+ ion of 2-45. 1H NMR spectroscopy 
showed the loss of a broad singlet with relative integration one at 1.95 ppm, 
corresponding to the loss of the piperazinyl nitrogen proton. This  provided 
supportive evidence for successful coupling to the analogue backbone.  
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Scheme 2.23: Synthesis of the protected petrobactin-ciprofloxacin conjugate using an 
HBTU mediated coupling 
 
2.3.2.7. Attempted NaOH mediated deprotection of the ciprofloxacin methyl 
ester 
With the conjugate 2-45 synthesised in protected form, deprotection 
was required in order to give 2-46. As the hydroxyl groups in the catechols 
are highly sensitive to oxidation at basic pH, the methyl ester needed to be 
removed first. The conjugate 2-45 was dissolved in 9:1 DCM: MeOH and the 
pH of the solution adjusted to 12 by addition of methanolic NaOH. After 
reaction and workup ESI mass spectrometric analysis of the reaction mixture 
showed that a peak with an m/z of 1278.5 corresponding to the molecular ion 
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of 2-46 was not evident. However, peaks with m/z 965.0 and 346.4 
corresponding to the molecular ion of the analogue backbone 2-42 and the 
methyl ester of ciprofloxacin 2-20 were present. 
 
Scheme 2.24: Attempted NaOH mediated deprotection of the analogue-ciprofloxacin 
conjugate 2-45 
 
1H NMR spectroscopy also suggested that the amide bond in the  
product 2-46 had been cleaved to give 2-42 and 2-20, as a resonance at 1.95 
ppm consistent with the piperazinyl amine of the methyl ester of ciprofloxacin 
2-20 was present. The reason for the breakdown of the product was acid 
hydrolysis. It has been reported that some tertiary amide bonds can be 
susceptible to hydrolysis[165]. As the product was purified by flash 
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chromatography in 9:1:0.1 CHCl3: MeOH: CHOOH, it is likely that the amide 
bond was cleaved by the formic acid used during purification.   
2.3.2.8. Modification of the ciprofloxacin moiety 
In an attempt to increase the yield of the coupling reaction between the 
petrobactin analogue 2-42 and the methyl ester of ciprofloxacin 2-20, it was 
decided to add a glycine spacer to the methyl ester of ciprofloxacin. This 
would provide a primary amine for the coupling reaction with the analogue 
backbone 2-42, which was expected to react more readily than the 
secondary amine in the piperazinyl ring of ciprofloxacin 1-20. Additionally, the 
glycine introduces more space between the antimicrobial and iron binding 
components of the conjugate. The glycine spacer was introduced by coupling 
the methyl ester of ciprofloxacin 2-20 to Boc protected glycine. This required 
compound was synthesised using a EDC·HCl/HOBt·H2O mediated amide 
coupling[117]. After reaction and workup 2-48 was isolated in 68% yield 
(Scheme 2.25).  
ESI mass spectrometric analysis of the product showed two peaks at 
m/z 503.23 and 525.21, corresponding to the [M+H]+ and [M+Na]+ ions of 2-
48. Additionally, 1H NMR spectroscopy showed a singlet resonance at 1.45 
ppm with a relative integration of nine, corresponding to the Boc group, and 
an apparent doublet at 4.33 ppm with a relative integration of two 
corresponding to the CH2 group of glycine. Furthermore, the loss of the 
resonance at 1.95 ppm corresponding to the piperazinyl nitrogen proton of 
ciprofloxacin 1-20 was observed, supporting successful conjugation of the 
linker to form the product 2-48. 
 
Chapter 2: Studies towards the synthesis of a siderophore-
ciprofloxacin conjugate based on petrobactin  
112 
 
 
Scheme 2.25: Preparation of the ciprofloxacin-glycine moiety  
 
To prepare the primary amine salt 2-49, the Boc protecting group was 
removed using acid-mediated hydrolysis, 4 M HCl in MeOH (Scheme 
2.25).The reaction gave 2-49 in 98% yield. The ESI mass spectrum showed 
peaks with m/z of 403.17 and 425.15 corresponding to the [M+H]+ and 
[M+Na]+ adducts of 2-49. Hydrolysis was confirmed by the loss of the 
resonance with relative integration 9 at 1.45 in the 1H NMR spectrum 
corresponding to the tert-butyl group. As a consequence of this modification, 
the structure of target compound was modified accordingly (Figure 2.6) 
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Figure 2.6: Modified petrobactin analogue-ciprofloxacin conjugate with glycine linker  
 
2.3.2.9. Coupling of ciprofloxacin-glycine 2-49 to the petrobactin analogue 
backbone 2-42 
The free amine 2-49 was coupled to the backbone 2-43 using the 
previously described EDC·HCl/HOBt·H2O mediated coupling. After 
purification the product 2-51 was isolated in 45% yield (Scheme 2.26)  
Successful formation of the product was confirmed by ESI mass 
spectrometry, where peaks with m/z 1371.57, corresponding to the [M+Na]+ 
ion, and 697.28, corresponding to the [M+2Na]2+ ion were observed in the 
spectrum. Further evidence was provided by 1H NMR spectroscopy where a 
triplet resonance with a relative integration of one at 6.77 ppm, corresponding 
to the amide proton, was observed. This strongly supported successful 
coupling of the amine to the free carboxylic acid on the backbone.  
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Scheme 2.26: Coupling of cpf-gly 2-49 to the analogue backbone using EDC·HCl and 
HOBt·H2O 
 
2.3.2.10. NaOH mediated deprotection of the petrobactin analogue-
glycine-ciprofloxacin conjugate 2-51 
With the fully protected conjugate 2-51 synthesised, the next step was 
to remove the methyl ester on the carboxylic acid of ciprofloxacin. After 
stirring in 9:1 DCM: MeOH at pH 12.0 overnight, the pH of the solution was 
adjusted to 5.5 using 2 M pyruvic acid in MeOH, before evaporating to 
dryness in vacuo. 
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Scheme 2.27: Attempted NaOH mediated deprotection of conjugate 2-50 using 9:1 
DCM: MeOH 
 
ESI mass spectrometric analysis supported successful formation of 2-
52. A peak at m/z = 1357.55 corresponding to the [M+Na]+ adduct of the 
required product was observed. However, an additional peak  at m/z = 987.39 
corresponding to the [M+Na]+ ion of the free acid backbone 2-42 was also 
observed. This suggested that the amide bond between the glycine linker 
and the central citrate had been partially cleaved, resulting in the 
regeneration of the free acid backbone and the ciprofloxacin-glycine. The 
mechanism of this cleavage is likely to be via a cyclisation, as observed with 
the deprotection of the analogue backbone 2-41. The cyclisation of the 
backbone results in the cleavage of the amide bond and release of 
ciprofloxacin glycine. Upon treatment with base during the work up, the  
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succinimidyl ring reopens to form the sodium salt form of the analogue 
backbone.  
 
Scheme 2.28: Likely mechanism of the cleavage of the citrate amide bond via 
cyclisation and subsequent ring opening to reform the sodium salt of the analogue 
backbone 
 
This cleavage of the amide bond between the central citrate and glycine 
has resulted in the failure to isolate the required compound 2-52 and 
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consequently the failure to obtain the required petrobactin analogue-
ciprofloxacin conjugate 2-50.  
2.4. Conclusions and future work 
In this chapter, the synthesis of a fully protected precursor to a 
siderophore fluoroquinolone Trojan horse has been reported. A procedure 
has been established for the synthesis of a petrobactin-analogue with 2,3-
configured catechols and a shortened backbone. The precursor has been 
prepared both with and without a linker between ciprofloxacin 1-20 and the 
analogue backbone. This precursor has been fully characterised using ESI 
mass spectrometry, 1H NMR, 13C NMR, and IR spectroscopy. 
Attempts to deprotect the conjugate have proved unsuccessful. It has 
been demonstrated, in agreement with previous work performed in the 
group[151], that the conjugate is unstable in the presence of strong acids. The 
bond to the central carboxylic acid of the citrate moiety cleaves, giving free 
ciprofloxacin 1-20 and the sodium salt of the analogue backbone 2-54. 
Future work in this area could involve the deprotection of the conjugate 
to yield the final Trojan horse compound with both its antimicrobial activity 
(via the β-keto acid of ciprofloxacin) and iron binding capacity (via the 
catechol groups) restored. For this to be possible a new protection strategy 
would be required, possibly using a benzyl ether protecting group on 
ciprofloxacin instead of a methyl group, allowing a universal deprotection 
instead of a two step deprotection. In addition, a variety of analogues could 
be prepared. Possibilities include using 3,4-configured catechols to more 
closely mimic the native structure of petrobactin, and varying the length of the 
linker between the central citrate and the catechol amide groups. There is 
also potential to make analogues using alternative fluoroquinolones such as 
norfloxacin. 
Future work should also include the biological evaluation of the Trojan 
horse compound and any analogues prepared. This would involve both disc 
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diffusion assays to determine the general efficacy of the compound against 
specific strains of bacteria, and DNA gyrase assay to determine if the 
compound acts by the same mechanism as the isolated fluoroquinolone 
component. An important aspect of any future work will be determining the 
MIC of the compounds to ascertain if they are active at a clinically useful 
level.  
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3. Investigation into the application of the Ugi 
multicomponent condensation to the Trojan Horse 
strategy 
3.1. Aims 
The aim of the research outlined in this chapter was to enable the 
synthesis of Trojan horse conjugates using the Ugi four component 
condensation, and create a set of building blocks which would form the basis 
of a potential library of Trojan horse conjugates using the fluoroquinolone 
ciprofloxacin.  
3.2. Overview 
3.2.1. Multicomponent reactions 
Synthesising natural products, such as siderophores, can be a complex 
process. The biosynthesis of these compounds is the result of a long 
evolutionary process and involves pathways under enzymatic control. While 
the total chemical synthesis of selected siderophores and other natural 
products has been achieved[122, 166-169], these often involve complex multistep 
syntheses, especially when stereocentres are present in the target molecule. 
Multicomponent condensation (MCC) reactions enable the synthesis of 
complex molecules in a single step. Three or more components are 
combined in a “one pot reaction” to produce a single product. There are two 
key advantages to this approach. The first is multistep syntheses can result 
in low overall yields of the target molecule if each step in the synthesis only 
gives a moderate yield. The second is that using a multicomponent reaction 
allows the rapid synthesis of structurally related compounds in a short space 
of time by varying one or more of the components, an approach exploited in 
combinatorial libraries[170]. A multicomponent condensation reaction (MCR) 
approach would allow the rapid synthesis of structurally related siderophore-
fluoroquinolone conjugates in a minimal number of steps. To demonstrate the 
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application of this methodology, conjugate 3-1 was designed (Figure 3.1), 
incorporating ciprofloxacin 1-18 and a model “siderophore like” component. 
 
Figure 3.1: Structure of the target compound 3-1 
 
3.2.2. Multicomponent condensation reactions 
MCC reactions have been known for at least 160 years. The Strecker 
synthesis, which generates α-amino acids from α-amino cyanides, was 
reported in 1850[171]. The use of isocyanides in MCC reactions was first 
published in 1921 by Passerini (Scheme 3.1). This reaction is a three 
component condensation (M-3CR), using an isocyanide 3-4, a carbonyl 3-3 
and an organic acid 3-2[172]. This reaction provided a one pot synthesis of α-
acyloxycarboxamides.  
 
Scheme 3.1: Overview of the Passerini reaction 
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3.2.3. The Ugi condensation  
The Ugi condensation was first published in 1959 by Ivar Karl Ugi [173]. 
The reaction was similar to the Passerini reaction, but with an additional 
amine component, giving α-aminoacyl amides. The Ugi condensation is a 
stepwise reaction that goes through several intermediates before the final α-
aminoacyl amide compound is formed (Scheme 3.2). The first reversible step 
is an imine formation between the aldehyde and amine component, which is 
then protonated by the organic acid to form an iminium ion. 
 
Scheme 3.2: Components and mechanism of the Ugi four component condensation  
 
Once the iminium ion is formed, the isocyanide attacks the electron 
deficient carbon of the imine to form a new nitrilium containing intermediate. 
The deprotonated acid can then attack the carbon of the isocyanide moiety to 
form the final intermediate. This adduct then undergoes an intramolecular 
1,3(O-N) acyl transfer, known as a Mumm rearrangement (Scheme 3.2). 
This final step is irreversible and gives the Ugi condensation product. A 
recent study by Neto et al. has suggested this step is also rate determining 
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within the reaction. They also determined that the rearrangement is less likely 
to occur in aprotic solvents[174]. Studies have shown that there are a number 
of different factors that influence the Ugi reaction. One key factor is the 
nucleophilicity of the amine, with amines that have reduced nucleophilicity 
resulting in low yields. Ugi condensation reactions have been reported in a 
variety of solvents[175]. The key elements in selecting a solvent are the 
solubility of reagents, polarity and insolubility of the Ugi product[175]. It has 
also been shown that the use of microwave irradiation can facilitate  the 
reaction, particularly when the reaction is performed using a polymer 
supported isocyanide[176]. In 2012 Ostaszewski et al. published studies on an 
enzyme catalysed version of the three component variation of the Ugi 
condensation[177]. There is also scope for added diversity in the Ugi 
condensation, Armstrong and Keating developed a “universal” isocyanide 3-8 
which participates in the Ugi condensation, but can subsequently be reacted 
further using a nucleophile (Figure 3.2)[178].  
 
Figure 3.2: A universal isocyanide developed by Armstrong and Keating  
 
3.2.4. Use of MCCs in the synthesis of bioactive molecules 
In recent years there have been a number of applications of MCCs to 
prepare biologically relevant molecules. The use of MCCs for biological 
applications has been reviewed in detail by Dömling et al. and focuses on the 
use of MCCs to synthesise molecules to target a variety of protein targets [170]. 
This is often done by combining the Ugi condensation in a cascade with other 
reactions e.g. Ugi-Smiles or Ugi-Michael-aza Michael[179].  
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3.2.4.1. The use of MCCs in the synthesis of compounds targeting proteins 
A significant area of research using MCCs is protein inhibitors and there 
are numerous examples of this in the literature, with a variety of different 
protein classes targeted[170]. One example is the synthesis of hydantoin 
based compounds (Figure 3.3)[180]. Torroba et al. synthesised a complex 
hydantoin based structure 3-9 using an Ugi/cyclisation/Ugi sequence. Such 
compounds are useful as hydantoins have shown activity as anti-
convulsants, anti-tumor agents and anti-arthritic drugs[181]. Vacca et al. used 
the Ugi condensation to prepare spiropiperidine iminohydantoins as inhibitors 
of the protein β-secretase[182].  
 
Figure 3.3: Structure of a hydantoin containing structure synthesised by Torroba et 
al.3-9 and a spiropiperidine iminohydantoin by Vacca et al. 3-10.  
 
Multicomponent condensations have also been used to synthesise 
bioactive peptidomimetics through the use of specific building blocks and 
post condensation reactions[183-186]. Cai et al. utilised an Ugi/click reaction to 
generate triazole modified peptidomimetics (Scheme 3.3)[186].  
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Scheme 3.3: Synthesis of a triazole functionalised Ugi product by Cai et al. using a 
tandem Ugi/click reaction
[186]
. 
 
An alternative method was used by Lesma et al. they synthesised 
tryptophan-based peptidomimetics using an Ugi/Pictet-Spengler reaction[183]. 
The synthesis of peptidomimetics in this fashion creates core structures 
which can be further derivatised to generate ligands for different proteins 
(Scheme 3.4). 
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Scheme 3.4: Protected tryptophan-based peptidomimetics synthesised by Lesma et 
al. using an Ugi/Pictet-Spengler reaction 
 
3.2.4.2.  The use of MCC reactions in the synthesis of antimicrobial 
compounds  
The use of MCC reactions in synthesising antimicrobial compounds is 
less well explored than its applications for the synthesis compounds for 
protein based drug targets. Sureshbabu et al. utilised an Ugi condensation to 
prepare β-lactams, using chiral Nβ-Fmoc amino alkyl isonitriles[185]. 
Additionally, they utilised amino acids to incorporate both the amine and 
carboxylic acid functionalities in a single component. 
 
Scheme 3.5: Example of a β-lactam synthesised utilising the Ugi condensation  
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Scheme 3.6: General mechanism for the formation of β-lactams using the Ugi 
condensation 
  
Shiskin et al. used an azido-Ugi condensation, followed by cyclization to 
form spyrocyclic γ-lactams. This particular methodology utilises an oxo ester 
and as the aldehyde component and an azide in place of the carboxylic acid 
(Figure 3.4)[187].  
 
Figure 3.4: Example of a tetrazole substituted spirocyclic γ-lactam 3-43 synthesised 
by Shiskin et al. 
 
MCC reactions have also been successfully used to synthesise peptide 
containing antibiotics. Ichikawa et al. used an Ugi MCC to synthesise the 
antimicrobial pacidamycin 3-44 and its 3’-hydroxy analogue 3-45 (Figure 
3.5).  
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Figure 3.5: Pacidamycin (3-44) and its 3’-hydroxyl analogue (3-45) synthesised by 
Ichikawa et al.  
 
The use of MCC reactions to generate compounds which target specific 
proteins also has applications in generating antimicrobials. Larhed et al. 
synthesised 3-aminoimidazo[1,2-a]pyridines as glutamine synthetase 
inhibitors[188] (Figure 3.6). Nenajdenko et al. published N-acetyl cysteine and 
glutathione compounds synthesised using the Ugi condensation. These 
compounds could have potential use as inhibitors of the bacterial malonyl 
CoA transferase[189].  
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Figure 3.6: 3-Aminoimidazo[1,2-α]pyridines (3-46 and 3-47) synthesised by Larhed et 
al.
[188]
 and N-acetyl cysteine 3-48 and glutathione 3-49 derivatives synthesised by 
Nenajdenko et al.
[189]
 
 
A similar use of MCC reactions in medicine is in the synthesis of anti -
viral compounds and anti-parasitical compounds. Torrence et al. published a 
series of nucleoside derivatives prepared using the Ugi reaction, with the 
intention of developing antivirals for the smallpox virus (Figure 3.7). A 
number showed promising activity against the parasite Leishmania 
donovani[190].  
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Figure 3.7: Nucleoside (5-formyl-2'-deoxyuridine-3',5’-diacetate) derivates formed 
using the Ugi condensation by Torrence et al.
[190]
 
 
Chibale et al. have also exploited multicomponent condensations to 
develop anti-parasitic compounds, specifically anti-malarial drugs. Using the 
Ugi condensation they were able to develop novel 4 -aminoquinoline 
compounds with activity against both chloroquine susceptible and resistant 
strains of Plasmodium falciparum [191].  
 
Figure 3.8: Examples of 4-aminoquinoline compounds synthesised by Chibale et 
al.
[191]
 
 
Although there are several examples of the Ugi condensation being 
used to synthesise antimicrobial compounds, as of yet there is no precedent 
for using multicomponent condensations in the synthesis of Trojan horses. 
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This research seeks to establish the principle of synthesising Trojan horses 
in a multicomponent reaction by using a known antimicrobial as one of the 
reaction components.  
. 
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3.3. Results and discussion 
3.3.1. Synthesis of the protected conjugate 3-56 using the Ugi 
condensation 
The Ugi condensation requires an amine component and ciprofloxacin 
was a logical choice due to the secondary amine in the piperazinyl ring. 
However, as a primary amine could be expected to be more reactive, it was 
decided to introduce a primary amine via glycine linked ciprofloxacin 3-56[151].  
 
Scheme 3.7: Components and structure of the target Ugi conjugate 3-1.  
 
Commercially available cyclohexylisocyanide 3-55 was used as the 
isocyanide component, 2,3-dihydroxybenzaldehyde 2-18 (chapter 2) and 2,3-
dihydroxy benzoic acid 3-54 were selected as the aldehyde and acid 
components, respectively. The ciprofloxacin glycine moiety 2-49 was 
synthesised as previously described (chapter 2).  
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The reaction was initially performed using 2,3 -
bis(benzyloxy)benzaldehyde 2-25, 2,3-bis(benzyloxy)benzoic acid 2-26, 
cyclohexyl isocyanide  3-55, and the methyl ester of glycine-ciprofloxacin 2-
49, following the method of Marcacinni and Torroba [175]. This involved 
reacting 2-25 with 2-49, then once the imine had formed adding 2-26 and 3-
54 in quick succession. After 24 hours the reaction mixture was evaporated 
to dryness in vacuo. The residual solid was analysed by ESI mass 
spectrometry and 1H NMR spectroscopy, which suggested that some product 
was present.  
The imine formation did not appear to be proceeding efficiently in the 
reaction. The synthesis was subsequently modified to isolate the imine 
intermediate 3-57 (Scheme 3.8). 2,3-bis(Benzyloxy)benzaldehyde 2-25 was 
reacted with the hydrochloride salt of 2-49 in MeOH. Two equivalents of 
DIPEA were added and after 18 hours 3-57 was isolated by filtration in 71% 
yield.  
 
Scheme 3.8: Synthesis of the imine intermediate 3-57 for the Ugi condensation using 
ciprofloxacin glycine 2-49  and 2,3-bis(benzyloxy)benzaldehyde 2-25 in MeOH 
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1H NMR spectroscopic analysis supported the successful formation of 3-
57 with a singlet with a relative integration of one at 8.59 ppm, present in the 
spectrum. This signal corresponded to the imine proton in 3-57. ESI mass 
spectrometric analysis showed a peak with m/z of 703.29 corresponding to 
the [M+H]+ ion of 3-57. Peaks corresponding to starting materials were also 
observed in the ESI mass spectrum. However, there were no signals 
corresponding to the free amine of 2-49 or the aldehyde proton of 2-25 in the 
1H NMR, which suggests that any unreacted starting materials were present 
at a level below NMR detection limits. 
Having successfully prepared imine 3-57, it was then reacted with 2,3-
bis(benzyloxy)benzoic acid 2-26 and cyclohexylisocyanide 3-54. After 30 
hours at room temperature the formation of a precipitate was observed, 
which was isolated by filtration. Analysis of the precipitate by ESI mass 
spectrometry confirmed the presence of the product, as a peak with m/z of 
1146.50 corresponding to the [M+H]+ ion of 3-58 was observed in the 
spectrum However, 1H NMR spectroscopic analysis showed a significant 
number of impurities.  
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Scheme 3.9: Comparison of the initial attempts at synthesising Ugi conjugate 3-58, 
generating the imine intermediate in situ, and generating and isolating the imine 
before proceeding with the reaction.  
 
It was apparent that the Ugi reactions were not proceeding efficiently to 
the final product, with only a limited amount of product that had undergone 
the irreversible Mumm rearrangement detected[172, 175, 192]. Both methods 
(Scheme 3.9) resulted in a mixture of 3-58 and unreacted starting material. It 
was therefore decided to attempt the synthesis using microwave irradiation. 
Barreto et al. established that multicomponent reactions can be performed 
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under microwave irradiation, applying the technology to both the Ugi [193] and 
Passerini[194] reactions. Andreana and Santra have also demonstrated the 
use of microwave-assisted synthesis in Ugi condensation chemistry[195]. 
The microwave conditions used for our Ugi chemistry were a 
temperature of 90 °C at 50 W for 60 min. Using microwave irradiation 
appeared to improve the crude yield of 3-58, with an increase from 60% to 
80% observed. Column chromatography in 12:1 DCM was used to purify 3-
58. This resulted in the successful isolation of pure 3-58 in 38% yield. Mass 
spectrometric analysis showed an m/z peak of 1146.50, corresponding to the 
[M+H]+ ion of 3-58. However the 1H NMR spectrum was more complex than 
expected (Figure 3.9). 
1H NMR analysis suggested multiple species were present in solution. 
For example, where there should be four singlet resonances with relative 
integration two at approximately 5 ppm, corresponding to four sets of benzyl 
CH2 groups, there is a convoluted multiplet, suggesting several species. The 
resonance at 4.03 ppm in the spectrum of 2-49, which corresponds to the 
glycine CH2 group, appeared as a pair of roofed doublets instead of a singlet, 
suggesting that those protons were now diastereotopic.   
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Figure 3.9: H NMR spectrum of 3-58 with key signals identified 
 
In order to analyse why the 1H NMR spectrum of 3-58 was complex, a 
3D structure was generated using Chemdraw 3D pro 7.0. Examination of the 
3D structure of suggested that the complex 1H NMR spectra could be due to 
rotamers about the amide bonds within the structure. 1H NMR analysis 
suggested multiple species were present in solution. Additionally, the 3D 
structure showed that the close proximity of the benzyl protecting groups to 
the cyclohexyl groups could result in hindered rotation. 
In order to investigate if rotamers were responsible for the complex 
NMR spectrum, 3-58 was dissolved in d6-DMSO and variable temperature 
500 MHz 1H NMRs were recorded at 298 K, then heating to 383 K, and 
lowering the temperature back to 298 K. (Figure 3.10). In the high 
temperature spectrum the resonances in the aromatic region and the CH2 
resonances due to the benzyl groups became more resolved.  
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Figure 3.10: Variable temperature 
1
H NMR spectra A) full spectrum B) resonances 
corresponding to the benzyl CH2 groups of 3-58. Blue spectra T=298 K, Green spectra 
T= 383 K 
 
These spectra support the theory that rotamers are present in 3-58, 
providing evidence that, in spite of a complex 1H NMR spectrum, the Ugi 
reaction was successful. 
3.3.2. Hydroxide-mediated deprotection of the conjugate 3-58 
With the protected conjugate 3-58 in hand deprotection of the 
carboxylate functionality was investigated. The protected conjugate 3-58 was 
insoluble in hydrophilic solvents: therefore our established hydroxide-
B) 
A) 
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mediated deprotection was not viable. A deprotection strategy which utilised 
a two phase system was investigated[164]. Conjugate 3-58 was dissolved in a 
9:1 DCM: MeOH and three molar equivalents of methanolic NaOH were 
added (Scheme 3.10). After 18 hours the reaction mixture was evaporated to 
dryness in vacuo. Analysis of the crude residue by TLC and ESI mass 
spectrometry confirmed the presence of the free carboxylate 3-59. This was 
further supported by 1H NMR, as the 3H singlet at 3.76 ppm due to the 
methyl ester was absent from the spectrum. 
 
Scheme 3.10: Hydrolysis of the methyl ester using the method of Theodorou et al.
[164]
 
 
The reaction was repeated, followed by an acidification to pH 5 to 
ensure the free acid of 3-59 was obtained rather than the sodium salt. The 
solution was then evaporated to dryness under reduced pressure to yield an 
orange solid. The solid residue  was redissolved in DCM, washed with brine 
and the organic solvent removed in vacuo, yielding 3-59 in 58% yield.  
3.3.3. Hydrogenolysis of the conjugate 3-59 
The final stage in the synthesis was to remove the benzyl ether 
protecting groups on the catechol units. This was performed by 
hydrogenolysis using a palladium catalyst (Scheme 3.11).  
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Scheme 3.11: Removal of the benzyl ether protecting groups by hydrogenation using 
a palladium black catalyst 
 
The palladium catalyst chosen was palladium black. It had previously 
been shown that compounds containing ciprofloxacin 1-18 gave low yields 
and poor mass recovery when deprotected by hydrogenolysis using 
palladium on charcoal. The poor mass recovery was due to absorption of 
either the starting material or the product onto the catalyst surface [148]. 
Conjugate 3-59 was dissolved in DMF and a catalytic amount of palladium 
black was added. The resultant suspension was stirred under H2 at 50 atm. 
After 24 hours the reaction was examined. TLC analysis suggested partial 
deprotection, as a spot corresponding to a new species was observed along 
with starting material. Additional catalyst was added, and the reaction stirred 
under H2 for a further 24 hours. After work up, 3-1 was isolated in 99% yield. 
ESI mass spectrometric analysis supported the presence of 3-1 with a peak 
at m/z 772.29 corresponding to the [M+H]+ ion of 3-1, observed in the 
spectrum. 1H NMR confirmed the successful removal of the benzyl ethers as 
the complex resonances at ~5.0 ppm due to the CH2 groups of the benzyl 
moieties were absent. However despite the successful hydrogenolysis of 3-1 
the 1H NMR spectrum was still complex than expected, suggesting rotamers 
were still present in 3-1 
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LC-MS analysis was performed using a gradient elution and detection 
at 280 nm. The starting solvent system was 9:1 H2O:MeCN, increasing to 
45:55 H2O: MeCN after 20 minutes, then to 1:4 H2O:MeCN after 25 minutes. 
One strong peak with a small shoulder was observed in the chromatographic 
trace (Figure 3.10). Upon examination of the mass spectrum of each peak, it 
was found that both main peak and the shoulder region contained MS peaks 
with m/z values that could be assigned to the same chemical species. This 
suggests that there is still an issue with hindered rotation, even once the 
product is fully deprotected, and the two overlapping bands observed in the 
LC trace were rotameric forms of 3-1.  
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Figure 3.11: A) UV trace (280 nm) from the LC-MS column with expanded view of the 
detected peak inset, B) Mass spectral trace from main peak (taken at 22.7 minutes), 
C) Mass spectral trace from the shoulder (taken at 22.8 minutes) 
 
The purity of the product was assessed by HPLC analysis using a 
reverse phase column (Figure 3.12). The product gave a single elution peak 
C) 
B) 
A) 
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using a gradient solvent system with MeCN as the organic phase and a 
phosphate buffer as the aqueous phase[196]. The gradient started with 0.1% 
organic phase, 99.9% aqueous phase. After five minutes the gradient was 
gradually increased to 0.5% organic. After a further five minutes, the gradient 
was increased to reach 20% organic after 20 minutes. After 24 minutes the 
gradient was set to 50% organic and slowly increased to 80% organic to flush 
the column. After 20 minutes, the gradient was returned to 0.1% organic 
phase to re-equilibrate the column. 
 Compound 3-1 was determined to be 98% pure by HPLC, however the 
rapid elution, raised questions as to the accuracy of the measurement. 
However, based on the LC-MS and HPLC results, conjugate 3-1 was 
sufficiently pure to allow biological screening. 
 
Figure 3.12: HPLC trace of the 2,3-2,3-configured Ugi conjugate 3-1 in 
aqueous/acetonitrile, detection at 280 nm. 
 
A qualitative solubility screen was undertaken on 3-1. It was noted that 
3-1 had limited solubility in organic solvents including DCM and MeOH. The 
compound was only readily soluble in DMF. However its solubility was 
sufficient in DMSO for 1H NMR spectroscopic analysis, and MeCN for HPLC 
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analysis. The solubility in DMSO was also sufficient to allow biological 
screening.  
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3.4. Screening of the Ugi conjugate 3-1 
3.4.1. Screening against E. coli on LB and M9 agar 
The antibacterial activity of the conjugate was assessed using a 
variation of a disc diffusion assay[118]. The key difference was that rather than 
using a disc impregnated with the compound, 3 µL of the solution was 
pipetted directly onto the agar plate. The compound was screened against E. 
coli BW25113 using ciprofloxacin 1-18 as a standard. The highest 
concentration used was 3.02 mM (equivalent to 1 mg/mL of ciprofloxacin 1-
18), and a 1 in 5 dilution series was prepared with four further concentrations 
(minimum 4.8 µM). Four plates were run concurrently, two plates using 
standard LB nutrient agar, and two using an M9 minimal agar (Chapter 7). In 
each plate both compounds were run in duplicate, allowing for four sets of 
data for each compound. The plates were spotted with ciprofloxacin 1-18 and 
conjugate 3-1 and grown overnight at 37°C. The plates were analysed and 
the radii of the zones of inhibition were measured (Figure 3.13). The data 
indicates that compound 3-1 is active against wild type E. coli. However, the 
antimicrobial efficacy was approximately 50% of that demonstrated by 
ciprofloxacin 1-18 at the same concentration. This was consistent with other 
ciprofloxacin conjugates reported[117-118]. It is proposed that a bulky 
substituent conjugated via the piperazinyl ring of ciprofloxacin 1-18 inhibits 
the  ability of 3-1 to form the required dimer in the DNA replication complex[45-
46]. This theory was further explored using a DNA gyrase assay.  
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Figure 3.13: Plots of radii of inhibition for the Ugi conjugate 3-1 (light green) with a 
ciprofloxacin 1-18 control (dark green) on A) LB and B) M9 media. The experiments 
were performed in triplicate. Error bars represent ± one standard deviation from the 
mean.  
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3.4.2. DNA gyrase assay 
While the zone of inhibition assay confirmed that the Ugi Trojan horse 
conjugate 3-1 was active against wild type E. coli, it did not prove that the 
ciprofloxacin moiety in the compound was the pharmacologically active 
component. To confirm this, a DNA gyrase assay was performed to ascertain 
if the compound inhibited the supercoiling of DNA by the gyrase protein. The 
assay involved incubating relaxed DNA with gyrase and the conjugate, at 
37°C for 30 minutes, then separating the samples using electrophoresis on 
an agarose gel. Supercoiled and relaxed DNA run at different rates on the gel 
and so can be visualised as two separate bands after staining with ethidium 
bromide. A compound inhibiting DNA gyrase will give a result that shows high 
levels of relaxed DNA with relatively little supercoiling. Conversely an inactive 
compound, or one with lower activity, wi ll show the opposite. 
Initially, the assay used ciprofloxacin 1-18 over a range of 
concentrations ranging from 10 µM-0.1 µM, with two controls (no 
ciprofloxacin, no gyrase). After electrophoresis, the stained gel indicated a 
clear decrease in inhibition of DNA gyrase with decreasing concentration. 
The assay was repeated with both ciprofloxacin and the conjugate 3-1 over 
the same concentration range (Figure 3.14).  
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Figure 3.14: DNA gyrase supercoiling assay of A) ciprofloxacin 1-18 and B) the Ugi 
conjugate 3-1 with concentrations ranging from 10-0.5 µM. + = positive control, DNA 
gyrase present without the antimicrobial. − = negative control, no DNA gyrase or 
antimicrobial.  
 
The assay showed ciprofloxacin acting on the DNA gyrase down to a 
concentration of 1 µM. This provides a reference point for comparing the 
activity of 3-1. At 5 and 10 µM, there is evidence of some relaxed DNA. 
However, this may be due to the small amount of nicked DNA present in all 
the samples. A second assay was performed, using the conjugate 3-1 over a 
wider range of concentrations, from 200-1 µM. The resultant gel indicated 
that there was significant inhibition of DNA gyrase at higher concentrations 
(Figure 3.15) 
B) 
A) 
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Figure 3.15: DNA supercoiling assay of the Ugi conjugate 3-1 with concentrations 
ranging from 200-1 µM. + = positive control, DNA gyrase present without the 
antimicrobial. − = negative control, no DNA gyrase or antimicrobial.  
 
From the assay, an approximate MIC value can be elucidated, with a 
gradual, visible increase in activity with increasing concentration. The data 
shows that the MIC required for activity of 3-1 is between 10-20 µM, and the 
MIC for 100% inhibition is demonstrated to be 100 µM. This data supports 
the MIC value suggested by the zone of inhibition assay, where the lowest 
concentration that resulted in killing was 120 µM. The fact that the MIC for 
partial gyrase inhibition is lower than this value is due to the nature of the two 
assays. In the zone of inhibition assay the conjugate has to enter the cell and 
pass both the outer membrane and cytoplasmic membrane to reach its 
target, whereas in the DNA gyrase assay the compound is delivered directly 
to the gyrase. In this situation the ability to bind DNA gyrase is the key to 
activity and subsequently the observed activity is higher than that observed 
when using live bacterial cells. The biological data demonstrates that the 
B) 
A) 
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conjugate 3-1 is active as an antimicrobial compound; however its activity is 
significantly lower than the parent antimicrobial ciprofloxacin, due to steric 
hindrance of binding. Additionally it can be concluded from the difference in 
MIC between the two different assays; that reduced uptake of the  conjugate 
is a factor in the lack of activity relative to the parent drug ciprofloxacin, but 
not as significant a factor as the inhibition of binding caused by steric 
hindrance.  
3.5. Towards the synthesis of alternative siderophore-
ciprofloxacin conjugates using the Ugi MCC 
In conjugate 3-1 (Figure 3.16), there is only one atom between the two 
catecholamides, the minimum number of atoms between binding groups 
required for 1:1 complexation of iron is four, consequently 3-1 theoretically 
cannot form a 1:1 complex with iron. Chelators with short inflexible linkers 
favour the formation of binuclear complexes[197]. 
 
Figure 3.16: Structure of the Ugi conjugate 3-1 
 
Consequently, 3-1 is likely to form complexes with a 3:2 ligand:metal 
stoichiometry or 2:2 dimers. This would be problematic, as dimers and 3:2 
complexes of 3-1 would have a molecular weight of over 1500 Daltons. As 
such, a complex would be more than double the size of a natural siderophore 
Fe(III) complex. It would be too large for siderophore transporters to 
accommodate. Consequently new analogues were designed to allow for 
greater flexibility and an increased distance between the iron binding 
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catechol groups. In addition, there are also alternative iron binding groups 
such as carboxylates which could be utilised in this synthesis. 
3.5.1. Alternative iron binding groups 
There are several examples of catechol siderophores with 2,3-
dihydroxybenzoic acid groups such as bacillibactin 2-3 and enterobactin 1-34 
(Figure 1.16 and figure 2.1)[125, 198], and also a number of citrate 
(carboxylate) based siderophores[199-200]. The Ugi condensation allows the 
use of catechols with different hydroxyl configurations or combining 
catecholate and citrate binding groups in a single molecule, similar to 
petrobactin[74] (see chapter 2).  
 
Figure 3.17: Structures of potential Ugi conjugates with alternative iron binding 
groups. 
 
3.5.1.1. Synthesis of alternative iron chelating components 
A citrate component had been synthesised in the development of a 
petrobactin analogue (Chapter 2)[122]. It was decided to also prepare 
precursors that would allow the incorporation of 3,4-dihydroxybenzoic acid 
units into an Ugi MCC synthesised conjugate. The protected 3,4-
bis(benzyloxy)benzaldehyde 3-65 and benzoic acid 3-66 precursors were 
prepared using the method of Rastetter et al. and Chimiak et al.[138, 153] 
(Chapter 2). 
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Scheme 3.12: Synthesis of 3,4-bis (benzyloxy)benzaldehyde 3-65 and oxidation to the 
corresponding benzoic acid 3-66 
 
In a small scale reaction the aldehyde 3-65 was obtained in 62% yield, 
and subsequently oxidised to the carboxylic acid 3-66 in 84% yield, (Scheme 
3.12). The citrate component, 1,5-dimethyl citrate 2-21 was synthesised as 
previously described (chapter 2) using the method of Hirota et al.[149].  
3.5.1.2. Acid components with flexible linkers 
Introducing a longer flexible linker between the carboxylic acid and the 
catechol units could modify the acid component of the Ugi MCC. This could 
also potentially reduce the hindered rotation seen which in 3-58 made 
analysis by 1H NMR complex.  
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Figure 3.18: Two acid components for the Ugi condensation with pentyl 3-67 and 
hexyl 3-68 linkers, and the expected final structure of the condensation products 3-69 
and 3-70 
 
It was decided to use two different aminated acids to generate linkers: 
5-aminopentanoic acid 3-71, and 6-aminohexanoic acid (Figure 3.18). The 
carboxylic acid of 5-aminopentanoic acid was protected using the same 
method used to protect the free carboxylic acid of ciprofloxacin 1-18 
(Scheme 3.13)[117]. However the purification utilised a protocol specifically for 
the methyl ester of 5-aminopentanoic acid 3-72[201], which gave the 
hydrochloride salt of 3-72 in 99% yield. The identity of the product was 
confirmed by an m/z peak of 132.1 in the ESI mass spectrum, corresponding 
to the [M+H]+ ion of the required product 3-72. A resonance at 3.67 ppm with 
a relative integration of three was present in the 1H NMR spectrum. This 
supported the presence of the methyl ester. 6-aminohexanoic acid methyl 
ester was supplied commercially as the hydrochloride salt 3-73.  
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Scheme 3.13: Synthetic route to a catechol based carboxylic acid component with a 
pentyl linker. The hexyl linker was purchased as the methyl ester.  
 
Both linkers were then coupled to 2,3-bis(benzyloxy)benzoic acid 2-26. 
The coupling reaction was performed using the same amide coupling method 
as previously described[117]. The reactions were followed by TLC analysis. 
When the starting materials had been consumed, reaction mixtures were 
concentrated in vacuo and purified using flash chromatography. The hexyl 
linker 3-75 in 5:1 EtOAc: Pet. Ether, the pentyl linker 3-74 in 1:1 EtOAc: Pet. 
Ether. ESI mass spectrometry supported the successful formation of the 
pentyl linker 3-74, as a peak with m/z 448.2 corresponding to the [M+H]+ ion 
of the product 3-74 was observed in the spectrum. The 1H NMR spectrum 
showed singlet resonances at 5.16 ppm and 5.09 ppm with relative 
integration of two corresponding to the benzyl CH2 groups, a singlet 
resonance at 3.65 ppm with relative integration of three corresponding to the 
methyl ester and a triplet resonance at 7.97 ppm with relative integration of 
one corresponding to the amide proton. Formation of the hexyl linker 3-75 
was supported by peaks of m/z 462.2 and 484.2 in the ESI mass spectrum, 
corresponding to the [M+H]+ and [M+Na]+ ions of 3-75 respectively. 1H NMR 
analysis of 3-75 revealed the presence of the appropriate resonances at 4.9 
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and 5.1 ppm (benzyl CH2 groups) and 3.57 ppm (methyl ester) with relative 
integrations of two, two and three respectively. This supported the formation 
of the product 3-75. The pentyl linked 3-74 was isolated in 83% yield, and the 
hexyl linked product 3-75 in 92% yield.  
The hexyl linker 3-75 was then deprotected to give 3-77 in 72% yield. 
The successful formation of the product was supported by two peaks with 
m/z of 448.2 and 470.2 in the ESI mass spectrum, corresponding to the 
[M+H]+ and [M+Na]+ ions of 3-77 respectively. In addition, the resonance of 
relative integration three at 3.57 ppm corresponding to the methyl ester was 
absent from the 1H NMR spectrum The pentyl linked compound 3-74 was 
deprotected to give 3-76 in 68% yield. Successful deprotection was 
confirmed by ESI mass spectrometry where peaks with m/z of 462.25 and 
484.21 were observed, corresponding to the proton and sodium adducts of 3-
76 respectively. In the 1H NMR spectrum, the singlet resonance with a 
relative integration of three at 3.65 ppm, corresponding to the methyl ester, 
was absent.  
3.5.1.3. Rearrangement of functional groups 
A second approach to prepare more flexible Ugi MCC synthesised 
conjugates is to alter the spatial arrangement of the components within the 
conjugate. It was decided to convert the ciprofloxacin amine to an acid 
component, and one of the catechol binding groups to an amine. (Figure 
3.19) 2,3-bis(benzyloxy)benzoic acid 2-26 was reacted with 1,4-
diaminobutane 2-40 as previously described (Chapter 2) to create the HCl 
salt of aminochelin 2-41[161]. The methyl ester of ciprofloxacin was reacted 
with glutaric anhydride 3-80 to generate an acid functionalised linker 3-78 in 
99% yield (Scheme 3.14). 
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Figure 3.19: Structure of alternative acid and amine components for the Ugi 
condensation.  
 
 
Scheme 3.14: Conjugation of an extended acid functionalised alkyl linker to the 
piperazinyl nitrogen of the methyl ester of ciprofloxacin  
 
The formation of 3-78 was confirmed by ESI mass spectrometry and 1H 
NMR spectroscopy. ESI mass spectrometry showed a peak at m/z 460.18, 
corresponding to the [M+H]+ molecular ion of 3-78. The 1H NMR spectrum 
showed the resonance with a relative integration of one at 1.95 ppm was 
absent, confirming successful coupling to the piperazinyl nitrogen. 
Aminochelin 2-40 was reacted with 2,3-bis(benzyloxy)benzaldehyde 2-
25 to produce imine 3-80 (Scheme 3.15). Aminochelin 2-40 and 2,3-
bis(benzyloxy)benzaldehyde 2-25 were suspended in anhydrous EtOH, and 
two molar equivalents of DIPEA added. After 18 hours stirring, a white 
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precipitate was observed. This was isolated by filtration giving 3-80 in 84% 
yield 
 
Scheme 3.15: Synthesis of an imine intermediate 3-81 for an Ugi conjugate with a 
catechol based moiety as the amine component  
 
Product formation was supported by ESI mass spectrometry and 1H 
NMR analysis. The ESI mass spectrum contained peaks of m/z 705.3 and 
727.3, corresponding to the [M+H]+ and [M+Na]+ ions of 3-81 respectively. 1H 
NMR showed a singlet with relative integration one at 8.42 ppm, 
corresponding to the CH proton of the imine. A similar reaction was 
attempted using aminochelin with the protected version of the 3,4-(bis) 
benzyloxy benzaldehyde 3-66. However, the reaction only proceeded in 10% 
yield and was not pursued further. With new building blocks successfully 
synthesised, future work can now be pursued preparing Ugi MCC conjugates 
with a variety of binding groups and varying linker lengths.   
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3.6. Summary, conclusions and future work 
In summary, a novel Trojan horse antimicrobial compound has been 
synthesised from four components using the Ugi condensation. The 
compound contains two iron chelating groups and ciprofloxacin as the 
antimicrobial component. The compound has been characterised using 1H 
NMR, IR spectroscopy and ESI mass spectrometry, with its purity assessed 
using HPLC. The antimicrobial activity has been assessed using a disc 
diffusion assay on nutrient rich and minimal media. The compound has been 
found to possess antimicrobial activity against E. coli, albeit at a lower level 
than the parent antimicrobial ciprofloxacin, which was used as the control. A 
DNA gyrase binding assay indicated that the compound acts in the same way 
as ciprofloxacin by inhibiting the action of DNA gyrase. 
In addition, a number of building blocks have been synthesised with the 
potential to give alternative Trojan horse conjugates using the Ugi 
condensation. These include acid and aldehyde components with alternative 
iron binding groups, specifically citrate and 3,4-dihydroxybenzoic acid. 
Components have also been prepared containing alkyl linkers to act as 
precursors for more flexible Ugi conjugates with greater intramolecular 
distance between iron binding groups. This was achieved by conjugating 
amino acids to an existing acid component, and also by using an amine 
component for an iron binding group and using glutaric anhydride to convert 
the antimicrobial amine component to an acid component. 
Future work in this area could be to see how effectively the proposed 
precursors can be employed in the Ugi condensation, and how effective the 
new Trojan horse conjugates are as antimicrobials. The proposed, more 
flexible, compounds may have limited activity due to their increased size, 
which may make them less likely to be taken up by bacteria. Additionally, 
further work could be performed to investigate the limits of the synthesised 
compound in terms of its spectrum of activity, and investigations could be 
carried out using iron transport E. coli mutants to probe whether or not the 
compound is actively transported. 
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4. Synthesis and biological evaluation of 
tetradentate catechol based ligands 
4.1. Aims 
The primary aim of the research in this chapter was to prepare a series 
of tetradentate bis-catecholate ligands with alkyl linkers of varying length. 
The secondary aim was to assess the stability and biological activity of the 
ligands with a view to using them as metal-chelating antibacterial agents, or 
as a means to smuggle cytotoxic metals into bacterial cells.  
4.2. Introduction 
4.2.1. Tetradentate ligands for the formation of metal complexes 
The use of tetradentate ligands as metal chelators has been studied 
extensively in recent years, specifically their ability to self-assemble 
supramolecuar structures[202]. Tetradentate ligands, composed of two 
bidentate ligands joined via a spacer, have been shown to form bi-nuclear 
helical structures (Figure 4.1) with a variety of metal ions including gallium, 
titanium, copper and molybdenum[197, 203-204].  
 
Figure 4.1: Schematic representation of double and triple stranded dinuclear helicates  
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The earliest example of the formation of helicates using tetradentate 
ligands was published by Lehn et al. They demonstrated the formation of 
double stranded helicates using a tetradentate bipyridine ligand (Figure 
4.2)[204] . Subsequent work by Lehn also demonstrated the formation of tri 
nuclear double and triple stranded helicates using oligobypridine ligands [205].  
 
Figure 4.2: Bipyridine ligand synthesied by Lehn et al. 
 
4.2.1.1. Tetradentate catecholamide ligands 
The work of Lehn et al. has subsequently been built on by several 
groups to investigate the complexes of bis-catecholate ligands. Raymond et 
al. had already investigated the use of catecholamide based compounds for 
the sequestration of actinides, which included the early LICAMs (Figure 
4.3)[206] 
 
Figure 4.3: Structure of the first LICAM ligands by Raymond. 
 
In subsequent work Raymond produced catecholamide based ligands 
capable of forming 1:1 complexes with oxovanadium[207]. Duhme et al. 
produced similar mononuclear complexes using analogues of the 
Azotobacter vinelandii siderophore azotochelin (Figure 4.4). By mimicking a 
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natural siderophore they were able to prepare 1:1 complexes of 
dioxomolybdenum using their ligands[203, 208].  
 
Figure 4.4: Bis-catecholamide ligands based on the A. vinelandii siderophore 
azotochelin (4-5) 
 
 Stack et al. demonstrated the formation of dinuclear complexes and 
triple helices using simple catecholamide ligands. These were based on 
alkane linkers, similar to ligands synthesised by Raymond designed for 
sequestering actinides (Figure 4.5)[206, 209-210]  
 
Figure 4.5: Alkyl linked bis-catecholamides synthesised by Stack et al. with ethyl 4-8 
and propyl 4-9, 4-10 and 4-11 spacers 
 
Stack demonstrated that the ethyl ligand 4-8 could form both dinuclear 
triple helices and 2:2 complexes with ferric iron. When using gallium with the 
propyl ligand 4-9 they observed only two species: free ligand and a 3:2 
complex. Additionally, by using modified, chiral analogues 4-10 and 4-11, 
they found that they could produce helicates stereoselectively. Subsequently 
Raymond et al. designed a series of rigid aryl linked bis-catecholate ligands 
(Figure 4.6), and successfully prepared discrete dinuclear helical complexes 
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using both gallium and iron[211-213]. Additionally, Raymond et al observed that 
if a mixture of their aryl linked ligands was reacted with Gallium 
acetylacetonate (Ga acac), rather than obtaining a range of mixed ligand 
complexes, they obtained three discrete helicates containing only one type of 
ligand[213]. Another key conclusion that has been drawn from the study of this 
type of ligand is that linker length is critical in the formation of the ligand-
metal complexes. Specifically, a linker length of four atoms or less between 
the amides prevents the formation of 1:1 complexes and consequently 
favours the formation of 2:2 dimers, and 3:2 helicates. Duhme et al. and 
Raymond et al. both demonstrated that linkers with five atoms or more 
between the amide functionality were capable of co-ordinating to metal ions 
in a 1:1 ratio in tetradentate fashion[203, 207]. 
 
Figure 4.6: Aryl linked bis-catecholamides synthesised by Raymond et al.
[207]
 
 
4.2.1.2. Tetradentate catecholimine ligands 
Further work in the field of tetradentate bis-catecholate ligands has also 
focused on catecholimines. The key advantage to this type of ligands is their 
easy synthetic availability[214]. Albrecht et al. prepared a broad range of 
catecholimine based ligands uti lising both alkyl and aryl linkers (Figure 
4.7)[214-216]. In their initial work on bis-catecholimine ligands, Albrecht et al. 
found that like bis-catecholamides, their ligands readily formed triple stranded 
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helicates. They also observed that the orientation of the binding group to the 
transition metal cation could be modulated using counter-ions. In the solid 
state the imine nitrogen was on the outside of the helicate (4-18), due to 
repulsion between the lone pairs on the nitrogen and the adjacent catechol 
hydroxyl oxygen (Figure 4.8).However, in solution in the presence of an 
alkali metal cation, the imine nitrogen faced inwards (4-19), adopting a 
conformation similar to the one observed by Raymond et al. with 
catecholamides (4-20)[214, 217].  
 
 
Figure 4.7: Examples of catechol imine ligands synthesised by Albrecht et al.
[214]
 
 
 
Figure 4.8: Binding modes of catecholimines in the absence 4-18 and presence 4-19 
of an alkali metal cation, and the binding mode of a catecholamide 4-20. M = transition 
metal cation, M’ = alkali metal cation. 
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In later work Albrecht also demonstrated that the nature of the linker 
between the imine groups was important in the formation of metal helicates, 
by synthesising bis-catecholimines with sterically bulky backbones. They 
observed that sterically bulky ligands, while capable of forming triple 
helicates, also formed both oligomers and polymers, due to the steric bulk of 
the linkers suppressing binding of the alkali metal counter ions that direct 
helicate assembly[216]. 
4.2.2. Use of metal chelators as antimicrobials 
Recently, the use of hydroxypyridininone ligands as antimicrobial 
compounds has been explored. Hydroxypyridinones are isostructural and can 
be isoelectronic with catecholates. As catechols are a common structural 
motif in siderophores[64], their iron binding capacity is well documented. As 
hydroxypyridinones are capable of binding ferric iron, but not mediating iron 
uptake, they can prevent bacteria from accessing it and consequently have 
potential as antimicrobial agents. Hider et al. have developed hexadentate 
ligands that demonstrated inhibitory activity (Figure 4.9)[218-219]. Activity was 
observed against both Gram-positive and Gram-negative bacteria. 
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Figure 4.9: Hexadentate hydroxypyridinone ligands synthesised by Hider et al.
[219]
 and 
DTPA 4-23, a commercially iron chelator 
 
The MIC values observed for Hider’s compounds were comparable to a 
commercially available chelator: diethylene triamine pentaacetic acid 4-23 
(DTPA). Hider observed MIC values as low as 40 µg/ml against S. aureus; 
with one compound (an analogue of 4-21) displaying an MIC of 16 µg/ml 
against E. coli and P. aeruginosa.  
The work of Hider demonstrates the potential that iron chelators have 
as antimicrobial agents. They could be applied as iron chelators to induce 
iron starvation in bacteria, or as delivery agents for cytotoxic metals such as 
gallium in the form of metal complexes.  
Chapter 4: Synthesis and biological evaluation of tetradentate catechol 
based ligands 
165 
 
4.3. Results and discussion 
4.3.1. Synthesis of ligands 
4.3.1.1. Design of ligands 
The design of the ligands took into account several factors. The first 
factor was ease of synthesis. Alkyl linked bis-catecholimine ligands can be 
rapidly prepared by combining 2,3-dihydroxybenzaldehyde with the desired 
diamine linker in MeOH[214, 220], and the analogous amines prepared by using 
2,3-(bisbenzyloxy)benzaldehyde in the imine condensation and subsequently 
reducing the imines and cleaving the benzyl ethers in a single step by 
palladium catalysed hydrogenolysis. Using catecholimines and amines is 
also advantageous, as it reduces the likelihood of the ligand-Fe(III) complex 
being recognised as a siderophore and uti lised by bacteria as natural 
catecholate siderophores utilise catechol amides[64]. Catechol groups were 
used as donors as due to the high electron density of the oxygen atoms [67], 
they have a high affinity for tri-cations, reducing the risk of the ligands 
chelating important biologically relevant di-cations such as Zn(II) and Cu(II) in 
vivo[67]. Additionally it has been demonstrated that tetradentate siderophores 
can also form stable complexes with molybdenum[203, 208], which could 
provide an additional target against bacteria which rely on molybdate as well 
as iron for growth. The reason for using tetradentate bis-catecholate ligands 
is that while their ability to form metal complexes is well established[202, 211], 
their potential for use as antimicrobial agents has not been explored, with 
existing work in the literature more focused on bidentate and hexadentate 
ligands[219]. 
4.3.1.2. Unsymmetrical ligand 
The initial idea for this work came from the synthesis of a component for 
the Ugi condensation chemistry described in the previous chapte r. The Schiff 
base generated by combining benzyl protected aminochelin 2-37 with 2,3-bis 
(benzyloxy)benzaldehyde 2-25 provided an ideal precursor for an 
unsymmetrical bis-catecholate ligand 3-81. It was decided to reduce the 
precursor using the same method used to deprotect the Ugi ciprofloxacin 
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conjugates (Scheme 4.1). This had the advantage of removing the benzyl 
ethers and reducing the imine to a secondary amine in a single step.  
 
Scheme 4.1: Conversion of the imine 3-81 to give the unsymmetrical bis-catecholate 
ligand 4-24 
 
The precursor 3-81 was prepared using the method described in 
chapter 3. The deprotection was performed by catalytic hydrogenolysis. As 
the precursor was not EtOH soluble, a 1:1 mixture of EtOH and toluene was 
used to dissolve the precursor. Pd black was added as catalyst and the 
solution was stirred under H2 at 50 atmospheres. After reaction workup the 
required product 4-24 was isolated in 79% yield. Product formation was 
confirmed by the presence of a molecular ion peak with m/z 347.16 in the 
ESI mass spectrum, confirming the removal of all four benzyl ethers and the 
successful reduction of the imine to a secondary amine. The 1H NMR 
spectrum provided further confirmation. The resonance at 8.47 ppm with a 
relative integration of one was replaced by a resonance at 3.83 ppm with a 
relative integration of two. This confirms the transformation from a CH 
adjacent to an imine to a CH2 adjacent to an amine. In addition, the 
resonances at 5.09 and 5.17 ppm, corresponding to the CH2 groups of the 
benzyl ethers were no longer present. 
4.3.1.3. Synthesis of bis-imine ligands 
It was decided to prepare a series of bis-imine ligands to uti lise as a 
comparison for the unsymmetrical ligand 4-24. The chemistry for this had 
already been established by Smith and Winstanley, by reacting 2,3-dihydroxy 
benzaldehyde 2-18 in a 2:1 ratio with 1,8-diaminooctane in MeOH[220]. A 
series of compounds was synthesised using a range of linkers (Scheme 4.2).  
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.   
Scheme 4.2: Overview of the synthesis of a series of bis-imine ligands  
 
The ligands were all synthesised using a slightly modified method of 
Smith and Winstanley. In each synthesis 2,3-dihydroxybenzaldehyde 2-18 
was dissolved in dry MeOH. 0.5 equivalents of the appropriate diamine were 
added and the solution stirred. After a brief period of stirring a brightly 
coloured precipitate, yellow or orange depending on the linker length, of the 
required imine was observed and isolated by filtration. A purification step was 
added to the method reported by Smith and Winstanley, the recovered imine 
was washed with ice cold MeOH to remove any remaining starting material, 
and yield the pure product. The colour of the product varied depending on the 
linker length. The yields of each synthesis are summarised in (Table 4.1) 
  
Chapter 4: Synthesis and biological evaluation of tetradentate catechol 
based ligands 
168 
 
 
Linker Compound 
number 
Yield (%) 
Ethyl 4-30 89 
Propyl 4-31 90 
Butyl 4-32 100 
Pentyl 4-33 72 
Hexyl 4-34 75 
Heptyl 4-35 100 
Dodecyl 4-36 80 
Table 4.1: Summary of bis-imine ligand syntheses 
 
Successful synthesis was confirmed by ESI mass spectrometry and 1H 
NMR spectroscopy. Successful formation of all ligands 4-30−4-36 was 
confirmed by the presence of a singlet resonance of relative integration two 
in the region 8.45-8.55 ppm. Additionally, there was no resonance 
corresponding to the starting material 2-18 in the spectra of the purified 
products.  
4.3.1.4.  Synthesis of bis-amine ligand precursors 
To ascertain the impact of the linker between the catechol moieties and 
the alkyl backbone, a series of benzyl protected bis-imine ligands was 
prepared (Scheme 4.3). The intention was to hydrogenate these ligands 
using the same methodology used to convert the imine 3-81 to the amine 4-
24. 
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Scheme 4.3: Synthesis of benzyl protected bis-imine ligands  
 
The ligands were prepared using the same method as bis-imines 4-30 – 
4-36. As 2,3-bis(benzyloxy)benzaldehyde 2-25 is significantly less soluble in 
MeOH than 2,3-dihydroxybenzaldehyde 2-18, the required reaction time was 
longer. The yellow suspension was stirred overnight, a white precipitate was 
observed and isolated by filtration. The resultant white solid was then stirred 
in hot MeOH and filtered whilst hot to remove unreacted starting material, 
yielding a white solid as the product. The syntheses are summarised in 
(Table 4.2). Successful synthesis was confirmed by ESI mass spectrometry 
and 1H NMR spectroscopy. In each 1H NMR spectrum a singlet with relative 
integration of two was observed at approximately 8.52 ppm.  
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Linker Compound 
number 
Yield (%) 
Ethyl 4-37 89 
Propyl 4-38 90 
Butyl 4-39 99 
Pentyl 4-40 72 
Hexyl 4-41 75 
Heptyl 4-42 74 
Dodecyl 4-43 56 
 
Table 4.2: Summary of benzyl protected bis-imine syntheses  
 
Despite the successful synthesis of the precursors for bis-amine 
ligands, Smith and Winstanley reported that their octyl bis-amine ligand was 
highly unstable, and decomposed in the solid state in approximately seven 
days [220]. It was unfeasible to deprotect, characterise and perform all the 
necessary tests on the ligands within that time scale and consequently the 
work on these ligands did not proceed further. 
4.3.2. Biological screening of symmetrical bis-imine ligands and 
gallium 
4.3.2.1. Use of gallium as a cytotoxic metal 
Gallium was selected for use as a cytotoxic metal as it possesses the 
same electron configuration as ferric iron, and consequently can be 
incorporated into proteins which would usually contain iron. However, as it 
does not possess a variable oxidation state, gallium is incapable of 
undergoing the redox chemistry required for the function of such protein, and 
therefore blocks their function. Gallium has been shown to possess 
bactericidal activity against P. aeruginosa and has also been shown to 
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disrupt biofilm formation[221]. This can be a crucial property in treating more 
persistent infections. Consequently a treatment involving gallium nitrate 
entered clinical trials in 2009 for the treatment of P. aeruginosa in cystic 
fibrosis patients[222]. In 2012 a study by Visca et al. demonstrated the activity 
of gallium nitrate (Ga(NO3)3) against resistant strains of A. baumannii with 
activity observed down to a concentration of  4 µM in a human serum 
media[223]. Chen et al. also demonstrated the efficacy of Ga(NO3)3 against A. 
baumannii, they demonstrated that in the presence of transferrin Ga(NO3)3 
had a bacteriostatic effect, due to the reduced availability of iron. Additionally 
Trojan horses using the siderophore desferrioxamine B and gallium have 
been studied, and found to kill both planktonic and mature biofilms of P. 
aeruginosa [224]. 
4.3.2.2. Screening of bis-imine ligands on solid media 
Initially, it was decided to screen the ligands on solid media, using the 
same method as previously described (Chapter 3). Solutions (20 mM) were 
prepared of the propyl 4-31 and butyl 4-32 ligands, and gallium acetyl 
acetonate in DMSO. In addition, solutions of the propyl and butyl ligands 
were prepared containing gallium at ratios of 1:1 and 3:2 ligand:metal. A 1 in 
5 dilution series was prepared in sterile H2O, giving a set of solutions with 
concentrations ranging from 20 mM to 32 µM. The ligands were screened 
against E. coli BW25113 on LB agar. Ciprofloxacin was used as a control 
compound. After incubation, examination of the plates revealed that bacterial 
growth had occurred, but there was no sign of inhibition caused by the 
ligands, or by gallium acac. As gallium is known to have antimicrobial 
activity[221], this was an unexpected result. A likely explanation is the 
adsorption of gallium onto the agar, subsequently reducing the bioavailability 
of the metal and consequently its uptake into the bacterial cells. It was 
decided to rescreen the ligands and gallium acac in liquid culture. 
4.3.2.3. Initial liquid culture screening of ligands 
For the liquid cultures, cells were pre-grown in LB media. After 
overnight incubation at 37 °C the cells were centrifuged at 3500 rpm for three 
minutes, the supernatant removed, and resuspended in M9 glucose. The 
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process was then repeated. After the second resuspension, the culture was 
diluted 1 in 10 into sterilins containing M9 glucose. Each sterilin was then 
inoculated with 0.5 µM of each test compound (ligand, ligand: gallium or 
gallium) giving an active concentration of 100 µM in each culture. The 
cultures were incubated at 37 °C and their optical density at 650 nm (O/D650) 
was measured after 0.5 hours, 6 hours and after overnight incubation (Figure 
4.10). 
 
Figure 4.10: Initial liquid culture screening at 100 µM of ligands 4-13, 4-32 and in M9 
agar with 0.2% glucose. The experiments were performed in triplicate. Error bars 
represent ± one standard deviation from the mean. 
 
The results of the test screen were unexpected. All the solutions 
containing gallium acac exerted an antimicrobial effect: however the solutions 
containing only ligands 4-31 and 4-32 also showed evidence of growth 
inhibition. This suggested that the ligands could potentially act as 
antimicrobial agents in their own right, without the requirement for added 
gallium. Further investigation into the properties of the ligands was required.  
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4.3.2.4. Assessment of the impact of gallium on E. coli BW25113 
While gallium acac displayed a high level of efficacy in the preliminary 
screening of the symmetrical ligands, it was decided to switch to gallium 
nitrate as an alternative gallium salt. The reason for the change was the 
potential toxicity of acac[225]. Using nitrate would allow certainty that gallium 
was the species exerting the antimicrobial effect. In addition, nitrate is non 
toxic and consequently would be safe for use in a drug preparation. A 20 mM 
solution of gallium nitrate (Ga(NO3)3) was prepared in DMSO. The E. coli 
cultures were prepared as previously described. The experiment was run in 
triplicate. Each culture was inoculated with Ga(NO3)3 solution to a specific 
concentration ranging from 100 – 0 µM, with six cultures for each 
concentration. Half of the cultures were also inoculated with 1 equivalent of 
iron nitrate (Fe(NO3)3). The cultures were incubated as previously described 
and their O/D650 measured after 0.5 hours, 4 hours and after overnight 
incubation (Figure 4.11). The data showed that over a 24 hour period, 
Ga(NO3)3 inhibited the growth of E. coli, down to a concentration of 40 µM in 
the absence of iron, relative to a control solution containing no gallium. 
However, while the cultures incubated with an equimolar amount of iron 
present suggested inhibition occurred after 4 hours, after 24 hours the O/D650 
measurements observed were greater or equal to those observed for the 
control culture, even at 100 µM. This initial run demonstrated that Ga(NO3)3 
was a suitable salt for use in further screening of the bis-imine ligands 4-30–
4-36. However subsequent assays using gallium nitrate yielded inconsistent 
results, with some assays showing normal growth of E. coli, even in the 
presence of high Ga(NO3)3 concentrations. A possible explanation for the 
lack of reproducibility could be the behaviour of Ga(NO3)3 in aqueous 
solutions. Under the assay conditions, the predominant gallium species 
formed is gallium hydroxide [Ga(OH)4
−], which has poor bioavailability[226]. 
This could have resulted in lower accumulation of gallium in bacterial cells, 
and the subsequent lack of a bactericidal effect. Consequently, further 
experiments using gallium were not pursued as the data would not have 
been suitably reliable. 
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Figure 4.11: Effect of Ga(NO3)3) on the growth of E. coli in the A) absence and B) 
presence of one molar equivalent of Fe(NO3)3. The experiments were performed in 
triplicate. Error bars represent ± one standard deviation from the mean.  
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4.3.3. UV analysis of symmetrical bis-imine- ligands 
As the small scale test screening on the ethyl and propyl ligands had 
yielded promising results, it was necessary to assess the stability of the 
ligands under the conditions used in the assay. Determining the stability 
would allow conclusions to be drawn about whether the ligands or a 
breakdown product were exerting the observed bacteriostatic effect.  
4.3.3.1.  UV analysis of symmetrical bis-imine ligands  
To replicate the screening conditions, a buffer was prepared containing 
a phosphate concentration equivalent to the bacterial growth media (See 
experimental section). The carbon source and additional salts (MgSO4, NaCl, 
and NH4Cl) were omitted. As the ligands are not water soluble, an organic 
co-solvent was required. Consequently, the solutions for the UV analysis 
were prepared in a mixture of MeCN and buffer (5:3 ratio). For the 
experiments, a 2 mM solution (equivalent to 5 mg in 8 mL of the ethyl ligand) 
of each ligand was prepared in the MeCN: buffer solution. The stock solution 
of the ligand was then subjected to a 1 in 5 dilution (80 µM). The diluted 
sample was then analysed over a period of 8 hours with a reading taken 
every hour (Figure 4.12). The dodecyl ligand 4-36 was not subjected to 
analysis due to poor solubility in the solvent system used. The UV data 
showed clear variation over the specified time frame, indicating the 
breakdown of the bis-imine ligands, and the formation of a new species, 
determined to be 2,3-dihydroxybenzaldehyde 2-18 by comparison with the 
UV spectrum of the aldehyde. The increase in absorbance over time is 
attributed to the oxidation of the catechols to the corresponding quinone  
(Scheme 4.4). This was also observable as a colour change over time in the 
stock solution, as the solution gradually darkened from yellow to brown 
(Figure 4.13). 
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Figure 4.12: A) UV/vis spectra of the ethyl bis-imine ligand 4-30 recorded over 8 
hours. B) UV/vis spectrum of 2,3-dihydroxybenzaldehyde 2-18.  
A) 
B) 
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Scheme 4.4: Oxidation of a catechol to a quinone via the radical semiquinone 
intermediate 
 
 
Figure 4.13: Solution of ethyl bis-imine ligand 4-30 in 5:3 MeCN:phosphate buffer at 
(left to right) T0, 8 hours, 24 hours  
 
It was observed by comparing the UV spectra of the ligands 4-30–4-36, that 
the rate at which the ligands decomposed was inversely proportional to the 
length of the linker between the catechol units. (See appendix 1). As ligands 
4-30 and 4-31 decomposed very rapidly, it was decided to analyse their 
decomposition over a shorter time frame. The short time frame experiments 
on the two smallest ligands 4-30 and 4-31 confirmed the hypothesis that they 
were rapidly hydrolysing in aqueous solution. Whilst the remaining ligands 4-
32−4-35 showed increasing stability, they were still unstable over the 24 hour 
time scale utilised for liquid culture biological screening experiments. An 
additional factor to consider is that the UV/vis experiments were performed at 
room temperature. As the ligands were unstable in solution at this 
temperature, it would be logical to presume that the hydrolysis of the ligands 
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would proceed at a higher rate during a biological assay performed at 37°C. 
Consequently it was decided not to proceed further with the screening of 
these ligands.  
 
 
 
Figure 4.14: Changes in the UV/vis spectra of A) the ethyl bis-imine 4-30 over 1 hour 
and B) the propyl bis-imine 4-31 over two hours. 
A) 
B) 
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4.3.4. Biological screening of unsymmetrical ligand 4-24  
4.3.4.1. Wild type screening in liquid culture 
As screening of the symmetrical bis-imine ligands on solid media had 
yielded no useful data due to gallium adsorption onto the agar, the 
unsymmetrical ligand 4-24 was only screened in liquid culture. The cultures 
of E. coli were prepared and incubated as previously described. A 3 mM 
solution of the unsymmetrical ligand 4-24 was prepared in DMSO. The 
experiments were again run in triplicate. The cultures were inoculated with a 
specific volume of the unsymmetrical ligand 4-24, using a concentration 
range from 100–0 µM. The cultures were incubated with shaking at 37°C, 
and the O/D650 was measured after 0.5 hours, 3 hours, 6 hours, and after 
overnight incubation (Figure 4.15). The results obtained indicated that the 
unsymmetrical ligand 4-24 possessed antimicrobial activity, with statistically 
significant levels of inhibition observed down to a concentration of 20 µM. In 
addition, unlike the bis-imines, where normal growth was restored after a 
period of 24 hours, cell growth was still repressed after the same period by 4-
24 relative to the control culture.  
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Figure 4.15: Inhibition of growth of E. coli BW25113 in the presence of unsymmetrical 
ligand 4-24. The experiments were performed in triplicate. Error bars represent ± one 
standard deviation from the mean. Control culture solution contains no ligand.  
 
The next step was to ascertain how 4-24 was exerting its bactericidal 
effect. As the compound 4-24 had been designed as a metal chelator, a 
potential explanation is that the ligand 4-24 sequesters iron from the culture 
medium, inhibiting the growth of bacterial cells via iron starvation. To test this 
hypothesis, the assay was repeated with 1 equivalent of Fe(NO3)3 added to 
each culture (Figure 4.16)  
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Figure 4.16: Inhibition of growth of E. coli BW25113 by unsymmetrical ligand 4-24 in 
the presence of 1 equivalent of Fe(NO3)3. The experiments were performed in 
triplicate. Error bars represent ± one standard deviation from the mean.  Control-F 
culture contains no ligand and 50 µM Fe(NO3)3. Control contains no ligand or 
Fe(NO3)3.  
 
The results of the assay indicated that while the addition of iron to the 
cultures increased the MIC of 4-24 to approximately 40 µM, there was still 
significant inhibition observed. This suggests that 4-24 is inhibiting the growth 
of E. coli via a mechanism other than iron starvation. Furthermore, at 
concentrations below 20 µM, higher levels of growth were achieved than 
those observed in the control cultures, suggesting that the ligand 4-24 could 
be behaving as a siderophore under those conditions.  
4.3.4.2. Screening of the unsymmetrical ligand 4-24 against E. coli deficient 
in enterobactin synthesis 
The results obtained by growing E. coli BW25113 in the presence of 4-
24 and iron demonstrated that iron sequestration by the ligand and 
subsequent iron starvation is unlikely to be the mechanism of action of 4-24. 
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Further investigation was required to confirm that iron sequestration was not 
the mechanism of action. To achieve this, the unsymmetrical ligand 4-24 was 
screened against an E. coli mutant EntA-. The mutant was deficient for the 
EntA protein, a key part of the enterobactin biosynthetic pathway[227]. EntA 
catalyses the final step in the biosynthesis of 2,3 -dihydroxy benzoic acid in 
an NAD dependent reaction (Scheme 4.5)[228]. The protein is a member of 
the short chain oxidoreductase (SCOR) family. The protein exists as a 
tetramer, each subunit is composed of a central 7 strand β-sheet, with 7 α 
helices located around the central sheet[228].  
 
Scheme 4.5: NAD+ dependent biosynthesis of 2,3-dihydroxybenzoic acid from 2,3-
dihydro 2,3-dihydroxybenzoic acid 
 
Without this critical final step, E. coli is unable to synthesise 
enterobactin. Consequently it is deprived of its most efficient iron chelator. 
Additionally its ability to synthesise the alternative siderophore salmochelin 
S4 may also compromised as salmochelin S4 also contains the 2,3- 
dihydroxy benzoic acid moiety[64]. While the bacteria will still be able to 
scavenge iron through its mixed citrate/hydroxamate alternative siderophore 
aerobactin[62], its ability to obtain iron from its extracellular environment is 
significantly reduced.  
The screening was performed as previously described, using the same 
concentration range as the wild type screening (Figure 4.17). The data 
indicated that against the mutant strain, inhibition was not observed, even at 
a concentration of 100 µM. In addition, it was observed that at most 
concentrations the unsymmetrical ligand 4-24 aided growth. Cultures that 
contained concentrations that were sub-lethal against the wild type strain, 
<30 µM, showed statistically significant growth above the level observed in 
the control. 
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Figure 4.17: Mean O/D650 of EntA- E. coli BW25113 grown in M9 media in the 
presence of the unsymmetrical ligand 4-24. The experiments were performed in 
triplicate. Error bars represent ± one standard deviation from the mean. Control culture 
contains no ligand. 
 
From the data it can be deduced that prevention of iron sequestration 
by bacteria is not the mechanism of action for the unsymmetrical ligand 4-24. 
If that was the case then greater inhibition would have been observed in the 
absence of enterobactin, due to enterobactin’s ability to remove iron from 
chelators with lower affinity[229-230]. The data suggests the opposite is true, 
and implies that the ligand 4-24 is gaining access to the cell and supplying 
iron, resulting in the observed increase in growth at sub-lethal 
concentrations. The reduced inhibition at higher concentrations could be due 
to ligand 4-24 forming complexes with extracellular iron and copper, present 
as trace elements in the buffer components. Complexation of metal ions 
would reduce the concentration of the free ligand within the cell and 
consequently it’s antimicrobial effect. This is observed more easily in the 
absence of enterobactin as there is less competition for 4-24 when binding to 
these metal ions, and consequently the concentration of free ligand is 
reduced more than would be observed in the wild type screen (Figure 4.18).  
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Figure 4.18: Schematic diagram of proposed explanation of the activity of 4-24 in the 
presence (A) and absence (B) of EntA. Bi) shows situation at concentrations above 40 
µM Bii) shows the situation at concentrations below 40 µM 
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4.3.4.3. Screening of unsymmetrical ligand 4-24 against TonB E. coli 
The results obtained in the previous assay indicated that in addition to 
possessing antimicrobial activity, the ligand 4-24 appeared to behave as a 
siderophore. To further investigate this possibility, the ligand 4-24 was 
screened against an E. coli mutant TonB-. As TonB is essential for 
siderophore uptake in E. coli, its removal should result in a loss of activity if 
4-24 is being actively transported as an iron complex through a siderophore 
transporter. The assay was performed as previously described, with an 
additional reading taken after 48 hours of growth (Figure 4.19).  
 
Figure 4.19: Growth of TonB- E. coli in the presence of unsymmetrical ligand 4-24. 
The experiments were performed in triplicate. Error bars represent ± one standard 
deviation from the mean. Control culture contains no ligand 
 
The data observed demonstrates that the ligand 4-24 is not actively 
transported by a TonB dependent mechanism. However, the conclusion can 
also be drawn that the ligand does transport iron into the cells to allow 
growth, potentially through outer membrane porins as a 1:1 complex would 
be small enough (<600 Da) to pass through. The control culture shows 
minimal growth, as expected, due to the lack of siderophore-mediated iron 
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transport. Concentrations of 4-24 which were sub-lethal in the wild type 
screen show high levels of growth, suggesting that they are giving bacteria 
access to the iron required for growth. As the iron concentration in the media 
is a minimum of 3 µM due to trace amounts of iron in the buffer components, 
it is possible that this was complexed by 4-24 and transported via a porin into 
the cell. At concentrations above 40 µM, less growth is observed, suggesting 
that above this concentration some of the ligand may be still be transporting 
iron into the intracellular environment . However, as there is a sufficient 
concentration of non-complexed ligand, inhibition is observed. This explains 
the concentration dependence of activity observed for concentrations of 50 
µM and above. 
 
Figure 4.20: Schematic diagram of the proposed explanation of the activity of 4-24 in 
the absence of TonB 
 
4.3.4.4. Screening of 4-LICAM and citrate against wild type E. coli BW25113 
Screening against a TonB- mutant demonstrated that the ligand 4-24 
was acting as a source of iron for E. coli, albeit not via active transport. It was 
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decided to compare its previously observed antimicrobial activity with two 
known iron chelators. The two iron chelators chosen were citric acid 1-26, 
which is used as an exogenous siderophore by enteric bacteria[64], and 4-
LICAM 4-3 (Figure 4.21)[231]. 4-LICAM was synthesised by D. J. Raines. The 
screening was performed as previously described using the same range of 
concentrations. For the citric acid 1-13 experiment, tri-sodium citrate was 
used.  
 
Figure 4.21: Structure of the tetradentate siderophore mimic 4-LICAM 4-3 
 
The data obtained in the screen (Figure 4.22) yielded the expected 
result, that both citrate and 4-LICAM increased growth of E. coli BW25113 
relative to a control with no iron chelator added. The 4-LICAM result is useful 
as it provides further evidence that it can function as a siderophore, following 
on from the work of Duhme-Klair et al. where they demonstrated that the 4-
LICAM –Fe(III) complex can bind to a periplasmic binding protein[231]. The 
lack of antimicrobial activity demonstrated by the structurally similar 4-LICAM 
suggests that the antimicrobial effect observed when the unsymmetrical 
ligand 4-24 is added to cultures of E. coli is linked to the substitution of a 
secondary amine for one the amides in 4-LICAM. 
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Figure 4.22: Growth of E. coli BW25113 in the presence of 4-LICAM 4-3 (top) and 
citric acid 1-26 (bottom). The experiments were performed in triplicate. Error bars 
represent ± one standard deviation from the mean. Control culture contains no ligand  
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4.3.5. Assessment of the stability of the unsymmetrical ligand 4-24 
4.3.5.1. UV/vis analysis  
To ascertain the suitability of the unsymmetrical ligand 4-24 as an 
antimicrobial compound, it was necessary to assess its stability in solution. 
The compound 4-24 was analysed in the same manner as the symmetrical 
bis-imine ligands 4-30−4-36. A 2 mM stock solution was prepared and diluted 
to 80 µM. The ligand was initially analysed over a period of 1 hour, followed 
by a set of readings covering 8 hours (Figure 4.23). The UV spectra show 
minimal change over the course of 1 hour. On the 8 hour time scale, there is 
some evidence of a chemical change occurring. The most likely change is 
oxidation of the catechols to the corresponding quinones, as was observed 
with the symmetrical ligands.  
From the UV data obtained it can be concluded that the unsymmetrical 
ligand 4-24 does not hydrolyse to individual catechol units in the same 
manner as the symmetrical bis-imine ligands, but that over time it is 
susceptible to oxidation. From the data, it is not possible to determine which 
exact species is responsible for the antimicrobial effect. It could be the ligand 
4-24, the corresponding quinone, or a partially oxidised semiquinone species.  
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Figure 4.23: Changes in the UV spectra of 1mM unsymmetrical ligand 4-24 over A) 1 
hour and B) over 8 hours in phosphate buffer (2:1 Na2HPO4: KH2PO4) 
 
A) 
B) 
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4.3.5.2. Electrochemical analysis  
It was decided to undertake an electrochemical investigation on the 
ligand 4-24 in order to determine its redox potential, and to analyse its 
susceptibility to oxidation. The study was performed in MeCN using ferrocene 
as a standard and 0.1 M tetrabutylammonium hexafluorophosphate ([( t-
Bu)4N]PF6) as a supporting electrolyte. Ferrocene was used because it 
exhibits reversible single electron transfer in a number of solvents and is 
therefore a suitable species to calibrate the reference electrode [232]. The 
electrochemical cell was set up using a Saturated Calamel Electrode (SCE) 
for the reference, a platinum disc for the working electrode, and platinum wire 
for the counter electrode. To determine the experimental set up for the 
calibration, the experiment was run using only the electrolyte. The 
parameters were set with a starting potential of zero, P1 = 1000 mV and P2 = 
-500 mV. The scan rate was set to 50 mV/S. The SCE was then calibrated 
using this set up with 2 mM ferrocene (Figure 4.24) 
 
Figure 4.24: Cyclic voltammogram of  2 mM ferrocene, relative to a solution 
containing 0.1 M [(t-Bu)4N]PF6 as an electrolyte in MeCN 
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With the electrode calibrated, the parameters of the experiment were 
modified to identify a potential window where the ligand 4-24 could be 
oxidised. Initially, the ligand was analysed using a potential window starting 
at 1000 mV and scanning to −2000 mV at a concentration of 2 mM. No 
quantifiable change was observed. The potential window was changed to use 
more positive potentials, and the concentration of the ligand 4-24 solution 
increased to 10 mM. The final potential window utilised a potential range from 
700-2500 mV (P0 = 700 mV, P1 = 2500 mV, P2 = 700 mV) (Figure 4.25). 
 
Figure 4.25: Cyclic voltammogram of 10 mM ligand 4-24 shown compared to a 
solution containing 0.1 M [(t-Bu)4N]PF6 as the electrolyte in MeCN 
 
The cyclic voltammogram of ligand 4-24 indicated a single, irreversible 
oxidation at a potential of approximately 1.5 V. While the oxidation of the 
catechol groups appears irreversible, it is possible that diffusion effects 
prevented reduction back from the keto group to the alcohol. As MeCN is 
aprotic, protons removed from the hydroxyl groups may have diffused away 
by the time the electrode potential became less positive than the oxidation 
potential, thus preventing reduction. Additionally, the precipitation of a dark 
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brown solid, presumed to be the oxidised form of 4-24, was observed upon 
completion of the experiment. Precipitation of the oxidised product is another 
potential explanation for why the oxidation appears irreversible. If the 
oxidised species is no longer in solution, it cannot be reduced back to its 
original state by the reversal of the electrode potential. Furthermore, as the 
resultant quinone can polymerise, it is possible the precipitated solid is an 
insoluble polymer. 
4.3.5.3. Spectroelectrochemical analysis  
To confirm that the transformation occurring under an applied potential 
was an oxidation, the ligand was also subjected to spectroelectrochemical 
analysis. The experiment was performed using the same solution of 0.1 M [(t-
Bu)4N]PF6 in MeCN as the electrolyte. An electrochemical cell was set up in a 
quartz cuvette using an Ag/AgCl reference electrode, a platinum mesh for the 
working electrode, and platinum wire for the counter electrode. The reference 
electrode was calibrated using ferrocene as before. The first experiment was 
observed using photography, with the ligand concentration at 10 mM. The 
electrochemical cell was set up, and a working potential of 2V was passed 
through the solution. A photograph was taken every minute for the first 10 
minutes, and every three minutes thereafter up to a time of 25 minutes 
(Figure 4.26). The test experiment shows the rapid oxidation of the ligand 
under the stated conditions. The solution darkens and in the later photograph 
timed at 5 minutes a small amount of precipitate can be seen beginning to 
form on the counter electrode. A control UV spectrum of the ligand 4-24 was 
taken using the 0.1 M [(t-Bu)4N]PF6 solution as the solvent, with readings 
taken every three minutes for thirty minutes (Figure 4.28). The UV/vis 
absorption experiment was then repeated with a working potential of 2 V 
across the electrochemical cell (Figure 4.29).  
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Figure 4.26: Oxidation of Ligand 4-24 in situ under a working potential of 2V relative 
to a Ag/AgCl electrode in 0.1 M [(t-Bu)4N]PF6 in MeCN  
 
 
Figure 4.27: Schematic diagram of the experimental setup for the 
spectroelectrochemical analysis of 4-24 
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Figure 4.28: UV/vis spectrum of 10 mM 4-24 in 0.1 M [(t-Bu)4N]PF6 in MeCN over 30 
minutes  
 
Figure 4.29: UV/vis spectrum of 10 mM 4-24 over time with a working potential of 2V 
applied in 0.1 M [(t-Bu)4N]PF6 in MeCN 
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The UV/vis spectra measured confirmed the observation made when 
following the electrochemical process using photography. The ligand 4-24 is 
rapidly oxidised at a working potential of 2V. The increase in the baseline 
absorbance with time is due to scattering, caused by the precipitation of an 
unknown species. From these studies it can be concluded that the ligand  is 
highly susceptible to oxidation, and will gradually oxidise over time, within the 
time frame of the biological assays.  
4.4. Summary, conclusions and future work 
In summary, three different types of compounds have been synthesised 
and characterised: an unsymmetrical bis-catechol ligand linked via an amide 
and a secondary amine; a set of bis-catecholimine ligands, and a set of 
benzyl protected bis-catecholimine compounds as precursors to bis-
catecholamine ligands. The work on the protected bis-catecholimine 
compounds was not pursued further due to the instability of the target bis-
catecholamine ligands. 
The antimicrobial activity of the symmetrical bis-imine ligands was 
briefly analysed, but further screening was not pursued due to their 
susceptibility to hydrolysis when dissolved in phosphate buffer, with the 
smallest ligands (4-30 and 4-31) decomposing to their corresponding alkyl 
diamine and 2,3-dihydroxybenzaldehyde in under 2 hours. The dodecyl 
spacer containing ligand in the series 4-36 was not subjected to analysis due 
to its low solubility in the solvent systems used. 
The unsymmetrical ligand 4-24 was assessed for antibacterial activity 
and showed promising results against wild type E. coli, with an MIC of <10 
µM. Experiments to elucidate its mechanism of action were undertaken. The 
results indicated that there was an element of iron starvation, but that there is 
likely be an additional component, as evidenced by the compound retaining 
activity against E. coli in the presence of excess iron. Additional experiments, 
however, also demonstrated that the compound 4-24 is capable of acting as 
a siderophore, as in experiments against a TonB deficient strain the 
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compound aided growth of the bacteria at sub-lethal concentrations. 
Investigations into the stability of the compound have shown that the 
compound is unsuitable for use as an antimicrobial agent. UV/vis 
spectroscopy and electrochemistry have shown that the compound is 
susceptible to oxidation. Consequently, it cannot be said definitively whether 
4-24 or one of its oxidation products  is the active species. 
For future work in this area, a key aspect is developing a reliable assay 
to give reproducible results for testing the efficacy of gallium nitrate against 
E. coli. Experiments could also be performed to determine if complexing the 
ligands with iron or gallium has a stabilising effect and prevents hydrolysis in 
buffer. If this is the case, the ligands could be complexed with gallium and 
rescreened to determine if the complexes have an antimicrobial effect. The 
same experiments could also be performed with the unsymmetrical ligand. If 
these experiments were successful, new synthetic work could be undertaken 
to prepare unsymmetrical bis-catechol ligands with varying linker lengths to 
examine the impact of linker link on the efficacy of the compounds. Additional  
work should also focus on the analysis of the oxidation products of 4-24, 
specifically determining the identity of the products and assessing their 
stability and antimicrobial activity.
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5. Studies into the bacterial uptake mechanism 
of glycosylated fluoroquinolones 
5.1. Aims 
The aim of the research in this chapter was to establish whether a set of 
glycosylated fluoroquinolones were capable of gaining access to their 
intracellular target via active transport. Additionally experiments were 
undertaken to establish whether or not the glycosylated fluoroquinolone 
retained the capacity to gain access to the cell through OMPs. The research 
contained in this chapter is published in the journal ChemBiochem[233]. 
5.2. Introduction 
5.2.1. Overview 
The key concept behind the Trojan horse strategy is smuggling a 
bactericidal moiety into the cell with a nutrient required for microbial growth. 
Iron is by no means the only nutrient required for microbial survival. 
Therefore, it stands to reason that siderophores are not the only means of 
potentially carrying bactericidal moieties into a bacterial cell using a required 
nutrient. While the majority of work in the literature on Trojan horses has 
focused on siderophore conjugates, there are alternatives which have been 
explored using alternative natural ligands There are several examples of 
using this approach to improve bioavailability of drugs in a mammalian 
system[234]. These include using glucose transport to aid the bioavailability of 
Non-steroidal anti-inflammatory drugs (NSAIDs)[235]. Other examples of 
utilising transporters to deliver drugs also include using peptides [236] and 
vitamin C[237]. The vitamin C conjugate used the NSAID diclofenac; the role of 
the vitamin C component is to target diclofenac to its site of action within the 
brain. The other two conjugates used indomethacin (glucose) and 
nabumetone (thiopeptide). The indomethacin conjugate enabled the uptake 
of the drug to the brain via glucose transport in rats[235], while the 
nabumetone conjugate was targeted towards the PepT1 transporter[236], a 
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transporter which has also been demonstrated to transport β-lactam 
antimicrobials[238].   
 
Figure 5.1: Structures of three examples of NSAIDs conjugated to natural ligands: 
vitamin C 5-1, glucose 5-2 and a thiopeptide 5-3 
 
5.2.2. Sugar transport in bacteria 
As carbohydrates are highly hydrophilic, they are incapable of passive 
diffusion through the hydrophobic inner membrane. The requirement of a 
carbon source for bacterial growth has led to the evolution of several 
mechanisms for carbohydrate transport in bacteria. Lactose passes through 
the inner membrane by proton coupled transport. The hexopyranose sugars 
glucose and galactose are transported via group translocation in addition to 
proton coupled transport (Figure 5.2)[239]. The group translocation is 
catalysed by phosphoenolpyruvate (PEP). This initiates a series of 
phophorylations, ultimately phosphorylating glucose to form glucose-6-
phosphate (G6P) as glucose is transported through the IIC protein.  This is 
known as the PEP phosphotransferase system (PEP-PTS)[240-241].  
 
Chapter 5: Studies into the bacterial uptake mechanism of glycosylated 
fluoroquinolones 
200 
 
 
Figure 5.2: Schematic overview of lactose and glucose transport in E. coli 
 
Galactose can also be taken up via proton coupled transport, in a 
similar fashion to lactose. The protein GalP transports galactose in E. coli[242] 
and exists in functional trimers in the outer membrane. Furthermore, bacteria 
can also obtain glucose using GalP[243], which is the closest analogue to the 
human glucose transporters (GLUTs)[244-245]. There are also two known 
galactose transporters; mglC and ytfT[246]. YtfT is a more recent discovery 
and has been found to be specific for galactofuranose[247] 
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5.2.3. Previous examples of carbohydrate-fluoroquinolone 
conjugates 
Compared to siderophore based Trojan horses, carbohydrate based 
examples are extremely rare. Only two sets of carbohydrate based Trojan 
horses exist in the literature.  These examples both use glucose and 
galactose as the carbohydrate component with norfloxacin and ciprofloxacin 
as the fluoroquinolone component. 
5.2.3.1. Ciprofloxacin based carbohydrate conjugates 
The first carbohydrate based Trojan horses were published by Jung et 
al. in 1999. Their intention was to target the sugar/H+ symporters and 
phosphotransferase (PTP) transporters. They utilised ciprofloxacin 1-18 as 
their antimicrobial moiety, with glucose and galactose as the carbohydrate 
component[248]. The proteins responsible for active transport of carbohydrates  
are highly specific[249], therefore the use of glucose and galactose should 
allow the conjugates to be actively transported by the target organism. They 
also experimented with linkers to determine the impact this had on activity.  
The conjugates were tested for their antimicrobial activity using 
ciprofloxacin as a standard. It was found by Jung et al. that the conjugates 
with no linker 5-4 and 5-5, displayed activity which was comparable to 
ciprofloxacin 1-18. This was attributed to hydrolysis of the conjugates during 
incubation, resulting in the regeneration of ciprofloxacin. They observed that 
the conjugates 5-6−5-9, which contained ethyl or propyl linkers, had 
significantly reduced activity relative to ciprofloxacin. From this observation 
they drew the conclusion that the conjugates 5-6−5-9, containing an alkyl 
linker were stable under the assay conditions. 
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Figure 5.3: Examples of fluoroquinolone-carbohydrate conjugates prepared by Jung 
et al.
[248]
 
 
This led to a further conclusion that the glucose conjugate 5-6 was 
being actively transported. The fact that the glucose conjugate 5-6 showed a 
higher level of activity than the corresponding galactose conjugate 5-7 
against a variety of strains including S. aureus and P. aeruginosa was cited 
as evidence that the conjugates could be being differentially transported [248]. 
However, without screening of their conjugates against transport deficient 
mutants, this conclusion could not be confirmed.  
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5.2.3.2. Norfloxacin based carbohydrate conjugates 
In 2005, Zsoldos-Mady et al. produced a new set of carbohydrate based 
Trojan horses. Their initial synthesis was similar to the work of Jung et al., 
synthesising glycosyl amines utilising both glucose and galactose. The key 
difference was their use of norfloxacin 1-17 as the fluoroquinolone 
component instead of ciprofloxacin 1-18. Following this, they synthesised 
new conjugates using carbamoyl and thiocarbamoyl linkers (Figure 5.4). 
They claimed that the compounds possess antimicrobial activity at a level 
below that of pefloxacin, however no specific data is given for screening of 
the efficacy of the compounds. There is also no experimental detail given for 
how the antimicrobial screening may have been performed [250].  
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Figure 5.4: Examples of norfloxacin-carbohydrate conjugates prepared by Zsoldos-
Mady et al. and their control compound pefloxacin 5-14.  
 
Given the available data from these two studies, it is clear that there is 
scope for further study of both the potential efficacy of carbohydrate-
fluoroquinolone conjugates. Additionally further investigation is required to 
determine to what extent, if any, carbohydrate-fluoroquinolone conjugates 
are actively transported. 
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5.3. Results and discussion 
5.3.1. Screening of compounds on glucose and galactose media 
against wild type E. coli 
5.3.1.1. Glycosylated fluoroquinolones 
Three compounds that had previously been prepared by S.J. Milner 
were used (Figure 5.5)[151]. All of the compounds contained ciprofloxacin as 
the active pharmacophore, with a sugar component conjugated via the 
piperazinyl nitrogen. The sugar components were glucose, galac tose and 
lactose. 
 
Figure 5.5: Structures of the three sugar based Trojan horses with glucose 5-15, 
galactose 5-16, and lactose 5-17 as the carbohydrate components  
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5.3.1.2. Establishment of suitable growth conditions 
In order to determine whether or not the glycosylated fluoroquinolones 
were being actively transported into the cells, as hypothesised by Jung et 
al.[248], it was necessary to establish a set of conditions where bacterial 
growth was dependent on a specific mono-saccharide, with the hypothesis 
that the conjugate with the selected mono-saccharide would be actively 
transported by specific transporters and thus have greater activity under the 
assay conditions than the conjugates not containing the selected 
monosaccharide. As glucose is the preferred carbon source of E.coli, it was 
decided to utilise galactose as the limiting carbon source. To establish 
galactose as the limiting carbon source conditions were established were it 
could be demonstrated that galactose transport was required for growth. To 
enable this, a mutant strain was selected with deletions in three galactose 
transport genes: YtfT, GalP and MglC [242, 246-247]. The galP and mglC genes 
both encode galactose transporters. YtfT is part of the E.coli ytfQRTyjfF 
operon which encodes a galactofuranose transporter.  
Initially, growth of a double mutant with defects in GalP and MglC was 
grown in addition to a wild type strain (BW25113). These were grown 
overnight in M9 glucose, however no growth was observed, this was believed 
to be due to a problem with the stock culture. It was decided to test six 
different strains for viability. The BW25513 was used, in addition to: 
galP::kan, mglC::kan, ΔmglC. ΔGalPΔMglCytfT::kan, and ΔgalPΔmglCΔytfT. 
Out of these strains, three contained kanamycin resistance genes (GalP-, 
MglC-, and ΔGalP-ΔMglC-YTFT). The six strains were grown in LB media for 
three days. Observation of the cultures confirmed growth in all six, confirming 
that all the strains were viable. The O/D650 of the wild type and ΔGalP
-ΔMglC-
ΔYTFT strains were measured, and the cultures diluted into 12 cultures (3 
wild type in glucose M9, 3 ΔgalPΔmglCΔytfT in glucose M9, 3 wild type in 
galactose M9, and 3 ΔgalPΔmglCΔytfT in galactose M9). The cultures were 
incubated at 37°C and their O/D650 measured every thirty minutes (Figure 
5.6).  
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The data from this initial screen showed that under these conditions, 
where glucose was the carbon source the cultures grew with no problems 
However in the galactose media, no significant growth was observed during 
the time frame of the assay. However, the galactose cultures were left to 
incubate, and after 2 additional days at 37°C, growth was observed with the 
wild type strain. A further experiment using cultures grown in mannose, and 
gluconic acid lactone (in addition to glucose and galactose) was performed. 
The experiment was performed under the same conditions, mannose and 
gluconic acid lactone both yielded growth within 24 hours. The fact that these 
conditions gave rise to growth within 24 hours for mannose, gluconic acid 
lactone and glucose, but not galactose, suggests a prolonged lag phase in 
the bacterial growth cycle when galactose is the sole carbon source. As 
expression of galactose transporters is repressed in the presence of 
glucose[251-252], it is likely that after overnight growth in LB media the E.coli 
does not have any galactose transporters expressed. Consequently, the lag 
period is extended while the bacteria overcome the initial repression and 
expresses the required transporters to obtain galactose from the medium.  
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Figure 5.6: Growth data of wild type and ΔGalP
-
ΔMglC
-
ΔYtfT
-
 strains of E. coli grown 
in M9 glucose and M9 galactose with A) LB media pre-growth and B) M9 glycerol pre-
growth. The experiments were run in triplicate. Error bars correspond to the standard 
deviation of the data.  
 
While growth was observed in the E. coli cultures grown in M9 
galactose, the prolonged lag phase was undesirable due to the length of time 
used for the zone of inhibition assays (Figure 5.6). Conditions were required 
A) 
B) 
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where the cells enter the log phase of growth and reach a sufficient O/D650 in 
side 24 hours. It was decided to investigate the effect of the initial growth 
media. A culture of wild type E.coli was prepared in LB media and incubated 
at 37°C overnight. The cells were washed by being centrifuged at 3500 rpm 
for 3 minutes, removing the supernatant and re-suspending the cells in M9 
salts. This was repeated twice to remove as much of the LB media as 
possible. The cells were then resuspended in M9 containing either 0.2 % 
glucose or 0.2% glycerol. These cultures were then incubated overnight at 
37°C. The O/D650 was measured for both cultures and were determined to be 
1.43 for the M9 glycerol culture and 1.93 for the M9 glucose. The cultures 
were diluted to an approximate O/D650 of 0.1 in M9 with 0.2% galactose. The 
O/D650 after 7 hours was approximately 0.3 for both solutions. After 3 days 
the O/D650 was measured again and recorded as 0.958 for the culture pre-
grown with glycerol and 0.974 for the culture grown with glucose.  
Culture Observed 
O/D650 
Actual 
O/D650 
Dilution 
required  
Wild type 1 0.218 2.18 0.92 ml in 
20 ml 
Wild type 2 0.197 1.92 1.04 ml in 
20 ml 
Mutant 
strain 1 
0.150 1.50 1.33 ml in 
20 ml 
Mutant 
strain 2 
0.206 2.06 0.97 ml in 
20 ml 
Table 5.1: O/D650 data and dilutions for both wild type and mutant E. coli after 
overnight pre-growth in M9 glycerol  
 
Based on these results it was decided to repeat the initial assay using 
M9 glycerol as the pre-growth media instead of LB. 4 Cultures were prepared 
(2 Wild type, 2 mutants) and incubated overnight at 37°C in M9 glycerol. 
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O/D650 measurements were recorded for all four cultures (Table 5.1) and the 
dilution required for an O/D650 of 0.1 was calculated. 
The assay was then performed as before with O/D650 readings taken 
every hour. After growth overnight further readings were taken at 2 hour 
intervals. The data showed growth in both the wild type and mutant cultures 
grown with 0.2% glucose within the first 6 hours, with the cultures in 
stationary phase after overnight growth. Critically, while there was no 
observable growth in either of the cultures grown with 0.2% galactose in the 
first 6 hours, after overnight growth, the wild type strain was in log phase and 
after 30 hours had reached stationary phase. However no growth was 
observed with the mutant strain (Figure 5.6). This demonstrated that under 
the selected pre-growth conditions (M9 salts with 0.2% glycerol) that growth 
in galactose media was dependent on galactose transport. In addition to this 
it demonstrated that under these conditions, galactose transport was 
sufficiently up-regulated to allow growth after overnight incubation, unlike pre-
growth in LB media. 
5.3.1.3. Zone of inhibition assays 
With the pre-growth conditions determined, the next step was to 
determine the activity of the compounds in vitro, and compare the results to 
the activity of ciprofloxacin 1-18. Stock solutions of the compounds were 
prepared in 100 mM acetic acid, at a concentration of 3.02 mM (equivalent to 
1 mg/mL of ciprofloxacin). A dilution series was then prepared using 1 in 5 
dilutions down to a concentration of 0.965 µM. Initially, the compounds were 
screened against wild type E. coli on M9 agar, in order to establish rough 
MIC values. A wild type culture was grown overnight at 37°C in LB media, 
and then diluted to an O/D650 of approximately 0.1. The culture was then 
grown to an O/D650 of approximately 0.6 and inoculated into an agarose 
solution (4 ml culture in 100 ml of agar). This was added to the LB agar and 
left to set, 5 µL of each concentration of each compound was then spotted 
onto the agar, left to dry, and the plates incubated overnight at 37°C. After 
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incubation, the zones of inhibition around the antibiotic spots were measured 
and the data analysed (Figure 5.7) 
 
 
Figure 5.7: Mean zones of inhibition of ciprofloxacin 1-18 and the three glycosylated 
derivatives 5-15−17 against WT E.coli grown on LB media. The experiment was run 
as a single sample. Error bars correspond to plus or minus 0.5 mm. 
 
The data, as expected, shows concentration dependency for all four 
compounds. The key trend across the compounds in the data set is the 
decrease in activity with increasing molecular weight, with the largest 
derivative, cpf-lac 5-16 showing an MIC somewhere between 0.12-0.6 mM. 
There is also a statistically significant difference between the activities of the 
cpf-glc 5-14 and cpf-gal 5-15 with MICs in the range of 0.96-4.8 µM and 
0.024-0.12 mM respectively. As the molecular weight of these compounds is 
identical, it suggests there may be some kind of structure based recognition 
involved, thus supporting the conclusions of Jung et al. [248].  
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To test the hypothesis the compounds were screened again using the 
previously determined experimental conditions. M9 agar plates were 
prepared, half with 0.2% glucose, half with 0.2% galactose. The assay was 
performed using the same protocol as the LB agar assay, but using M9 
glycerol as the pre-growth media. This resulted in slower bacterial growth, 
however a suitable O/D650 was reached and the culture inoculated into the 
top agar. The plates were incubated as before and the zones of inhibition 
measured (Figure 5.8).  
The results of this assay show the same pattern of activity as previously 
observed with growth on LB media. However, the key finding is that the 
difference in activity between the cpf-glc and cpf –gal conjugates is negligible 
on both media. Taking into account experimental error the activity is 
approximately equal. While the cpf-gal conjugate has a slightly higher activity 
on the M9 galactose, approximately 15% more effective at 3 mM, the same 
can be also said for the other two conjugates and ciprofloxacin. 
Consequently the increase in activity on M9 galactose could be attributed to 
the conditions being less favourable for bacterial growth than M9 glucose. In 
addition to this, on both the glucose and the galactose media, cpf-glc is more 
effective than cpf-gal. If active transport was involved, it would be expected 
for this observation to be reversed in M9 galactose media. As this is not the 
case it must therefore be concluded that the tested conjugates were not 
being taken up by active transport. 
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Figure 5.8: Mean zones of inhibition for ciprofloxacin and the glycosylated derivates 
against WT E. coli grown on A) M9 glucose and B) M9 galactose. The experiments 
were run in triplicate. Error bars correspond to the standard deviation of the data.  
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5.3.2. Activity of compounds against E.coli deficient in ompF 
As the initial assays had suggested that the sugar transport systems 
were not responsible for the uptake of the conjugates in E. coli, further 
experiments were required to ascertain how the conjugates were gaining 
access to the bacterial cell. As it was well established in the literature that 
fluoroquinolones gain access to the cells via OMPs[253-256], this seemed a 
logical uptake mechanism to investigate. A new set of M9 agar plates were 
prepared, and cultures were set up using an E. coli strain deficient in ompF. 
OmpF is differentially expressed depending upon the environmental 
conditions[257], existing as a trimer of β-barrels (Figure 5.9) spanning the 
outer membrane.  
 
Figure 5.9: Top down crystal structure of ompF   
 
For the assay against the ompF, the glucose concentration of the 
medium was increased from 0.2% to 0.5%, to replicate the conditions o f a 
published procedure[117, 148]. The remaining aspects of the experiment were 
unchanged. The experiment was performed in triplicate using only the wild 
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type BW25113 E.coli strain and the OmpF- mutant. After overnight growth at 
37°C the radii of inhibition were measured and the data plotted (Figure 5.10). 
 
Figure 5.10: Zones of inhibition of ciprofloxacin and derivatives against wild type and 
OmpF
-
 E. coli. A) Ciprofloxacin Vs WT B) Ciprofloxacin Vs ompF
-
 C) Cpf-Glc Vs WT 
D) Cpf-Glc vs. OmpF
-
 E) Cpf-Gal Vs WT F) Cpf-Gal vs. OmpF
-
 G) Cpf-Lac Vs WT H) 
Cpf-Lac Vs OmpF
-
. The experiments were run in triplicate. Error bars correspond to 
the standard deviation of the data.  
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This experimental run showed a clear decrease in activity with the 
removal of OmpF from the E. coli. While activity was not completely 
eliminated, presumably due to the continued presence of OmpC, there was a 
statistically significant reduction in activity for all three conjugates. In all 
cases the MIC was raised to an extent whereby a previously lethal 
concentration proved to be sub-lethal in the OmpF- mutant.  
5.4. Conclusions and future work 
In this section a set of growth conditions have been established where 
galactose transport was essential for bacterial growth. In addition to this the 
conditions also allow bacterial growth in a galactose medium to occur without 
a prolonged lag phase. 
Experiments have been performed to determine to what extent, if any, 
the compounds synthesised by S.J. Milner are accessing bacterial cells by 
active transport via sugar uptake systems. The results obtained suggest that 
while the glycosylated conjugates retain their activity against E.coli, there is 
no significant variation in activity when the transport system required for the 
uptake of a specific carbon source is not present. Therefore it must be 
concluded that these conjugates are not entering the cell via active transport.  
Further experiments have determined that the likely mode of entry into 
the cell is via the outer membrane porins. While preliminary experiments on a 
variety of mutants yielded inconclusive data, a further assay focusing purely 
on the OmpF- mutant showed a clear and significant reduction in activity, in 
agreement with the literature[49, 256, 258]. This demonstrates that despite the 
additional steric bulk associated with the glycosylated conjugates, they can 
still pass through the outer membrane and ultimately reach their target.  
Potential future work in this area could be pursued by creating 
alternative glycosylated fluoroquinolones using monosaccharides such as 
xylose and arabinose to ascertain if conjugates containing these sugars 
could be actively transported. Another synthetic option would be to create 
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glycosylated fluoroquinolones with cleavable linkers, as previous research 
has shown that the added steric bulk of the sugar moiety reduces the ability 
of ciprofloxacin to bind to its target. Further screening work of mutants could 
also be undertaken to further substantiate the conclusion that glycosylated 
fluoroquinolones are still gaining access to the periplasm through porins, but 
aren’t gaining access to the cytoplasm via active transport.
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6. Conclusions and future work 
6.1. Conclusions 
An analogue of the Bacillus siderophore petrobactin has been 
synthesised and fully characterised. Attempts were also made to prepare a 
Trojan horse conjugate based on the analogue, using ciprofloxacin as the 
antimicrobial component. These attempts were unsuccessful as it was found 
the protected conjugates were unstable and decomposed when attempts 
were made to deprotect them to yield the final conjugate. This was due to the 
instability of the amide bond bound to the central citrate carboxylate group. 
When a glycine spacer was introduced, a similar process occurred. This was 
possibly due to cyclisation of the backbone, and subsequent release of the 
ciprofloxacin component.  
A Trojan horse conjugate was prepared using the Ugi condensation, 
and several compounds were synthesised to form a set of building blocks for 
a library of potential Ugi conjugates. The synthesised Ugi conjugate was 
screened for activity against Escherichia coli on both nutrient rich and 
minimal media. The Ugi conjugate was also subjected to a DNA gyrase 
assay. The conjugate was found to be active against E. coli and was 
demonstrated to still be exerting its antimicrobial effect by inhibiting the 
activity of DNA gyrase. However, the activity of the conjugate was found to 
be lower than that of the parent antimicrobial ciprofloxacin. This observation 
can be attributed to the steric bulk of the siderophore component inhibiting 
the ability of ciprofloxacin to bind DNA gyrase. Additionally, the steric bulk of 
the siderophore component may have been inhibiting rather than aiding 
uptake. This would explain the difference in the MIC observed between the 
disc diffusion assay and the gyrase assay.  
An asymmetric bis-catechol ligand and a series of bis-catecholimines 
were synthesised and fully characterised. The bis-imine ligands were 
subjected to preliminary screening against E. coli to ascertain if they 
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possessed antimicrobial activity. The initial screening showed promising 
results. However, stability studies determined that the compounds were 
unstable under the assay conditions. The asymmetric ligand also showed 
promising antibacterial activity however analysis by UV/vis 
spectrophotometry and electrochemistry demonstrated that the compound 
was susceptible to oxidation. Consequently the active species could not be 
identified. 
A set of glycosylated fluoroquinolones previously synthesised within the 
group was screened against a variety of E. coli strains to ascertain their 
mechanism of uptake. The studies determined that the conjugates were not 
being actively transported; when bacteria were grown under conditions 
requiring a specific sugar, galactose, there was no statistically significant 
difference in inhibition between the conjugates. Additionally, further 
experiments against an OMP mutant showed a decrease in activity, 
demonstrating that the conjugates were gaining access to the cells via 
OMPs. 
6.2. Future work 
The primary focus of future work should be completing the synthesis of 
the petrobactin analogue-ciprofloxacin conjugate. This would require a new 
protecting group strategy to try and avoid the problems observed with the 
methods attempted in this thesis. Additionally further analogues could be 
prepared using alternative antimicrobials, backbone lengths and different 
catechol configurations. 
The Ugi analogue has shown promise as a novel way of generating 
iron-chelator antimicrobial conjugates. With a new set of bui lding blocks 
prepared, a series of Ugi conjugates could be prepared and deprotected, and 
then screened to ascertain their activity against bacterial species. Using 
longer linkers between functional groups could potentially reduce the steric 
hindrance which inhibits the binding of ciprofloxacin to DNA gyrase. 
Additionally Ugi conjugates should be synthesised with different iron binding 
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groups including carboxylates as well as catechols to generate a range of 
novel iron chelators. There is also scope to introduce alternative 
antimicrobials other than ciprofloxacin, providing they contain a functional 
group required for the Ugi condensation.  
The bis-catecholate ligands showed promising activity, but are unstable 
in solution. Consequently, they are unsuitable for use as antimicrobials. 
Future work on this area should focus on the synthesis and analysis of the 
metal complexes of these ligands. Preparing complexes with gallium or an 
alternative antibacterial metal may provide a method of delivering 
antimicrobial metals into bacterial cells, as has previously been demonstrated 
using ferrioxamine. Additionally, complexation of the ligands with a metal ion 
may increase the stability of the ligands in solution, and therefore increase 
their suitability for use as antimicrobials.  
The glycosylated fluoroquinolones examined in this thesis utilised the 
sugars glucose, galactose and lactose. Future work in the area could focus 
on alternative sugars, or labile linkers. Examination of alternative sugars such 
as xylose or arabinose may yield conjugates that can be actively transported, 
and this should be investigated. 
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7. Experimental 
7.1. General Chemistry Procedures 
7.1.1. Mass Spectrometry 
Positive and negative ESI mass spectrometry (high and low resolution) 
was performed using a Thermo-Finnigan LCQ Spectrometer. LC-MS was 
performed using an Agilent 1200 series column using a H2O:MeCN gradient 
starting from 9:1, up to 1:4 after 25 minutes and Bruker MicrOTOF. MS-MS 
experiments were performed using a Bruker MicrOTOF. 
7.1.2. NMR 
1H NMR (399.785 MHz), 13C NMR (100.535 MHz), and 19F NMR 
(376.152 MHz) spectra were recorded on Jeol ECS 400 or Jeol ECX 400 
NMR spectrometers in the stated deuterated solvents. Variable temperature 
NMR was performed using a Bruker AV500 NMR spectrometer. All 
resonances were reported in parts per million (ppm) using the residual 
solvent signal as a reference. Multiplets corresponding to multiple protons 
are reported as ranges, single proton multiplets are reported from the 
midpoint of the resonance. J values are reported in Hertz to one decimal 
place. All 13C NMR spectra are proton de-coupled. Reference signals were 
as follows; 7.26 ppm and 77.16 ppm (CDCl3), 3.31 ppm and 49.00 ppm (d3-
MeOD), 2.50 ppm and 39.53 ppm (d6-DMSO). For 
19F NMR, fluorobenzene 
was used as a standard. Chemical shifts for multiplets are reported from the 
middle of the multiplet. 
7.1.3. IR 
IR spectra were recorded using a Thermo Nicolet Avatar FTIR 
spectrometer, using KBr discs. Discs were pressed under a pressure of 10 
tonnes. Oils were analysed by dissolving in a specified anhydrous solvent 
and their solution spectra recorded using the same instrument. IR spectra 
were processed using OMNIC software. 
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7.1.4. UV 
UV/vis absorption spectra were recorded using a Hitachi U-300 
spectrophotometer in 1 cm quartz cuvettes. The data was processed using 
Origin pro 7.0 software. 
7.1.5. Electrochemistry 
Electrochemical experiments were performed using a Voltalab PST050, 
and the data collected using Voltamaster 4 software. Experiments were run 
in MeCN with 0.1 M tetrabutyl ammonium hexafluorophosphate ([( t-
butyl)4N]PF6) as a supporting electrolyte at pH 7.0. Potentials were measured  
relative to a calomel electrode with a platinum disc as the working electrode 
and platinum wire as the counter electrode. 2 mM ferrocene was used as a 
standard to calibrate the electrode. Data was processed using Origin pro 7.0  
7.1.6. Spectroelectrochemistry 
Spectroelectrochemical experiments were performed using a Mom 
Technologies Compactstat.e and the data collected using IVIUM software, 
and a Hitachi U-300 UV spectrometer. Experiments were run in MeCN with 
0.1 M [(t-butyl)4N]PF6 as a supporting electrolyte, in a quartz cuvette with a 1 
mM path length. Potentials were measured relative to a Ag/AgCl electrode 
with a platinum mesh as the working electrode and platinum wire as the 
counter electrode. 2 mM ferrocene was used as a standard to calibrate the 
electrode. Data was processed using Origin pro 7.0 
7.1.7. HPLC 
HPLC was performed using Gilson HPLC apparatus (Gilson 234 auto-
injector, Gilson 321 pump, Gilson 170 diode array detector) with an HPLC 
technology Alphasil5ODS column (length = 25 cm internal diameter = 4.6 
mm) in an aqueous/MeCN system. Data was collected using Gilson Unipoint 
3.0 software and tabulated using Origin pro 7.0. 
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7.1.8. Melting Points 
Melting points were recorded using a Stuart Scientific SMP3 apparatus. 
These values are uncorrected and accurate to ±0.05 °C. 
7.1.9. Chemical Reagents 
All chemicals were purchased from Sigma Aldrich, Fischer Scientific or 
Alfa Aesar and were used as supplied unless otherwise stated. Chemicals 
were handled with appropriate safety measures according to toxicity and 
potential hazards. 
7.1.10. Solvents 
Solvents were supplied by Sigma Aldrich and Fischer scientific. 
Solvents were dried over 3 and 4 Å molecular sieves prior to use where 
appropriate. For all synthetic procedures deionised water was used. Dry THF 
DMF and MeCN were obtained using the departmental solvent stills (Prosolv 
MD 7 solvent purification system; solvents are passed through two columns 
of molecular sieves) and stored over 3 or 4 Å molecular sieves. 
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7.2. Chemical Synthesis 
7.2.1. Synthesis of a petrobactin analogue and the ciprofloxacin 
conjugate of the petrobactin analogue 
7.2.1.1. Methyl-1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-
dihydroquinoline-3-carboxylate(2-20)[36] 
 
Molecular Formula: C18H20FN3O3 
Molecular Weight: 345.368 g mol
-1
 
 
To a stirred solution of ciprofloxacin 1-18 (3.00 g, 8.68 mmol) in 
anhydrous MeOH (100 mL) in an ice bath at 0-5 °C was added thionyl 
chloride (13.1 mL, 181 mmol) dropwise. The resulting yellow solution was 
heated under reflux at 80 °C for 24 hours, and allowed to cool to room 
temperature. Excess solvent was removed in vacuo. The resultant solid 
residue was re-suspended in aqueous K2CO3 (0.05 g/mL, 200 mL) to yield a 
basic solution. The product was extracted from the solution with DCM (3 x 80 
mL).The aqueous layer was diluted further with aqueous K2CO3 (0.05 g/mL, 
100 mL), and re-extracted with DCM (3 x 40 mL). The organic layer was 
washed with H2O (2 x 40 mL). The organic layer was dried over MgSO4, 
filtered and concentrated in vacuo, yielding the product as a pale yellow solid. 
Yield: 1.89 g, 63% 
m.p: Decomposed 226-227 °C 
Rf (4:1, DCM: MeOH): 0.40 
m/z (ESI): 346.16 ([M+H]+, 100%) 
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HRMS (ESI): Calc. for C18H21FN3O3= 346.1561. Found [M+H]
+ 346.1556, 
mean error= 1.2 ppm  
1H NMR (400 MHz, CDCl3): δH 8.53 (1H, s, H4), 7.99 (1H, d, 
3JH-F 13.6 Hz, 
H8), 7.25 (1H, d, 4JH-F  6.8 Hz, H11), 3.90 (3H, s, CH3, H18), 3.42 (1H, m, 
CH, H1), 3.18-3.21 (4H, m, piperazine CH2, H14/15), 3.05-3.07 (4H, m, 
piperazine CH2, H13/16), 1.93 (1H, broad s, NH), 1.28 (2H, m, cyclopropyl 
ring, CH2, H2/3), 1.11 (2H, m, cyclopropyl ring CH2, H2/3).  
13C NMR (100 MHz, CDCl3 ): δC 173.46 (C=O, C6), 166.70 (C=O, C5-C=O, 
C17), 153.59 (ipso-Ar C-F, d, 1JC-F 249.3 Hz, C9), 148.59 (C-H, C4), 145.26 
(ipso-Ar C-C, d, 2JC-F = 10.68 Hz, C10), 138.22 (ipso-Ar C-C, C5), 122.99 
(ipso-Ar, d, 3JC-F = 8.0 Hz, C7), 113.19 (C-H, d, 
2JC-F = 24.0 Hz, C8), 109.95 
(ipso-Ar, C12) 104.83 (Ar C-H, d, 3JC-F = 3.1 Hz C11), 51.97 (CH3, C18), 
50.94 (CH2, C13/14/15/16), 50.89 (CH2, C13/14/15/16), 45.71 (CH2, 
C13/14/15/16/), 34.23(CH, C1), 7.65 (CH2, C2/3). 
19F NMR (CDCl3, 376 MHz, Fluorobenzene): δF -123.52 (dd, JH-F = 12.6 Hz, 
6.9 Hz, F9)  
IR (KBr cm-1): 3431.1 (N-H), 1724.0 (C=O), 1620.6 (C=O), 1270.7 (C-O) 
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7.2.1.2. Methyl-7-[4-(2-([tert-butoxy)carbonyl]amino)acetyl)piperazine-1-yl]-1-
cyclopropyl-6-fluoro-4-oxo-decahydroquinoline-3-carboxylate (2-
48)[151] 
 
Molecular Formula: C25H31FN4O6 
Molecular Weight: 502.223 g
 
mol
-1
 
 
To a stirred solution of Methyl-1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-
1,4-dihydroquinoline-3-carboxylate 2-20 (0.69 g, 1.99 mmol) in anhydrous 
DMF (60 mL) was added Boc-glycine 2-47 (0.35 g, 1.99 mmol), and 
EDC·HCl (0.38 g, 1.99 mmol). To the stirred solution was added DIPEA (0.35 
mL, 2.01 mmol). The solution was briefly stirred, then HOBt·H2O (0.27 g, 
1.99 mmol) was added. The mixture was left to stir. After 24 hours, the 
solvent was removed in vacuo. The residue was diluted with deionised H2O 
(60 mL) and extracted with DCM (3 x 110 mL). The organic layers were then 
washed with H2O, CH3SO3H (0.05 M), NaHCO3 (0.05 M), NaCl and H2O (all 
60 mL). The organic layer was dried over MgSO4 and filtered. The organic 
layer was concentrated in vacuo to yield the product as a cream coloured 
solid. The crude product was triturated in diethyl ether and isolated by 
filtration as a white solid. 
Yield: 0.47 g, 68%  
m.p: 186-187 °C (lit 194-195 °C [151])  
Rf (3:1, CHCl3: MeOH): 0.60 
m/z (ESI): 525.21 ([M+Na]+, 38%), 503.23 ([M+H]+, 100%). 
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HRMS (ESI): Calc. for C25H32FN4O6= 503.2300. Found [M+H]
+ 503.2303, 
mean error= -0.5 ppm. Calc. for C25H31FN4NaO6= 525.2120. Found [M+Na]
+ 
525.2122, mean error= -0.6 ppm. 
 1H NMR (400 MHz, CDCl3): δH 8.49 (1H, s, H4), 7.96 (1H, d, 
3JH-F =13.6 Hz, 
H8), 7.23 (1H, d, 4JH-F = 6.8 Hz, H11), 5.50 (1H, br s, NH), 4.01 (2H, d, 
3JH-H 
= 4.57 Hz, H20), 3.91 (3H, s, H18), 3.85-3.87 (2H, m, H14/15), 3.61-3.64 
(2H, m, H14/15), 3.42 (1H, m, H1), 3.22-3.27 (4H, m, H13, 16), 1.44 (9H, s, 
H23, 24, 25), 1.30-1.35 (2H, m, H2/3), 1.11-1.16 (2H, m, H2/3) 
13C NMR (100 MHz, CDCl3): δC 172.23 (C=O, C6), 172.202 (C=O, C19), 
167.13 (C=O, C21), 166.29 (C=O, C17), 154.65 (ipso-Ar, d, 1JC-F = 249 Hz, 
C9), 148.59 (CH, C4), 143.96 (ipso-Ar, d, 2JC-F = 10.7 Hz, C10), 138.01 (ipso-
Ar, C5), 123.72 (ipso-Ar, d, 3JC-F = 6.9 Hz, C7), 113.53 (CH, d, 
2JC-F = 23.0 
Hz, C8), 110.18 (ipso-Ar, C12), 105.36 (CH, d, 3JC-F = 3.1 Hz, C11), 79.95 
(4°C, C23), 52.18 (CH3, C18), 50.16 (CH2, C14/15), 49.73 (CH2, C14/15), 
44.40 (CH2, C20), 42.29 (CH2, C13/16), 41.86 (CH2, C13/16), 34.66 (CH, C-
1), 28.44 (CH3, C23/24/25), 8.26 (CH2, C2, 3) 
19F NMR (376 MHz, CDCl3): δF -124.01 (dd, JH-F = 12.6 Hz, 6. 9 Hz, F-9) 
IR (KBr, cm-1): 3427.2 (N-H), 1716.0 (C=O), 1653.3 (C=O), 1632.5 (C=O), 
1495.6 (C-O), 1456.0 (C-O). 
Spectral data consistent with literature values [151] 
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7.2.1.3. Methyl-7-[4-(2-aminoacetyl)piperazin-1-yl]-1-cyclopropyl-6-fluoro-4-
oxo-decahydroquinline-3-carboxylate hydrochloride salt (2-49)[151] 
 
Molecular Formula: C20H24ClFN4O4 (C20H23FN4O4 as free amine) 
Molecular Weight: 438.880 g mol
-1
 (402.419 g
 
mol
-1
 as free amine)
 
 
 
Methyl-7-[4-(2-([tert-butoxy)carbonyl]amino)acetyl)piperazine-1-yl]-1-
cyclopropyl-6-fluoro-4-oxo-decahydroquinoline-3-carboxylate 2-48 (0.39 g, 
0.77 mmol) was dissolved in ice cold HCl (4 M in MeOH, 37 mL). The 
reaction was stirred overnight. After 18 hours, the solvent was removed in 
vacuo. The solid residue was redissolved in MeOH (20 mL) and concentrated 
in vacuo a second time to remove any residual HCl. The solid residue was 
resuspended in anhydrous MeOH (20 mL) and precipitated using Et2O. The 
white precipitate was isolated by fi ltration and retained as the product.  
Yield: 0.34 g, 98% 
m.p: Dec. 230.0-230.5 °C 
m/z (ESI): 425.16 ([M+Na]+, 100%), 403.18 ([M+H]+, 44%), 202.09 ([M+2H]2+, 
38%). 
HRMS (ESI): Calc. for C20H24FN4O4= 403.1776. Found [M+H]
+ 403.1766, 
mean error= 2.7 ppm, Calc. for C20H23FN4NaO4 = 425.1596. Found [M+H]
+ 
425.1577, mean error= 4.6 ppm. 
1H NMR (400 MHz, d6-DMSO) δH 8.44 (1H, s, H4), 8.30 (2H, bs, NH2), 7.75 
(1H, d, 3JH-F =13.2 Hz, H8), 7.44 (1H, d, 
4JH-F = 7.3 Hz, H11), 4.01 (2H, bs, 
H20), 3.71-3.74 (5H, m, H 14, 15, 18), 3.61-3.66 (3H, m, CH, H1, CH2, H14, 
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15), 3.23-3.30 (4H, m, H13, 16), 1.22-1.27 (2H, m, H2/3), 1.08-1.12 (2H, m, 
H2/3) 
13C NMR (100 MHz, d6-DMSO): δC 172.25 (C=O, C6), 165.58 (C=O, C21), 
165.40 (C=O, C17), 152.77 (ipso-Ar, d, C-F, 1JC-F = 247.0 Hz, C9), 148.94 
(CH, C4), 143.98 (ipso-Ar, d, C-C, 2JC-F = 10.8 Hz, C10), 138.53 (ipso-Ar, 
C5), 122.57 (ipso-Ar, d, 3JC-F = 6.9 Hz, C7), 112.00 (ipso-Ar, C-H d, 
2JC-F = 
23.0 Hz, C8), 109.33 (ipso-Ar, C12), 106.97 (CH, d, 3JC-F = 3.1 Hz, C11), 
51.37 (CH3, C18), 49.55 (CH2, C14/15), 49.51 (CH2, C14/15), 43.89 (CH2, 
C20), 41.24 (CH2, C13/16), 39.32 (CH2, C13/16), 34.76 (CH, C-1), 7.40 (CH2, 
C2/3) 
19F NMR (376 MHz, d6-DMSO): δF -124.69 (m, F-9) 
IR (KBr, cm-1): 3429.0 (N-H), 1725.4 (C=O), 1667.3 (C=O) 
 
7.2.1.4. 2-Hydroxy-4-methoxy-2-(2-methoxy-2-oxoethyl)-4-oxobutanoic 
acid(2-21)[150] 
 
Molecular Formula: C8H12O7 
Molecular Weight: 220.177 g mol
-1
 
 
To a stirred solution of citric acid 1-26 (30.22 g, 0.157 mmol) in anhydrous 
MeOH (150 mL), was added concentrated H2SO4 (0.6 mL, 1.84 g/mL). The 
mixture was stirred under reflux for one hour. The mixture was then allowed 
to cool to room temperature. The mixture was diluted with deionised H2O and 
neutralised using Ca(OH)2. The resultant white precipitate was removed by 
filtration and discarded. The filtrate was reduced in vacuo, yielding a clear oil 
which solidified upon cooling. The white solid was broken down to a powder 
and dried under vacuum. The powder was re-suspended in deionised water 
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(100 mL), and the mixture was sonicated for 20 minutes. Any insoluble 
material was re-suspended in a further 100 mL of deionised water and 
sonicated as before. The insoluble material was removed by filtration. The 
filtrate was acidified to pH 0.0 using concentrated HCl (12 M), yielding a 
white precipitate. The precipitate was isolated by fi ltration and re-dissolved in 
aqueous NaHCO3 (0.08 g/mL). The resulting solution was washed with 
CHCl3 (3 x 40 mL). The organic layers were retained. The aqueous layer was 
re-acidified to pH 0.0 with concentrated HCl to yield a fine white precipitate. 
The precipitate was isolated by filtration and washed with CHCl3 (1 x 20 mL) 
and then dried to yield the product. The organic layers were kept and 
concentrated under vacuum yielding a white solid which was dried on the 
vacuum line. The by-product in the CHCl3 washes was found by 
1H NMR 
analysis to be 1,3,5-trimethyl citrate. 
Yield: 10.70 g, 31%  
m.p: 115-120 °C (lit 109-115 °C[259]) 
Rf (10:1:1, DCM: MeOH: HCOOH): 0.48 
m/z (ESI): 243.04 ([M+Na]+, 100%), 221.06 ([M+H]+, 68.4%). 
HRMS (ESI): Calc. for C8H13O7 = 221.0656. Found 221.0654; mean error= 
0.8 ppm Calc. for C8H12NaO7 = 243.0475. Found 243.0472; mean error= 1.4 
ppm. 
1H NMR (400 MHz, d6-DMSO): δH 3.55 (6H, s, CH3, H7, 8), 2.83 (2H, d, 
2JH-H 
= 15.0 Hz, CH2, H3/5), 2.72 (2H, d, 
2JH-H = 15.0 Hz, CH2, H3/5).  
13C NMR (400 MHz, d6-DMSO): δC 174.27(C=O, C1), 169.98 (C=O, C4, 7), 
72.61 (4° C, C-OH, C2), 51.47 (CH2, C3, 6), 42.71 (CH3, C5, 8).  
IR (KBr cm-1): 3474.1 (O-H), 1742.9 (C=O), 1634.1 (C=O) 
1H NMR data consistent with literature values [150] 
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7.2.1.5. 1,2,3-Trimethyl 2-hydroxypropane-1,2,3-tricarboxylate(2-22)[149] 
 
Molecular Formula: C9H14O7 
Molecular Weight: 234.203 g mol
-1
 
 
To a stirred solution of hydroxy-4-methoxy-2-(2-methoxy-2-oxoethyl)-4-
oxobutanoic acid 2-21 (2.51 g, 11.4 mmol) in anhydrous MeOH (30 mL) was 
added H2SO4 (0.2 mL, 1.84 g/mL) and 2,2-dimethoxy propane (1.6 mL, 13 
mmol). The initially white suspension became a clear solution upon stirring. 
The solution was stirred and heated under reflux for 7 hours. The solution 
was cooled to room temperature and the excess solvent removed in vacuo, 
yielding a white powder. This was further dried under vacuum. The product 
was recrystallised from a minimal amount of hot H2O to produce a white 
crystalline solid which was isolated by filtration. 
Yield: 21.60 g, 81% 
m.p: 70.2-73.5 °C (lit 75-77 °C[260]) 
Rf (10:1:1, DCM: MeOH: HCOOH): 0.54 
m/z (ESI): 257.06 ([M+Na]+, 100%), 235.08 ([M+H]+, 18.6%). 
HRMS (ESI): Calc. for C9H15O7= 235.0812. Found [M+H]
+ 235.0806 mean 
error= 2.6 ppm Calc. for C9H14NaO7= 257.0632. Found [M+Na]+ 257.0630 
mean error= 0.9 ppm.  
1H NMR (400 MHz, CDCl3,): δH 3.83 (3H, s, CH3, H9), 3.69 (6H, s, CH3, H7, 
8), 2.89 (2H, d, 2JH-H = 16.0 Hz, CH2, H3/5), 2.78 (2H, d, 
2JH-H = 16.0 Hz, CH2, 
H3/5). 
13C NMR (100 MHz, CDCl3): δC 173.82 (C=O, C1), 170.20 (C=O, C4, 6), 
73.247 (4°-C, C2), 53.22 (CH3, C9), 52.02 (CH3, C7, 8), 43.05 (CH2, C3, 5). 
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IR (KBr cm-1): 3481.8 (O-H), 1756.7 (C=O), 1742.6 (C=O), 1722.1 (C=O) 
Spectroscopic data is consistent with literature values[260] 
7.2.1.6. 3-Hydroxy-3-(methoxycarbonyl)pentanedioic acid (2-24)[149] 
 
Molecular Formula: C7H10O7 
Molecular Weight: 206.150 g mol
-1
 
 
To a stirred solution of 1,2,3-trimethyl 2-hydroxypropane-1,2,3-tricarboxylate  
2-22 (1.17 g, 5.0 mmol) in 70% MeOH (v/v in H2O, 7.5 mL) was added an 
aqueous solution of 1 M NaOH (10 mL). The solution was then left to stir. 
After three hours the solvent was removed in vacuo to yield a white solid. 
This was re-dissolved in MeOH and desalted using a Dowex (50WX8-400) 
ion exchange column, using MeOH as the eluent. The solvent was removed 
in vacuo to yield a white solid which was recrystallised from hot acetone to 
yield the product as a white crystalline solid. 
Yield: 0.54 g, 53% 
m.p: 163.4-166.4 °C (lit 167 °C [149]) 
Rf (10:1:1, DCM: MeOH: HCOOH): 0.24 
m/z (ESI): 229.03 ([M+Na]+, 100%), 207.05 ([M+H]+, 10.29%). 
(ESI): Calc. for C7H11O7= 207.0499 [M+H]+. Found 207.0494; mean error= 
3.3 ppm, Calc. for C7H10NaO7= 229.0319 [M+Na]+ Found 229.0319 mean 
error= 0.1 ppm. 
1H NMR (400 MHz, d3-MeOD): δH 3.75 (3H, s, CH3, H7), 2.74-2.93 (4H, m, 
CH2, H3,5). 
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13C NMR (100 MHz, d3- MeOD): δC 176.32 (C=O, C1), 174.11 (C=O, C4, 6), 
74.83 (4°C, C2), 53.23 (CH3, C7), 44.29 (CH2, C3, 5). 
IR (KBr, cm-1): 3388.9 (O-H), 1747.7 (C=O), 1716.1 (C=O)  
Spectroscopic data is consistent with literature values [149] 
7.2.1.7. 2-Tert-butyl 1,3-dimethyl 2-hydroxypropane-1,2,3-tricarboxylate (2-
23)[152] 
 
Molecular Formula: C12H20O7 
Molecular Weight: 276.283 g mol
-1
 
 
A solution of hydroxy-4-methoxy-2-(2-methoxy-2-oxoethyl)-4-oxobutanoic 
acid 2-21 (6.00 g, 27.2 mmol) in tert-butyl acetate (50 mL, 372 mmol) was 
prepared and sealed in a flask. The flask was purged of oxygen using a 
nitrogen balloon and a bleed needle. Concentrated perchloric acid (70%, 1 
mL, 4.6 mmol) was added by syringe to the solution. The solution was left to 
stir for 3 days under a nitrogen atmosphere. After 3 days the solution was 
adjusted to pH 6 by the slow addition of a saturated solution of NaHCO3. The 
organic layer was separated and retained. The aqueous layer was washed 
with diethyl ether (3 x 80 mL), the organic washes were combined, dried over 
MgSO4 and filtered. The dried washes were then concentrated in vacuo, and 
then dried further using a vacuum line. The oil was re -dissolved in 60-80 pet. 
ether and rapidly stirred, insoluble material was filtered and the filtrate 
concentrated in vacuo to yield the product as pale yellow oil. 
Yield: 3.69 g, 58% 
Rf (10:1:1, DCM: MeOH: HCOOH): 0.45 
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m/z (ESI): 299.11 ([M+Na]+, 100%). 
HRMS (ESI): Calc. for C12H20NaO7= 299.1101. Found [M+Na]
+ 299.1106, 
mean error= -1.6 ppm  
1H NMR (400 MHz, CDCl3,): δH 3.68 (6H, s, CH3, H7, 8), 2.74-2.88 (4H, m, 
CH2, H3/5), 1.49 (9H, s, CH3, H10, 11, 12).  
13C NMR (100 MHz, CDCl3): δC 172.76 (C=O, C1), 170.54 (C=O, C4, 7), 
83.28 (4°C, C−O, C9), 72.97 (4°C, C−OH, C2), 51.67 (CH3, C5, 8), 43.12 
(CH2, C3, 6), 27.43 (CH3, C10, 11, 12).  
IR (CHCl3, cm
-1): 3500.0 (O-H), 1739.6 (C=O), 1221.2 (C-O), 1155.2 (C-O) 
Spectroscopic data is consistent with literature values [152] 
7.2.1.8. 3-[(tert-Butoxy)carbonyl]-3-hydroxypentanedioic acid (2-15)[152] 
 
Molecular Formula: C10H16O7 
Molecular Weight: 248.230 g mol
-1
 
 
A solution of 2-tert-butyl-1,3-dimethyl-2-hydroxypropane-1,2,3-tricarboxylate 
2-23 (1.00 g, 3.63 mmol) in MeOH (30 mL) was cooled in an ice bath to 0 °C. 
A cold solution of NaOH (2 M, 10 mL) was added. The solution was allowed 
to warm to room temperature and left to stir. After three hours, the mixture 
was acidified to pH 2 using HCl (2 M). The solution was extracted using 
EtOAc (3 x 60 mL). The organic washes were combined and dried over 
MgSO4. The organic layer was filtered and concentrated in vacuo to yield 
pale oil, which solidified on the vacuum line to yield a white solid.  
Yield: 2.49 g, 75% 
m.p: 117.4-120.5 °C (lit 124 °C[152]) 
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Rf (10:1:1, DCM: MeOH: HCOOH): 0.33 
m/z (ESI): 271.08 ([M+Na]+, 100%). 
HRMS (ESI): Calc. for C10H9NaO7= 271.0788. Found [M+Na]
+ 271.0790, 
mean error= -0.8 ppm  
1H NMR (400 MHz, d3-MeOD): δH 2.86 (2H, d, 
2JH-H= 15.6 Hz, CH2, H3/5), 
2.71 (2H, d, 2JH-H= 15.6 Hz, CH2, H3/5), 1.48 (9H, s, CH3, H8, 9, 10) 
13C NMR (100 MHz, d3-MeOD): δC 173.80 (C=O, C1), 173.36 (C=O, C4, 6), 
83.42 (4°-C, C-OH, C2), 74.34 (4°-C, C(CH3)3, C9), 44.15 (CH2, C3,6), 28.04 
CH3 C10, 11, 12). 
IR (KBr, cm-1): 3477.2 (O-H), 1735.5 (C=O) 1707.7 (C=O), 1186.7 (C-O). 
Spectroscopic data consistent with literature values[152]. 
7.2.1.9. 2,3-Bis(benzyloxy)benzaldehyde (2-25)[138] 
 
Molecular Formula: C21H18O3 
Molecular Weight: 318.366 g mol
-1
 
 
To a stirred solution of 2,3-dihydroxy benzaldehyde 2-18 (5.00 g, 36.2 mmol) 
and benzyl chloride (10 mL, 86.9 mmol) in anhydrous EtOH (80 mL), was 
added K2CO3(S) (6.49 g, 46.9 mmol). The resulting suspension was refluxed 
at 80 °C. After 18 hours the suspension was cooled to room temperature and 
the solid formed removed by filtration. The solid was washed with acetone (3 
x 10 mL) and then discarded; the acetone wash was added to the filtrate. The 
filtrate was concentrated in vacuo to yield a pale waxy solid. The solid was 
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re-crystallised from hot MeOH to yield a pale brown solid which was isolated 
by filtration and retained as the product. 
Yield: 8.06 g, 70% 
m.p: 92.1- 93.1 °C  
Rf (10:1, CHCl3: MeOH): 0.85 
m/z (ESI): 341.12 ([M+Na]+, 76.47%,), 336.16 ([M+NH4]
+, 88.23%), 319.13 
([M+H]+, 100%,). 
HRMS (ESI): Calc. for C21H19O3= 319.1332. Found [M+H]
+ 319.1329, mean 
error= -0.8 ppm. Calc. for C21H18NaO3= 341.1150. Found [M+Na]
+ 341.1148, 
mean error= -0.7 ppm. 
1H NMR (400 MHz, CDCl3): δH 10.28 (1H, s, CH, H7), 7.41-7.43 (11H, m, Ar, 
C-H, H6, 10-14, 17-21), 7.26 (1H, m, Ar, C-H, H4), 7.12 (1H, m, Ar, C-H, H5) 
5.22 (2H, s, CH2, H8/15), 5.20 (2H, s, CH2, H8/15) 
13C NMR (100 MHz, CDCl3): δC 190.18 (C=O, C7), 151.98 (ipso-Ar, C-O, 
C2), 150.52 (ipso-Ar, C-O, C3), 136.24 (ipso-Ar, C-C, C9, 16), 130.44 (ipso-
Ar, C-C, C1), 129.90 (ipso-Ar, C-O, C2/3) 128.73-127.51(Ar. C-H, C10-14, 
17- 21), 124.20 (Ar, C-H, C5), 119.84 (Ar, C-H, C4), 119.51 (Ar, C-H, C6) 
76.40 (CH2, C8/15), 71.20 (CH2, C8/15) 
IR (KBr cm-1): 1699.4 (C=O), 1267.7 (C-O), 1247.0 (C-O).  
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7.2.1.10. 2,3-Bis(benzyloxy)benzoic acid (2-26)[153] 
 
Molecular Formula: C21H18O4 
Molecular Weight: 334.365 g
 
mol
-1
 
 
To a solution of 2,3-bis(benzyloxy)benzaldehyde 2-25 (3.61g, 11.3 mmol) in 
a 1:1 mixture of acetone (113 mL) and H2O (113 mL) was prepared. NaClO2 
(1.30 g, 14.4 mmol) in H2O (28 mL) and H3NSO3  (1.55 g, 16.0 mmol) in H2O 
(28 mL) were added in alternating portions over 45 minutes. The solution was 
left to stir in an open flask. After 1 hour the volume of the solvent was 
reduced in vacuo by approximately 50% until a white precipitate was 
observed. The precipitate was isolated by fi ltration and retained as the 
product.  
Yield: 3.40 g, 90% 
m.p: 123.9-124.7 °C (Lit 124-124.5 °C[138]) 
Rf: (10:1, CHCl3: MeOH): 0.57 
m/z (ESI): 357.109 ([M+Na]+, 84.2%), 352.15 ([M+NH4]
+, 100%), 335.13 
([M+H]+, 80.2%). 
HRMS (ESI): Calc. for C21H19O4= 335.1278. Found [M+H]
+ 335.1274, mean 
error= -3.5 ppm. Calc. for C21H22NO4= 353.1543. Found [M+Na]
+ 352.1543, 
mean error= 1.6 ppm.  
1H NMR (400 MHz, CDCl3): δH 11.44 (1H, s, COOH, H7), 7.75 (1H, dd,  
3JH-H 
= 7.9 Hz,  4JH-H = 1.6 Hz, Ar C-H, H6), 7.42 (10H, m, Ar, C-H, H10-14, 17-21), 
7.28 (1H,m, Ar, C-H, H4), 7.20 (1H, m, Ar, C-H, H5), 5.27 (2H,s, CH2, H8/15), 
5.21 (2H, s, CH2, H8/15). 
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13C NMR (100 MHz, CDCl3): δC 165.36 (C=O, COOH, C7), 151.30 (ipso Ar, 
C-O, C2), 147.08 (ipso Ar, C-O, C3), 135.81 (ipso Ar, C-C, C9/16), 134.66 
(ipso-Ar, C-C, C9/16) 129.25 -127.74 (Ar C-H, C10-14, 17-21), 124.98 (Ar, C-
H, C5 ), 124.35 (Ar C-H, C6), 118.93 (Ar, C-H, C4), 77.04(CH2, C8, 15),  
71.46 (CH2, C8, 15).  
IR (KBr cm-1): 1699.4 (C=O), 1267.7 (C-O), 1247.0 (C-O). 
 
7.2.1.11. 2,5-Dioxopyrrolidin-1-yl 2,3-bis(benzyloxy)benzoate (2-27)[153] 
 
Molecular Formula: C25H21NO6 
Molecular Weight: 431.437 g mol
-1
 
 
To a stirred solution of 2,3-bis(benzyloxy)benzoic acid 2-26 (1.36 g, 4.07 
mmol) in 1,4-dioxane (41 mL) was added NHS (0.49 g, 4.30 mmol). The 
solution was cooled to 0 °C in an ice bath. To the chilled solution, DCC (0.85 
g, 4.12 mmol) was added. The ice bath was removed and the reaction 
allowed to return to room temperature and left to stir. After 24 hours the solid 
urea formed was removed by filtration. The fi ltrate was concentrated in vacuo 
to leave an oil. The product was crystallised from the oil by addition of iso-
propanol. The crystals were then isolated by filtration and dried in vacuo. 
Yield: 1.51 g, 86% 
m.p: 95.6-98.2 °C (lit 112-114 °C [153]) 
Rf (10:1, CHCl3: MeOH): 0.69 
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m/z (ESI): 454.13 ([M+Na]+, 66.66%), 449.17 ([M+NH4]
+, 100%), 432.14 
([M+H]+, 21.79%). 
HRMS (ESI): Calc. for C25H22NO6 432.1442. Found [M+H]
+ 432.1450, mean 
error= -1.7 ppm. Calc. for C25H21NNaO6= 454.1261. Found [M+Na]
+ 
454.1270, mean error= -2.1 ppm error. 
1H NMR (400 MHz, CDCl3,): δH 7.61 (1H, m, Ar, C-H, H6), 7.52-7.27 (11H, m, 
Ar, C-H, H4, 10-14, 17-21), 7.15 (1H, m, Ar, C-H, H5), 5.16 (4H, s, CH2, 
H8/15), 2.88 (4H, s, CH2, H23, 24). 
13C NMR (100 MHz, CDCl3): δC 169.72 (C=O, C7), 161.08 (C=O, C22/25), 
153.28 (ipso-Ar, C−O, C2), 150.1 (ipso-Ar-C−O, C3), 137.224 (ipso-Ar, C−C, 
C9/16), 136.46 (ipso-Ar, C−C, C9/16), 128.85-127.8 (Ar C-H, C10-14, 17-21), 
124.45 (Ar, C−H, C6), 122.19 (Ar, C−H, C5), 121.19 (ipso-Ar, C-C ,C1), 
120.25 (Ar, C−H, C4), 75.79 (CH2, C8/15), 71.26 (CH2, C8/15), 25.36 (CH2, 
C23, 24). 
IR (KBr, cm-1): 1768.1 (C=O), 1739 (C=O), 1382.2 (N-O), 1262.1 (C-O), 
1247.9 (C-O). ` 
7.2.1.12. tert-Butyl N-(2-aminoethyl)carbamate (2-31)[157-158] 
 
Molecular Formula: C7H16N2O2 
Molecular Weight: 160.214 g mol
-1  
 
1,2-Diaminoethane 2-19 (10 mL, 150 mmol) was dissolved in DCM (20 mL). 
To this stirred solution was added dropwise, a solution of di-tert-
butyldicarbonate 2-30 (3.28 g, 15.0 mmol) in DCM (30 mL). The mixture was 
left to stir. After 20 hours, the solvent was removed in vacuo. The residue 
was taken up in NaCl: EtOAc (1:1). The aqueous layer was discarded, and 
the organic layer was washed with saturated NaCO3 (3 x 30 mL). The 
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aqueous washes were discarded. The organic layer was retained and dried 
over MgSO4 and filtered. The resulting filtrate was then concentrated in 
vacuo, yielding a pale yellow oil.  
Yield: 1.96 g, 81%  
Rf (10:1:0.1, CHCl3: MeOH: NH4OH): 0.55 
m/z (ESI): 161.13 ([M+H]+, 100%). 
HRMS (ESI): Calc. for C7H17N2O2= 161.1285, Found [M+H]
+ 161.1287, mean 
error= -0.9  
1H NMR (400 MHz, CDCl3): δH 4.92 (1H, Broad s, NH), 3.16-3.21 (2H, m, 
CH2, H2), 2.80 (2H, t, 
3JH-H = 6.0 Hz, CH2, H1), 1.73 (2H, Broad s, NH2), 1.43 
(9H, s, CH3, H5, 6, 7). 
13C NMR (100MHz, CDCl3) δC 156.20 (C=O, C3), 79.17 (4°C, C4), 42.66 
(CH2, C2), 41.46 (CH2, C1), 28.38 (CH3, C5, 6, 7) 
IR (CHCl3, cm
-1): 3455.5 (N-H), 1706.8 (C=O), 1167.4 (C-O). 
Spectroscopic data is consistent with literature values [157]. 
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7.2.1.13. tert-Butyl-N-(2-[[2,3-bis(benzyloxy)phenyl]formamido] 
[261]ethyl)carbamate (2-32) 
 
Molecular Formula: C28H32N2O5 
Molecular Weight: 476.564 g mol
-1
 
 
To a stirred solution of 2,5-dioxopyrrolidin-1-yl 2,3-bis(benzyloxy)benzoate 2-
27 (1.00 g, 2.32 mmol) in acetone (10 mL) was added a solution of tert-butyl 
N-(2-aminoethyl)carbamate 2-31 (0.40 g, 2.50 mmol) in H2O (3.5 mL) and 
triethylamine (1 mL, 7.20 mmol). A cloudy mixture was observed, followed by 
the precipitation of a cream coloured solid. The mixture was left to stir. After 
24 hours the solvent was removed in vacuo to yield a pale yellow solid. The 
solid was taken up in EtOAc (40 mL) and washed with HCl (0.1 M, 3 × 40 
mL). The organic layer was then washed with H2O (2 × 30 mL) until the 
aqueous washes were neutral. The organic layer was dried over MgSO4 and 
filtered. The filtrate was concentrated in vacuo to yield the product as a white 
solid. 
Yield: 1.10 g, 100% 
m.p: 128.2-131.5 °C 
Rf (10:1, CHCl3: MeOH): 0.63 
m/z (ESI): 499.22 ([M+Na]+, 39.1%), 477.24 ([M+H]+, 100%). 
HRMS (ESI): Calc. for C28H33N2O5= 477.2384, Found [M+H]
+ 477.2393, 
mean error= -1.8 ppm 
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1H NMR (400 MHz, CDCl3): δH 7.99 (1H, m, NH2), 7.61 (1H, m, Ar C-H, H6 
7.28-7.63 (10H, m, Ar C-H, H10-14, 17-21 ), 7.06-7.07 (2H, m, Ar C-H, H4, 5) 
5.0 (2H,s, CH2, H8/15), 5.01 (1H, s, CH2, H8/15), 3.25-3.29 (2H, m, CH2, 
H22), 3.07-3.08 (2H, m, CH2, H23), 1.32 (9H, s, CH3, H26, 27, 28).  
13C NMR (100 MHz, CDCl3): δC 166.11 (C=O, C7), 156.16 (C=O, C24), 
151.82 (ipso-Ar, C-O, C2), 146.91 (ipso-Ar, C-O, C3), 136.48 (ipso-Ar, C-C, 
C9/16), 136.40 (ipso-Ar, C-C, C9/16), 128.99-127.27 (Ar C-H, C10-14, 17-
21), 124.55 (Ar C-H, C6), 123.34 (Ar C-H, C5), 117.27 (Ar C-H, C4), 79.37 
(4°C, C25) 76.61 (CH2, C8/15), 71.44 (CH2, C8/15), 41.04 (CH2, C23), 39.72 
(CH2, C22), 28.49 (CH3, C26, 27, 28)  
IR (KBr cm-1): 3350.7 (N-H), 3327.5 (N-H), 1685.5 (C=O), 1638.0 (C=O), 
1217.3 (C-O). 
7.2.1.14. N-(4-aminobutyl)-2,3-bis(benzyloxy)benzamide hydrochloride 
(2-40)[161] 
 
Molecular Formula: C25H29ClN2O3 (C25H28N2O3 as free amine) 
Molecular Weight: 440.962 g mol
-1
 (404.501 g mol
-1
 as free amine) 
 
2,3-bis(benzyloxy)benzoic acid 2-26 (3.34 g, 10.0 mmol) was dissolved in 
anhydrous THF (15 mL). In a separate flask, 1,4-diaminobutane 2-39 (1.01 
mL, 0.88 g, 10.0 mmol) was dissolved in anhydrous THF (20 mL). N,N’-
carbonyldiimidazole (CDI) 2-37 (1.62 g, 10.0 mmol) was added to the 
benzoic acid solution, resulting in the evolution of CO2. Once CO2 evolution 
ceased, the benzoic acid solution was added dropwise to the diamine 
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solution over a period of 2 hours. Once addition was complete the solution 
was left to stir overnight. After stirring for 18 hours the excess solvent was 
removed in vacuo to yield a solid residue. This was redissolved in of CHCl3 
(150mL). The organic solution was then washed with saturated NaHCO3 (100 
mL), brine (100 mL), HCl (2 M, 100 mL) and brine (100 mL). The HCl and 
NaHCO3 solutions were both also saturated with brine to aid separation. The 
organic layer was dried over MgSO4 and filtered under gravity. The solution 
was then concentrated in vacuo to yield pale oil. EtOAc was added to the oil, 
producing the product as a white precipitate. This was isolated by filtration 
and retained as the product. Unreacted starting material was recovered by 
concentration of the filtrate in vacuo. 
Yield: 2.38 g, 54%  
m.p: 131-132 °C (Lit: 137 °C)[161] 
m/z (ESI): 427.19 ([M+Na]+ 3%), 405.22 ([M+H)+ 100%]. 
HRMS (ESI): Calc. for C25H29N2O3= 405.2173, found [M+H]
+ 405.2178; mean 
error= 0.5 ppm 
1H NMR (400 MHz, CDCl3): δH 8.33 (2H, br s, NH2), 8.04 (1H, m, NH), 7.59-
7.63 (1H, m, Ar C-H, H6), 7.33-7.45 (10H, m, Ar, C-H, H10-14, 17-21), 7.08-
7.09 (2H, m, Ar C-H, H4, 5), 5.10 (s, 2H, CH2, H8/15), 5.07 (2H, s, CH2, 
H8/15), 3.18-3.23 (2H, m,  CH2, H22 ), 2.92-2.96 (2H, m, CH2, H25), 1.68-
1.75 (2H, m, CH2, H24), 1.36-1.43 (2H, m, CH2, H23). 
13C NMR (100 MHz, CDCl3): δC 165.97 (C=O, C7), 152.01 (ipso-Ar, C-O, C2), 
147.07 (ipso-Ar, C-O, C3), 137.13 (ipso-Ar, C-C, C9/16), 136.82 (ipso-Ar, C-
C, C9/16), 129.14 (m, Ar, C-H, C10-14, 17-21), 124.59 (Ar, C-H, C6), 123.20 
(Ar, C-H, C5), 117.2 (Ar, C-H, C4), 75.13 (CH2), 70.19 (CH2), 38.40 ( CH2, 
C22), 38.27 (CH2, C25 ), 26.06 (CH2, C23/24 ), 24.47 (CH2, C23/24) 
IR (KBr cm-1): 3365.5 (NH), 1642.6 (C=O), 1264.7 (C-O) 
Data consistent with literature values [161]. 
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7.2.1.15. Methyl3-[(4-[[2,3-
bis(benzyloxy)phenyl]formamido]butyl)carbamoyl]-2-[[(4-[[2,3-
bis(benzyloxy)phenyl]formamido]butyl)carbamoyl]methyl]-2-
hydroxypropanoate (2-41) 
 
Molecular Formula: C57H62N4O11 
Molecular Weight: 979.112 g mol
-1  
 
3-hydroxy-3-(methoxycarbonyl)pentanedioic acid 2-24 (0.10 g, 0.50 mmol) 
and EDC·HCl (0.21 g, 1.10 mmol) were dissolved in anhydrous DMF (20 
mL). DIPEA (0.35 mL, 1.99 mmol) was added and the solution was left to stir. 
After 15 minutes, HOBt.H2O (0.15 g, 1.11 mmol) was added and the solution 
left to stir. After 30 minutes N-(4-aminobutyl)-2,3-bis(benzyloxy)benzamide 
hydrochloride 2-40 (0.442 g, 1.00 mmol) and DIPEA (0.35 mL, 1.99 mmol) 
were added. The solution was left to stir. After 18 hours, the solvent was 
removed in vacuo yielding a dark oil. The oil was re-suspended in 80 mL of 
H2O and extracted with DCM (3 × 100 mL). The organic layer was retained 
and washed with MeHSO3 (0.05 M, 80 mL), NaHCO3 (0.05 M, 80 mL), brine 
(80 mL) and H2O (80 mL). The organic layer was dried over MgSO4 and 
filtered. The filtrate was concentrated in vacuo to yield a yellow oil. This was 
purified using flash chromatography in 2:1 CHCl3: MeCN. The appropriate 
fractions were concentrated in vacuo to yield a white foam. 
Yield: 0.20 g, 41% 
m.p: 129.5-131.0 °C 
Rf (2:1, CHCl3: MeCN): 0.43 
m/z (ESI): 1001.43 ([M+Na]+ 100%), 969.40 ([M+H)+ 7%]. 
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 HRMS (ESI): Calc. for C57H62N4NaO11= 1001.4307, found [M+Na]
+ 
1001.4318; mean error= -1.3 ppm  
1H NMR (400 MHz, CDCl3): δH 8.01 (2H, t, 
3JH-H = 5.7 Hz, N-H), 7.66-7.69 
(2H, m, Ar C-H, H6, 43), 7.34-7.48 (20H, m, Ar, C-H, H10-14, 17-21), 7.13-
7.16 (4H, m, Ar, C-H, H4, 5, 41, 42) 6.84 (2H, t, 3JH-H = 5.7 Hz, NH), 5.07 
(2H, s, CH2, H7/14, 44/51), 5.00 (2H, s, CH2, H7/14, 44/51), 3.65 (3H, s, CH3, 
H32), 3.05-3.22 (8H, m ,CH2, H23, 24, 33, 36 ), 2.57-2.74 (m, 4H, CH2, H27, 
29), 1.25-1.42 (8H, m, CH2, H22, 25, 34, 35)  
13C NMR (100 MHz, CDCl3): δC 174.67 (C=O, C26, 30), 170.16 (C=O, 31) 
165.71 (C=O, C7, 37), 151.62 (ipso-Ar, C-O, C3, 40), 147.04 (ipso-Ar C-O, 
C2, 39), 136.61 (ipso-Ar, C-C, C9, 16, 45, 52), 131.14 (ipso-Ar, C-O), 128.42 
(m, Ar C-H, C10-14, 17-21), 127.35 (ipso-Ar, C-C, C1, 38) 124.63 (Ar, C-H, 
C6, 43), 120.78 (Ar, C-H, C5, 42), 115.81 (Ar, C-H, C4, 41), 75.13 (CH2, 
C7/14, 44/51), 70.19 (CH2, C7/14, 44/51), 52.73 (CH3, C32), 43.32 (CH2, 
C27, 29) 38.40 (CH2, C22/25, 33/36), 38.27 (CH2, C22/25, 33/36), 26.06 
(CH2, C23/24, 34/35 ), 24.47 (CH2, C23/24, 34/35) 
IR (KBr cm-1): 3379.9 (O-H), 3293.1 (N-H), 1649.6 (C=O) 1265.0 (C-O). 
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7.2.1.16. 3-[(4-[[2,3-bis(benzyloxy)phenyl]formamido]butyl)carbamoyl]-2-
[[(4-[[2,3-bis(benzyloxy)phenyl]formamido]butyl)carbamoyl]methyl]-2-
hydroxypropanoic acid (2-42)[164] 
 
Molecular Formula: C56H60N4O11 
Molecular Weight: 964.096 g mol
-1  
 
To a stirred solution of methyl3-[(4-[[2,3-
bis(benzyloxy)phenyl]formamido]butyl)carbamoyl]-2-[[(4-[[2,3-
bis(benzyloxy)phenyl]formamido]butyl)carbamoyl]methyl]-2-
hydroxypropanoate 2-41 0.34 g (0.35 mmol) in 9:1 DCM: MeOH (10 mL) was 
added NaOH (2 M in MeOH, 0.52 mL). The solution was left to stir. After four 
hours, the solution was concentrated in vacuo to yield a yellow oil. The 
residue was redissolved in DCM (15 mL) and washed with aqueous HCl (0.1 
M, 10 mL) and brine (10 mL). The organic layer was dried over MgSO4 and 
filtered. The organic layer was concentrated in vacuo to yield the product as 
a pale yellow solid.  
Yield: 0.28 g, 83% 
m.p: 82.9- 83.9 
m/z (ESI): 987.41 ([M+Na]+ 100%), 965.43 ([M+H)+ 100%]. 
 HRMS (ESI): Calc. for C56H61N4O11= 965.4331, found [M+H]
+ 965.4293, 
mean error= 4.3 ppm, Calc. for C56H60N4NaO11= 987.4151, found [M+Na]
+ 
987.4127; mean error= 2.7 ppm. 
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1H NMR (400 MHz, CDCl3): δH 8.11 (2H, t, 
3JH-H = 5.9 Hz, 
 N-H), 7.64-7.66 
(2H, m, Ar C-H, H6, 41), 7.32-7.47 (20H, m, Ar, C-H, H10-14, 17-21), 7.12-
7.13 (4H, m, Ar C-H, H4, 5, 39, 40), 5.14 (s, 2H, CH2, H7/14, 42/59), 5.07 (s, 
2H, CH2, H7/14, 42/59), 3.12-3.29 (m, 8H, CH2, H22, 25, 31, 34), 2.64-2.75 
(m, 4H, CH2, H27, 29), 1.36-1.43 (m, 8H, CH2, H23, 24, 32, 33)  
13C NMR (100 MHz, CDCl3): δC  181.78 (C=O, C31), 181.01 (C=O, C26, 30) 
165.72 (C=O, C7, 35), 151.62 (ipso-Ar, C-O, C3, 40), 145.14 (ipso-Ar C-O, 
C2, 37), 136.97 (m, ipso-Ar C-C, C9, 16), 128.15 (m, Ar, C-H, C10-14, 17-
21), 127.16 (ipso-Ar, C-C, C1, 36) 124.68 (Ar ,C-H, C6), 123.26 (Ar, C-H, 
C5), 117.17 (Ar, C-H, C4), 75.13 (CH2, C7/14, 42/49), 70.19 (CH2, C7/14, 
42/49), 42.72 (CH2, C27, 29) 38.40 (CH2, C22/25, 31/34), 38.27 (CH2, 
C22/25, 31/34 ), 26.06 (CH2, C23/24, 32/33 ), 24.47 (CH2, C23/24, 32/33) 
IR (KBr, cm-1): 3380.5 (O-H), 3276.7 (N-H), 1652.3 (C=O), 1265.2 (C-O) 
7.2.1.17. 2,3‐bis(benzyloxy)‐N‐[4‐(3‐([(4‐([2,3‐bis(benzyloxy)phenyl]forma
mido)butyl)carbamoyl]methyl)‐3‐hydroxy‐2,5‐dioxopyrrolidin‐1‐yl)buty
l]benzamide (2-43) 
 
Molecular Formula: C56H58N4O10 
Molecular Weight: 947.081 g mol
-1  
 
2-43 was observed as a by-product in the synthesis of 3-[(4-[[2,3-
bis(benzyloxy)phenyl]formamido]butyl)carbamoyl]-2-[[(4-[[2,3-
bis(benzyloxy)phenyl]formamido]butyl)carbamoyl]methyl]-2-
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hydroxypropanoic acid 2-42. The compound was identified in the ESI mass 
spectrum. The compound was not isolated. 
Rf (9:1, DCM: MeOH): 0.46 
m/z (ESI): 947.42 ([M+H]+, 100%) 
7.2.1.18. Methyl-
6‐(4‐[3‐[(4‐[[2,3‐bis(benzyloxy)phenyl]formamido]butyl)carbamoyl]‐2‐[
[(4‐[[2,3‐bis(benzyloxy)phenyl]formamido]butyl)carbamoyl]methyl]‐2‐
hydroxypropanoyl]piperazin‐1‐yl)‐4‐cyclopropyl‐7‐fluoro‐1‐oxo‐1,4‐dih
ydronaphthalene‐2‐carboxylate (2-45) 
 
Molecular Formula: C74H78FN7O13 
Molecular Weight: 1292.449 g mol
-1  
 
To a stirred solution of 3-[(4-[[2,3-
bis(benzyloxy)phenyl]formamido]butyl)carbamoyl]-2-[[(4-[[2,3-
bis(benzyloxy)phenyl]formamido]butyl)carbamoyl]methyl]-2-
hydroxypropanoic acid 2-42 (0.15 g, 0.155 mmol) and methyl-1-cyclopropyl-
6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylate 2-20 was 
added HBTU (0.066 g, 0.18 mmol) and DIPEA (0.03mL 0.15 mmol). The 
solution was stirred overnight. After 18 hours the solution was concentrated 
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in vacuo. The residue was dissolved in DCM (50 mL) and washed with HCl 
(0.05 M, 40 mL), NaHCO3 (0.05 M, 40 mL), and brine (40 mL). The organic 
layer was dried over MgSO4 and filtered. The filtrate was concentrated in 
vacuo. The product was purified by flash chromatography in 9:1 DCM: 
MeOH. 
Yield: 0.13 g, 65% 
Rf: (9:1, DCM: MeOH): 0.32 
m/z (ESI): 1292.56([M+H]+ 100%).  
 HRMS (ESI): Calc. for C74H79FN7O11= 1292.5714, found [M+H]
+ 1292.5662; 
mean error= 3.9 ppm  
1H NMR (CDCl3, 400 MHz): δH 8.55 (1H, s, CH, H4), 7.96-8.10 (3H, m, Ar, C-
H, 65 and NH),  7.65-7.67 (2H, m, Ar C-H, H35, 60), 7.34-7.47 (m, 21H, Ar, 
C-H, H11, 38-42, 45-49, 63-67, 70-74), 7.24-7.26 (2H, m, NH), 7.12-7.13 
(4H, m, Ar C-H, H34, 35, 58, 59) 5.13 (2H, s, CH2, H36/43, 61/68), 5.07 (2H, 
s, CH2, H36/43, 61/68), 3.90 (3H, s, CH3, H18), 3.76-3.84 (2H, m, CH2, 
H14/15), 3.57-3.59 (2H, m, CH2, H14/15)  3.10-3.26 (13H, m ,CH2, H13, 16, 
25, 28, 50 ,53 CH¸H3 ), 2.90 (2H, d, CH2 
4JH-H = 14.4 Hz, H21/23), 2.58 (d, 
2H, 4JH-H = 14.4 Hz, CH2, H21/23),1.28-1.45 (10H, m, CH2, H1/2,25, 28, 50, 
53), 1.08-1.12 (2H, m, CH2 , H1/2) 
19F NMR (CDCl3, 376 MHz, Fluorobenzene): δF −123.58- 64- −123.64 (m, JH-
F = 12.6 Hz, 6.9 Hz, F9)  
IR (KBr cm-1): 3379.9 (O-H) 1728.2 (C=O), 1621.3 (C=O), 1260.6 (C-O), 
1211.6 (C-O). 
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7.2.1.19. 7‐(4‐(3‐[(4‐([2,3‐bis(benzyloxy)phenyl]formamido)butyl)carbamo
yl]‐2‐([(4‐([2,3‐bis(benzyloxy)phenyl]formamido)butyl)carbamoyl]meth
yl)‐2‐hydroxypropanoyl)piperazin‐1‐yl)‐1‐cyclopropyl‐6‐fluoro‐4‐oxo‐1
,4‐dihydroquinoline‐3‐carboxylic acid (2-46)– Attempted synthesis 
 
Molecular Formula: C73H76FN7O13 
Molecular Weight: 1278.422 g mol
-1  
 
Methyl-
6‐(4‐[3‐[(4‐[[2,3‐bis(benzyloxy)phenyl]formamido]butyl)carbamoyl]‐2‐[[(4‐[[2,3
‐bis(benzyloxy)phenyl]formamido]butyl)carbamoyl]methyl]‐2‐hydroxypropano
yl]piperazin‐1‐yl)‐4‐cyclopropyl‐7‐fluoro‐1‐oxo‐1,4‐dihydronaphthalene‐2‐carb
oxylate (2-45)(0.11 g, 0.14 mmol) was dissolved in 9:1 DCM: MeOH (10 mL). 
NaOH (2 M in MeOH, 0.22 mL) was added and the solution left to stir.  
After stirring overnight the solution was neutralised with HCl (1 mL) and the 
solvent removed in vacuo. The resultant residue was redissolved in DCM (30 
mL) and washed with NaHCO3 (0.05 M, 20 mL) and brine (10 mL). The 
organic layer was dried over MgSO4 and filtered. The filtrate was 
concentrated in vacuo to yield a dark oil. Analysis of the residue indicated 
that the reaction was unsuccessful; as the compound appeared to have 
decomposed to 1-18 and 2-43. 
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7.2.1.20. Methyl 7-[4-(2-[3-[(4-[[2,3-
bis(benzyloxy)phenyl]formamido]butyl)carbamoyl]-2-[[(4-[[2,3-
bis(benzyloxy)phenyl]formamido]butyl)carbamoyl]methyl]-2-
hydroxypropanamido]acetyl)piperazin-1-yl]-1-cyclopropyl-6-fluoro-4-
oxo-1,4-dihydroquinoline-3-carboxylate (2-51) 
 
Molecular Formula: C76H81FN8O14 
Molecular Weight: 1348.512 g mol
-1  
 
of 3-[(4-[[2,3-bis(benzyloxy)phenyl]formamido]butyl)carbamoyl]-2-[[(4-[[2,3-
bis(benzyloxy)phenyl]formamido]butyl)carbamoyl]methyl]-2-
hydroxypropanoic acid 2-42 (0.19 g, 0.19 mmol) was dissolved in anhydrous 
DMF (20 mL). EDC·HCl (0.04 g, 2.10 mmol) and DIPEA (0.04 mL, 0.21 
mmol) were added and the solution was stirred. After 15 minutes HOBt·H2O 
(0.03 g, 2.20 mmol) was added. The solution was stirred for a further 15 
minutes. Methyl-7-[4-(2-aminoacetyl)piperazin-1-yl]-1-cyclopropyl-6-fluoro-4-
oxo-decahydroquinline-3-carboxylate hydrochloride salt 2-49 (0.88 g, 0.2 
mmol) was added followed by DIPEA (0.04 mL, 0.21 mmol). After 24 hours, 
the solvent was removed in vacuo to yield a dark oil. The oil was 
resuspended in H2O and extracted with DCM (3 × 80 mL). The organic layer 
was washed with pyruvic acid (0.05 M, 40 mL), NaHCO3 (0.05 M, 40 mL), 
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brine (40 mL) and H2O (40 mL). The organic layer was dried over MgSO4 
and filtered. The filtrate was concentrated in vacuo to yield a yellow oil. The 
oil was purified by flash chromatography (10:1 DCM: MeOH) to give the 
product as a white solid 
Yield: 0.12 g, 45% 
Rf: (10:1, DCM: MeOH): 0.31 
m/z (ESI): 1371.57 ([M+Na]+, 23%), 697.28 ([M+2Na]2+, 100%)  
HRMS (ESI): Calc. for C76H81FN8NaO11= 1371.5748, found [M+Na]
+ 
1371.5743, mean error= 0.0 ppm 
1H NMR (CDCl3, 400 MHz): δH 8.54 (1H, s, CH, H4), 8.04 (1H, d, 
3JH-F = 12.8 
Hz, Ar C-H8),  7.96-8.00 (2H, m, N-H), 7.81 (1H, m, N-H) 7.63-7.66 (2H, m, 
Ar C-H, H37, 62), 7.33-7.47 (21H, m, Ar, C-H, H11, 40-44, 47-51, 65-69, 72-
76), 7.26-7.28 (2H, m, NH) 7.09-7.13 (4H, m, Ar C-H, H35, 36, 60, 61) 5.13 
(2H, s, CH2, H38/45, 63/70), 5.07 (2H, s, CH2, H38/45, 63/70), 4.06 (2H, d, 
3JH-H = 4.2 Hz, CH2, H20), 3.91 (s, 3H, CH3, H18), 3.77-3.79 (2H, m, CH2, 
H14/15), 3.56-3.58 (2H, m, CH2, H14/15), 3.10-3.25 (13H, m ,CH2, H 13, 16, 
27, 30, 52, 55, CH¸H3), 2.75 (2H, d, CH2 
4JH-H = 14.4 Hz, H23/25), 2.58 (2H, 
d, 4JH-H = 14.4 Hz, H23/25) CH2, 1.26-1.43 (m, 10H, CH2, H1/2,28, 29, 53, 
54), 1.07-1.10 (2H, m, CH2, H1/2)
  
19F NMR (CDCl3, 376 MHz, Fluorobenzene): δF −124.02-−123.94 (m, JH-F = 
12.6 Hz, 6.9 Hz, F9)  
IR (KBr cm-1): 3386.4 (O-H), 1649.1 (C=O) 1263.8 (C-O), 1244.2 (C-O) 
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7.2.1.21. 7‐[4‐(2‐(3‐[(4‐([2,3‐bis(benzyloxy)phenyl]formamido)butyl)carba
moyl]‐2‐([(4‐([2,3‐bis(benzyloxy)phenyl]formamido}butyl)carbamoyl]m
ethyl)‐2‐hydroxypropanamido)acetyl)piperazin‐1‐yl]‐1‐cyclopropyl‐6‐fl
uoro‐4‐oxo‐1,4‐dihydroquinoline‐3‐carboxylic acid (2-52)- Attempted 
synthesis 
 
Molecular Formula: C75H79FN8O14 
Molecular Weight: 1335.473g mol
-1 
 
Methyl 7-[4-(2-[3-[(4-[[2,3-bis(benzyloxy)phenyl]formamido]butyl)carbamoyl]-
2-[[(4-[[2,3-bis(benzyloxy)phenyl]formamido]butyl)carbamoyl]methyl]-2-
hydroxypropanamido]acetyl)piperazin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-
dihydroquinoline-3-carboxylate 2-51 (0.11 g, 0.14 mmol) was dissolved in 9:1 
DCM: MeOH (10 mL). NaOH (2 M in MeOH, 0.22 mL) was added and the 
solution left to stir.  
After stirring overnight the solution was adjusted to pH 5.5 using pyruvic acid 
(2 M). The solvent was removed in vacuo. The resultant residue was 
redissolved in DCM (20 mL) and washed with H2O (10 mL) and brine (10 
mL). The organic layer was dried over MgSO4 and filtered. The filtrate was 
concentrated in vacuo to yield a dark oil. Analysis of the residue indicated 
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that the reaction was unsuccessful, and that the compound had decomposed 
to 2-49 and 2-43. 
7.2.1.22. 3-([4-[(2,3-dihydroxyphenyl)formamido]butyl]carbamoyl)-2-[([4-
[(2,3-dihydroxyphenyl)formamido]butyl]carbamoyl)methyl]-2-
hydroxypropanoic acid (2-44) 
 
Molecular Formula: C28H36N4O11 
Molecular Weight: 604.606 g mol
-1  
 
3-[(4-[[2,3-Bis(benzyloxy)phenyl]formamido]butyl)carbamoyl]-2-[[(4-[[2,3-
bis(benzyloxy)phenyl]formamido]butyl)carbamoyl]methyl]-2-
hydroxypropanoic acid 2-42 (0.19 g, 0.20 mmol) was dissolved in 2:1 EtOH: 
toluene (15 mL). To the stirred solution was added a  catalytic amount of 
palladium (10% on charcoal) was added. The flask was purged with N2, and 
then placed under H2. After 48 hours, the solution was filtered through a 
glass sinter to remove palladium. The solvent was removed in vacuo to yield 
the product as a yellow solid. 
Yield: 0.024 g, 20% 
m.p: 93.5-94.5 °C 
m/z (ESI): 627.22 ([M+Na]+, 45%), 605.24 ([M+H]+, 100%). 
HRMS (ESI): Calc. for C28H37N4O11= 605.2453 Found [M+H]
+ 605.2440, 
mean error= 1.4 ppm  
1H NMR (400 MHz, d3-MeOD): δH 7.21 (2H, dd, 
3JH-H = 6.4 Hz, 
4JH-H = 1.6 Hz, 
Ar C-H, H6, 28), 6.92 (2H, dd, 3JH-H = 6.4 Hz , 
4JH-H = 1.2 Hz, Ar C-H, H4, 26), 
6.70 (2H, t, 3JH-H = 8 Hz. Ar C-H, H5, 27). 3.82 (4H, t, 
3JH-H = 6.8 Hz¸CH2, H8, 
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21), 3.212 (4H, t, 3JH-H = 6.8 Hz, CH2, H11, 18), 2.61-2.75 (m, 4H, CH2, H13, 
15), 1.54-1.67 (8H, m, CH2, H9, 10, 19, 20). 
13C NMR (100 MHz, d3-MeOD): δC 172.29 (C=O, C7, 22) , 150.96 (ipso-Ar, 
C-O, C2, 3, 39, 40), 147.98 (ipso-Ar C-C, C1, 23) 120.76 (Ar C-H, C4, 6, 26, 
28), 119.15 (Ar C-H, C5. 27) 40.17 (CH2, C13, 15), 40.02 (CH2, C8, 11, 18, 
21) 27.76 (CH2, C9, 10, 19, 20). 
IR (KBr cm-1): 3356.2 (N-H), 1717.5 (C=O) 1640.32 (C=O), 1261.9 (C-O) 
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7.2.2. Synthesis of fluoroquinolone containing compounds using 
the Ugi 4CR 
7.2.2.1. Methyl-7-[4-[2([[2,3-
bis(benzyloxy)phenyl]methylidene]amino)acetyl]piperazine-1-yl]-1-
cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoloine-3-carboxylate (3-
57) 
 
Molecular Formula: C41H39N4O6F 
Molecular Weight: 702.770 g mol
-1  
 
Methyl-7-[4-(2-aminoacetyl)piperazin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-
decahydroquinline-3-carboxylate hydrochloride salt 2-49 (0.52 g, 1.18 mmol) 
was dissolved in anhydrous MeOH (20 mL). DIPEA (1.12 mL, 6.45 mmol) 
was added by syringe and the solution was stirred for 10 minutes. 2,3 
bis(benzyloxy) benzaldehyde 2-25 (0.411 g, 1.29 mmol) was added. The 
solution was left to stir overnight. After 18 hours a white precipitate had 
formed. This was isolated by filtration and then dried in vacuo to yield the 
product. 
Yield: 0.58 g, 71% 
m.p: 177.5-180 °C 
Rf: N/A, Decomposes during TLC 
 m/z(ESI): 725.27 ([M+Na]+, 100 %), 702.29 ([M+H]+, 14%). 
Chapter 7: Experimental 
257 
 
HRMS (ESI): Calc. for C41H40FN4O6= 703.2926 Found [M+H]
+ 703.2907 
mean error= 3.6 ppm. Calc. for C41H39NaFN4O6= 725.2746, Found [M+Na]
+ 
725.2728 mean error= 2.6 ppm. 
 1H NMR (400 MHz, CDCl3): δH 8.59 (1H, s, CH=N, H21), 8.54 (1H, s, H4), 
8.06 (1H, d, 3JH-F = 12.8 Hz, H8), 7.26 (14H, m, H), 5.15 (2H, s, CH2 H28/35), 
5.08 (2H, s, CH2, H28/35), 4.43 (2H, s, CH2, H20), 3.96-3.99 (2H, m, 
H14/15), 3.92 (3H, s, CH3, H18), 3.85-3.87 (2H, m, CH2, H14/15), 3.40 (1H, 
m, CH, H30), 3.30-3.32 (2H, m, CH2, 13/16), 3.20-3.22 (2H, m, CH2, H13/16), 
1.26-1.30 (2H, m, CH2, H1/2), 1.14-1.11 (2H, m, CH2, H1/2)   
13C NMR (100 MHz, CDCl3): δC 173.10 (C=O, C6), 168.15 (C=O, C19), 
166.44 (C=O, C17), 160.35 (C=N, C21), 153.43 (ipso-Ar, d, 1JC-F = 251.6 Hz, 
C9), 152.13 (ipso-Ar C-C, C22), 148.77 (ipso-Ar C-C, C29/36), 148.54 (CH, 
C4), 144.28 (ipso-Ar, d, 2JC-F = 10.7 Hz, C10), 138.06 (ipso-Ar, C5), 136.93-
136.62 ( ipso-Ar C-C, C29/36) 130.59, (ipso-Ar C-O, C23/24), 128.77-128.38 
(Ar C-H, C30, 31, 32, 33, 34, 37, 38, 39, 40, 41), 127.61 (Ar C-H, C26), 
124.27 (Ar C-H, C27/25), 123.57 ( Ar C-H, C27/25), 123.53 (ipso-Ar, d, 3JC-F 
= 6.90 Hz, C7), 119.12 (CH, C26), 113.52 (CH, d, 2JC-F = 23.0 Hz, C-8), 
110.21 (ipso-Ar, C12), 105.28(CH, d, 3JC-F = 3.1 Hz, C11), 76.12 (CH2, 
C28/35), 71.11 (CH2, C28/35), 64.51 (CH2, C20), 52.18 (CH3, C18), 50.89 
(CH2, C14/15), 49.57 (CH2, C14/15), 46.07 (CH2, C13/16), 41.76 (CH2, C-
13/16), 34.63 (CH, C3), 8.24 (CH2, C1/2). 
19F NMR (CDCl3, 376 MHz, Fluorobenzene): δF -123.76 (m, F9)  
IR (KBr, cm-1): 1722.0 (C=O), 1695.3 (C=O) 1650.4 (C=O), 1609.5 (C=N), 
1495.1 (C-O), 1470.6 (C-O)  
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7.2.2.2. Methyl-7-[4-(2-[1-[2,3-bis(benzyloxy)phenyl]-N-[[2,3-
bis(benzyloxy)phenyl](cyclohexylcarbamoyl)methyl]formamido]acetyl)
piperazine-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-
carboxylate (3-58) 
 
Molecular Formula: C69H68N5O10F 
Molecular Weight: 1145.495 g mol
-1  
 
Methyl-7-[4-[2([[2,3-
bis(benzyloxy)phenyl]methylidene]amino)acetyl]piperazine-1-yl]-1-
cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoloine-3-carboxylate 3-57 (0.21 g, 
0.3 mmol), 2,3-bis(benzyloxy)benzoic acid 2-26 (0.03 g, 0.3 mmol) and 
cyclohexyl isocyanide 3-54 (12.3 μl, 0.3 mmol), were combined in a 
microwave vial and suspended in anhydrous MeOH (2mL). The suspension 
was microwaved with stirring at 90 °C, 50 W for 60 minutes. The resultant 
solution was diluted with DCM, and then concentrated in vacuo to yield a 
pale yellow solid. The solid was redissolved in DCM (30 mL), and washed 
with HCl (1 M, 20 mL), saturated NaHCO3 (20 mL) and brine (20 mL). The 
organic layer was dried over MgSO4 and filtered. The fi ltrate was evaporated 
to dryness in vacuo to yield a yellow solid. The product was purified by flash 
chromatography in 12:1 DCM: MeOH 
Yield: 0.13 g, 38% 
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m.p: 85.3-86.3 °C 
Rf (12:1, DCM: MeOH): 0.23 
m/z (ESI): 1168.5 ([M+Na]+, 16%)1146.5, ([M+H]+, 100%). 
HRMS (ESI): Calc. for C69H69N5O10F= 1146.5023 Found [M+H]
+ 1146.5007, 
mean error= 1.7 ppm.  
1 H NMR (d6-DMSO, 500 MHz, 383 K): δH 8.40 (1H, s, H4), 7.78 (1H, d, 
3JH-F 
= 10.8 Hz, H8), 6.80-7.46 (26H, m, Ar, C-H, H25, 26, 27, 30-34, 37-41, 46, 
47, 48, 51-55, 58-62), .5.91 (1H, s, CH, H42), 5.01-5.16 (8H, m, CH2, H28, 
35, 49, 56), 4.05-4.09 (2H, m, CH2, H20), 3.77 (3H, s, CH3, H18), 3.57-3.66 
(3H, m, CH2 and CH, H13/15, 64), 3.29-3.33 (3H, m, CH2 and CH, H3, 13/15), 
2.89-3.01 (4H, m, CH2, H14, 16), 1.54-1.79 (4H, m, CH2, H65, 69), 1.19-1.31 
(8H, m, CH2 H1/2, 66, 67, 68), 1.05-1.10 (2H, m, CH2, H1/2). 
19F NMR (376 MHz, d6-DMSO): δF-124.58 (m, F9) 
IR (KBr, cm-1): 3433.0 (N-H), 1728.9 (C=O), 1621.7 (C=O), 1263.9 (C-O), 
1229.5 (C-O) 
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7.2.2.3. 6‐[4‐(2‐[1‐[2,3‐bis(benzyloxy)phenyl]‐N‐[[2,3‐bis(benzyloxy)phenyl](cy
clohexylcarbamoyl)methyl]formamido]acetyl)piperazin‐1‐yl]‐4‐cyclopr
opyl‐7‐fluoro‐1‐oxo‐1,4‐dihydronaphthalene‐2‐carboxylic acid (3-
59)[164] 
 
Molecular formula: C68H66N5O10F 
Molecular weight: 1132.278 g mol
-1 
 
To a stirred solution of methyl-7-[4-(2-[1-[3,4-bis(benzyloxy)phenyl]-N-[[3,4-
bis(benzyloxy)phenyl](cyclohexylcarbamoyl)methyl]formamido]acetyl)piperazi
ne-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate 3-56 
(0.20 g, 0.175 mmol) in 9:1 DCM: MeOH (4.5 mL) was added NaOH (2 M in 
MeOH, 0.5 mL). After four hours the solvent was removed in vacuo. The 
residue was redissolved in DCM (20 mL) and washed with HCl (0.1 M, 10 
mL) and brine (10 mL). The organic layer was dried over MgSO4 and filtered. 
The fi ltrate was evaporated to dryness in vacuo to yield the crude product. 
The crude product was purified using flash chromatography in 9:1:0.1 CHCl3: 
MeOH: HCOOH and recovered as a white solid. 
Yield: 0.12 g, 58% 
m.p: 110.4-11.3 °C 
Rf: (9:1:0.1, CHCl3: MeOH: HCOOH): 0.54 
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m/z (ESI): 1154.46 ([M+Na]+, 10%), 1132.48 ([M+H]+, 100%). 
HRMS (ESI): Calc. for C68H67N5O10F= 1132.4866 Found 1132.4846, mean 
error= 2.4 ppm. Calc. for C68H66NaN5O10F= 1154.4686 Found 1154.4670, 
mean error= 0.2 ppm. 
1 H NMR (400 MHz, d6-DMSO 353 K): δH 8.42 (1H, s, H4), 7.75 (1H, d, 
3JH-H 
= 10.8 Hz, H8), 7.08-7.49 (26H, m, Ar, C-H, H24, 25, 26, 29-33, 36-40, 45, 
46, 47, 50-54, 57-61), .5.91 (1H, s, CH, H41), 4.96-5.18 (8H, m, CH2, H27, 
34, 48, 55), 4.07-4.10 (2H, m, CH2, H19), 3.58-3.65 (3H, m, CH2 and CH, 
H13/15, 63), 3.30-3.34 (3H, m, CH2 and CH, H3, 13/15), 3.08-3.18 (4H, m, 
CH2, H14, 16), 1.60-1.84 (4H, m, CH2, H64, 68), 1.25-1.30 (8H, m, CH2 H1/2, 
65, 66, 67), 0.99-1.01 (2H, m, CH2, H1/2). 
19F NMR (376 MHz, d6-DMSO): δF-123.69 (m, F9) 
IR (KBr, cm-1): 3432.9 (N-H), 1728.9 (C=O), 1621.7 (C=O) 
7.2.2.4. 7‐[4‐(2‐[N‐[(cyclohexylcarbamoyl)(2,3‐dihydroxyphenyl)methyl]‐1‐(2,3
‐dihydroxyphenyl)formamido]acetyl)piperazin‐1‐yl]‐1‐cyclopropyl‐6‐flu
oro‐4‐oxo‐1,4‐dihydroquinoline‐3‐carboxylic acid 3-1 
 
Molecular formula: C40H42FN5O10 
Molecular weight: 771.787 g mol
-1  
 
6‐[4‐(2‐[1‐[2,3‐Bis(benzyloxy)phenyl]‐N‐[[2,3‐bis(benzyloxy)phenyl](cyclohexy
lcarbamoyl)methyl]formamido]acetyl)piperazin‐1‐yl]‐4‐cyclopropyl‐7‐fluoro‐1‐
oxo‐1,4‐dihydronaphthalene‐2‐carboxylic acid 3-58 (0.01 g, 0.1 mmol was 
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dissolved in 1:1 EtOH: Toluene (50 mL). To the stirred solution was added a 
catalytic amount of Pd black. The solution was stirred under H2 at 50 bar. 
After 48 hours, the solution was filtered through a glass fi lter to remove the 
catalyst and the solvent removed in vacuo to yield the product as a yellow 
solid. 
Yield: 0.08 g, 100% 
m.p: 123.5-124.4 
m/z (ESI): 794.28 ([M+Na]+, 100%). 
HRMS (ESI): Calc. for C40H43N5O10F= 772.2988 Found 772.3005, mean 
error= -1.5 ppm. Calc. for C40H42NaN5O10F= 794.2808 Found 794.2819, 
mean error= -1.3 ppm. 
1 H NMR (500 MHz, d6-DMSO): δH 8.82 (1H, s, Ar, C-H, H4), 7.93 (1H, m, Ar, 
C-H, H26), 7.64 (1H, m, Ar, C-H, H24), 6.51-6.77 (6H, m, Ar, C-H, H8, 11, 
25, 29, 30, 31), 5.82 (s, 1H, CH, H27), 4.20-4.22 (2H, m, CH2, H19), 3.85 
(1H, m, CH, H35), 3.37-3.44 (4H, m, CH2, H13, 15), 3.08-3.16 (2H, m, CH2, 
H13/16), 2.84-2.92 (2H, m, CH2, H13/16), 2.74 (1H, m, CH, H3), 1.18-
1.37(14H, m, CH2, H1, 2, 36-40)  
13C NMR: Compound not sufficiently soluble to obtain a 13C NMR spectrum 
19F NMR (376 MHz, d6-DMSO): δF -121.99 (m, F9) 
IR (KBr, cm-1): 3432.9 (N-H) 1729.0(C=O), 1628.7 (C=O), 1247.5 (C-O) 
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7.2.2.5. 3,4-bis(benzyloxy)benzaldehyde (3-65)[138] 
 
Molecular Formula: C21H18N2O3 
Molecular Weight: 318.366 g mol
-1  
 
3,4-Dihydroxybenzaldehyde 2-7 (0.55 g, 4 mmol) was dissolved in anhydrous 
EtOH (10 mL). To the stirred solution was added benzyl chloride (1.05 mL, 
9.2 mmol). To the resultant yellow solution was added K2CO3(s) (0.72 g, 5.2 
mmol). The mixture was then heated under reflux. After 24 hours the solution 
was cooled to room temperature and filtered. The solid recovered was 
washed with acetone and any insoluble material discarded. The acetone 
washes were added to the filtrate which was then concentrated in vacuo to 
yield the crude product. The crude product was recrystallised from a minimal 
amount of hot MeOH to yield the product as a brown crystalline solid.  
Yield: 0.79 g, 62%  
m.p: 84.4-85.2 °C 
Rf: (3:1, EtOAc: Pet Ether): 0.62 
m/z (ESI): 341.11 ([M+Na]+, 57%), 336.16 ([M+NH4]
+, 42%), 319.13 ([M+H]+, 
100%). 
HRMS (ESI): Calc. for C21H19O3= 319.1329. Found [M+H]+ 319.1331, mean 
error= -1.1 ppm. Calc. for C21H18NaO3= 341.1148. Found [M+Na]+ 319.1149 , 
mean error= -0.5 ppm. 
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1H NMR (400 MHz, CDCl3): δH 9.81 (1H, s, CHO, H7), 7.31-7.49 (12H, m, Ar, 
C-H, H2, 6, 10-14, 17-21), 7.02 (1H, d, 3JH-H = 8.2 Hz, Ar C-H, H5), 5.26 (2H, 
s, CH2, H8/15), 5.21 (2H, s, CH2, H8/15).  
13C NMR (100 MHz, d6-DMSO): δC 191.33 (C=O, C7) 153.59 (ipso-Ar, C-O, 
C4), 148.44 (ipso-Ar, C-O, C3), 136.84 (ipso-Ar, C-C, C9/16), 136.50 (ipso-
Ar, C-C, C9/16), 128.57 (Ar. C-H, Benzyl group, C10-14, 17-21), 126.24 (Ar, 
C-H, C5), 113.26 (Ar, C-H, C-2/6), 111.97 (Ar, C-H, C-2/6) 75.40 (CH2, C-
8/15), 70.52 (CH2, C-8/15) 
IR (KBr, cm-1): 1676.1 (C=O), 1270.6 (C-O), 1264.1 (C-O) 
7.2.2.6. 3,4-bis(benzyloxy)benzoic acid(3-66)[153] 
 
Molecular Formula: C21H18O4 
Molecular Weight: 334.365 g mol
-1
 
 
3, 4-Bis(benzyloxy)benzaldehyde 3-64 (0.30 g, 9.4 mmol) was dissolved in 
10 mL 1:1 acetone: H2O (10 mL). Sulfamic acid (0.13 g, 1.32 mmol) was 
dissolved in H2O (4 mL) and sodium chlorite (0.11 g, 1.24 mmol) was 
dissolved in H2O (4 mL). These two solutions were added to the 
benzaldehyde solution in alternating portions over 15 minutes. After two 
hours stirring the volume of solvent was reduced in vacuo by 50%. The 
resultant white precipitate was isolated by filtration and retained as the 
product.  
Yield: 0.26 g, 84%  
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m.p: 180.2-181.0 °C  
Rf: 0.24 (3:1, EtOAc: Pet Ether)  
m/z (ESI): 357.11 ([M+Na]+, 100%), 335.13 ([M+H]+, 52%). 
HRMS (ESI): Calc. for C21H19O4= 335.1278. Found [M+H]+ 535.1271, mean 
error= 1.8ppm. Calc. for C21H18NaO4= 357.1097. Found [M+Na]+ 357.1082, 
mean error= 3.9 ppm  
1H NMR (400 MHz, d6-DMSO) δH 12.21 (br s, 1H, COOH, H7), 7.27-7.55 
(12H, m, Ar, C-H, H2, 6, 10-14, 17-21), 7.15 (1H, d, 3JH-H = 9.2 Hz, Ar, C-H, 
H5), 5.22 (2H, s, CH2, H8/15), 5.18 (2H, s, CH2, H8/15).  
13C NMR (100 MHz, d6-DMSO): δC 166.99 (C=O, C7), 152.12 (ipso-Ar, C-O, 
C4), 147.65 (ipso-Ar, C-O, C3), 137.06 (ipso-Ar, C-C, C9/16), 136.75 (ipso-
Ar, C-C, C9/16), 127.99 (Ar C-H, C10-14, 17-21), 127.74 (ipso-Ar C-C, C1 
123.52 (Ar C-H, C6), 123.30, (Ar C-H, C2) 114.61 (Ar C-H, C5) 70.03 (CH2, 
C8/15), 69.90 (CH2, C8/15)  
IR (KBR, cm-1) 3440.2 (OH), 1679.3 (C=O), 1275.5 (C-O) 1225.7 (C-O), 
7.2.2.7. Methyl 5-aminopentanoate hydrochloride salt (3-72)[201] 
 
Molecular Formula: C6H13NO2 
Molecular Weight: 131.173 g mol
-1  
 
5-Aminopentanoic acid 3-71 (2.00 g, 17 mmol) was dissolved in anhydrous 
MeOH (10 mL). The suspension was cooled to approximately 0 °C in an ice 
bath. Distilled thionyl chloride (3.7 mL, 51 mmol) was added by syringe. The 
solution was then stirred under reflux. 
After 18 hours the reaction was cooled to room temperature and the excess 
solvent removed in vacuo. The resultant residue was resuspended in MeOH 
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and precipitated using Et2O. The resultant white precipitate was filtered and 
the process repeated. The final product was isolated by fi ltration as a white 
solid. 
Yield: 2.21 g, 99 %  
m.p: 135-136.2 °C (lit 122-123 °C [201]) 
m/z (ESI): 132.10 ([M+H]+, 100%).  
HRMS (ESI): Calc. for C6H14NO2= 132.1019. Found [M+H]
+ 132.1019, mean 
error= 0.0[ppm].  
1H NMR (400 MHz, MeOH-d3): δH 3.67 (3H, s, CH3, H6), 2.92-2.96 (2H, m, 
CH2, H5), 2.39-2.43 (2H, m, CH2, H2), 1.68-1.72 (4H, m, CH2, H3/ 4).  
13C NMR (100 MHz, MeOH-d3): δC 175.27 (C=O, C5), 52.13 (CH3, C6), 
40.40 (CH2, C1), 33.92 (CH2, C2), 27.91 (CH2, C3/4), 22.70 (CH2CH2, C3/4) 
IR (KBR, cm-1): 3460.6 (N-H), 1736.7 (C=O), 1197.0 (C-O)  
Methyl-5-[[2,3-bis(benzyloxy)phenyl]formamido]pentanoate(3-74) 
 
Molecular Formula: C27H29NO5 
Molecular Weight: 447.205 g mol
-1  
 
2,3-Bis(benzyloxy) benzoic acid 2-26 (2.00 g, 5.9 mmol), methyl-5-
aminopentanoate hydrochloride salt 3-72 (1.00 g, 5.9 mmol) and HOBt·H2O 
(0.81 g, 5.9 mmol) were dissolved in anhydrous DMF (15 mL). DIPEA (1.04  
mL, 5.9 mmol) was added and the solution was stirred. After 30 minutes 
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stirring EDC.HCl (1.15 g, 5.9 mmol) was added to the solution followed by a 
further portion of DIPEA (1.04 mL, 5.9 mmol). The solution was left to stir. 
After 24 hours the solvent was removed in vacuo to yield an orange solid. 
The residue was resuspended in H2O (40 mL) and extracted with DCM (3 × 
60 mL). The organic layer was then washed with H2O, CH3SO3H (0.05 M), 
NaHCO3 (0.05 M), brine and H2O (all 50 mL). The organic layer was dried 
over MgSO4 and filtered. The solvent was removed in vacuo to yield the 
product as a white solid 
Yield: 2.19 g, 83%  
m.p: 63.2-63.6 °C  
Rf: (1:1, EtOAc: Pet ether): 0.33 
m/z (ESI): 470.19 ([M+Na]+, 100%), 448.21 ([M+H]+, 18%). 
HRMS (ESI): Calc. for C27H30NO5= 448.2118. Found [M+H]
+ 448.2113, mean 
error= 1.2 ppm. Calc. for C27H29NaNO5= 470.1938 Found [M+Na]
+ 470.1934, 
mean error= 1.0 ppm. 
1H NMR: (400 MHz, CDCl3): δH  7.97 (1H, t, 
3JH-H = 5.2 Hz, H), 7.75 (1H, m, 
H6) 7.33-7.49 (10H, m, Ar C-H, H10-14, 17-21), 7.15-7.16 (2H, m, Ar, C-H, 
H4/5), 5.16 (2H, s, CH2, H8/15), 5.09 (2H, s, CH2, H8/15), 3.65 (3H, s, CH3, 
H28), 3.26-3.10 (2H, m, CH2, H22) 2.25 (2H, t, 
3JH-H = 7.3 Hz, CH2, H25), 
1.55 (2H, qn, 3JH-H, 7.6 Hz, CH2, H24), 1.37 (2H, qn, 
3JH-H = 7.6 Hz, CH2, 
H23). 
13C NMR: (100 MHz, CDCl3) δC 174.20 (C=O, C26), 165.46 (C=O, C7), 
152.08 (ipso Ar C-O, C3), 146.87 (ipso Ar, C-O, C2), 136.64 (ipso Ar, C-C, 
C9, 16), 128.34 (Ar C-H, C10-14, 17-21), 127.75 (ipso-Ar C-C, C1), 124.57 
(Ar C-H, C4), 123.54 (Ar C-H, C6), 117.03 (Ar, C-H, C5), 76.12 (CH2, C8/15),  
71.16 (CH2, C8/15), 51.30 (CH3, C27), 38.93 (CH2, C22), 33.26 (CH2, C25) 
28.39 (CH2, C23), 21.92 (CH2, H24). 
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IR (KBr, cm-1): 3385.7(N-H), 1729.2 (C=O), 1654.8 (C=O), 1213.2 (C-O) 
7.2.2.8. 5-[(2,3-dihydroxyphenyl)formamido]pentanoic acid (3-76) 
 
Molecular Formula: C26H27NO5 
Molecular Weight: 433.189 g mol
-1  
 
Methyl-5-[[2,3-bis(benzyloxy)phenyl]formamido]pentanoate 3-74 (0.45 g, 1 
mmol) was dissolved in9:1 DCM: MeOH (13.5 mL). NaOH (2 M in MeOH, 1.5 
mL) was added and the solution was left to stir. After 18 hours the solvent 
was removed in vacuo to yield a dark oil.  
The residue was dissolved in EtOAc (25 mL) and washed with HCl (1 M, 20 
mL). The organic layer was separated and the aqueous layer washed with 
EtOAc (3 × 10 mL). The organic layers were combined and washed with 
brine (20 mL). The organic layer was dried over MgSO4 and filtered. The 
filtrate was concentrated in vacuo to yield a pale oil. The product was purified 
using flash chromatography in 5:1:0.5 EtOAc: Pet ether (40-60): HCOOH.  
Yield: 0.29 g, 68% 
m.p: 70.3-71.0 °C 
Rf (5:1:0.1, EtOAc: 40-60 pet ether: HCOOH): 0.43 
m/z (ESI): 456.18 ([M+Na]+, 100%), 434.19. ([M+H]+, 96%). 
HRMS (ESI): Calc. for C26H28NO5= 434.1962. Found [M+H]
+ 434.1976, mean 
error= -2.7 ppm. Calc. for C26H27NaNO5= 456.1781. Found [M+Na]
+ 
456.1800, mean error= -3.2 ppm. 
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1H NMR: (400 MHz, CDCl3) δH  8.04 (1H, m, H), 7.74 (1H, m, H6) 7.34-7.49 
(10H, m, Ar, C-H, H10-14, 17-21), 7.15-7.16 (2H, m, Ar, C-H, H5), 5.08 (2H, 
s, CH2, H8/15), 5.12 (2H, s, CH2, H8/15), 3.25-3.30 (2H, m, H22) 2.27-2.30 
(2H, m, CH2, H25), 1.51-1.58 (2H, m, CH2, H24), 1.33-1.41 (2H, m, CH2, 
H23). 
13C NMR: (100 MHz, CDCl3) δC 174.18 (C=O, C26), 165.15 (C=O, C7), 
151.82 (ipso Ar, C-O, C3), 146.87 (ipso Ar, C-O, C2), 136.53 (ipso Ar, C-C, 
C9, 16), 129.0 (ipso-Ar, C-C, C1), 128.34 (Ar, C-H, C10-14, 17-21), 
124.57(Ar, C-H, 6), 123.54 (Ar, C-H, C4), 116.95 (Ar, C-H, C5), 76.50 (CH2, 
C8/15), 71.39 (CH2, C8/15), 38.92 (CH2, C22) 33.25 (CH2, C25) 28.40 (CH2, 
C23) 21.93 (CH2,  C24). 
IR (KBr, cm-1): 3385.7 (N-H) 1715.3 (C=O), 1237.4 (C-O) 
7.2.2.9. Methyl 6-[[2,3-bis(benzyloxy)phenyl]formamido]hexanoate(3-75) 
 
Molecular Formula: C28H31NO5 
Molecular Weight: 461.549 g mol
-1  
 
2,3-Bis(benzyloxy)benzaldehyde 2-26 (0.33 g, 1 mmol), methyl-6-
aminohexanoate hydrochloride 3-73 (0.18 g, 1 mmol) and HOBt·H2O (0.17 g, 
1 mmol) were dissolved in anhydrous DMF (50 mL). DIPEA (0.17 mL, 1 
mmole) was added by syringe, followed by EDC·HCl (0.19 g, 1 mmol). The 
solution was left to stir. 
After 36 hours the excess solvent was removed in vacuo leaving a yellow oil. 
This was resuspended in H2O (40 mL) and extracted with DCM (2 × 50 mL). 
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The organic layer was then washed with H2O (50 mL), CH3SO3H (0.05M, 50 
mL), NaHCO3 (0.05 M, 50 mL), brine (50 mL) and H2O (50 mL). The organic 
layer was dried over MgSO4 and filtered. The organic layer was then dried in 
vacuo to yield the product as colourless oil.  
Yield: 0.43 g, 92%  
Rf: (5:1, EtOAc: Pet ether (40-60)): 0.65 
m/z (ESI): 484.21 ([M+Na]+, 100%), 462.23 ([M+H]+, 96%). 
HRMS (ESI): Calc. for C28H32NO5= 462.2275. Found [M+H]
+ 462.2268, mean 
error= 1.5 ppm. Calc. for C28H31NaNO5= 484.2094. Found [M+Na]
+ 
484.2092, mean error= 0.5 ppm. 
1H NMR: (400 MHz, CDCl3) δH  7.95 (1H, m, H), 7.75(1H, m, H6) 7.24-7.40 
(10H, m, Ar, C-H, H10-14, 17-21), 7.15-7.16 (2H, m, Ar, C-H, H5, 6), 5.16 
(2H, s, CH2, H8/15), 5.08 (2H, s, CH2, H8/15), 3.66 (3H, s, CH3, H28), 3.25-
3.30 (2H, m, H22) 2.23 (2H, t, 3JH-H = 7.6 Hz , H26), 1.55 (2H, qn, 
3JH-H = 7.6 
Hz, CH2, H24), 1.31-1.38 (2H, m, H23), 1.21-1.27 (2H, m, H25). 
13C NMR: (100 MHz, CDCl3) δC 174.50 (C=O, C27) 165.42 (C=O, COOH, 
C7), 152.05 (ipso Ar C-O, C3 ), 147.075 (ipso Ar, C-O, C2), 136.679 (ipso Ar, 
C-C, C9, 16), 128.977-127.91 (Ar, C-H, C10-14, 17-21), 124.57(Ar, C-H, C5), 
123.54 (Ar, C-H, C6), 116.95 (Ar, C-H, C4), 76.50 (CH2, C8/15),  71.39 (CH2, 
C8/15), 51.62 (CH3, C28), 39.22 (CH2, C22), 33.59 (CH2, C26), 28.64 (CH2, 
C25), 26.20 (CH2, C23) 24.25 (CH2, C24). 
IR (CHCl3, 0.1 M, cm
-1): 3370.7 (N-H), 1738.4 (C=O), 1651.7(C=O), 1238.4 
(C-O) 
Spectroscopic data is consistent with literature values [262]. 
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7.2.2.10. 6-[(2,3-dihydroxyphenyl)formamido]hexanoic acid(3-77) 
 
Molecular formula: C27H29NO5 
Molecular weight: 447.523 g mol
-1  
 
Methyl 6-[[2,3-bis(benzyloxy)phenyl]formamido]hexanoate 3-75 (0.24 g, 05.2 
mmol) was dissolved in 9:1 DCM: MeOH (10 mL). NaOH (2 M in MeOH, 0.75 
mL) was added and the solution was left to stir. After 18 hours the solvent 
was removed in vacuo to yield a dark oil.  
The residue was dissolved in EtOAc (30 mL) and washed with HCl (1 M, 20 
mL). The organic layer was separated and the aqueous layer washed with 
EtOAc (2 × 20 mL). The organic layers were combined and washed with 
brine (20 mL). The organic layer was dried over MgSO4 and filtered. The 
filtrate was concentrated in vacuo to yield a white solid 
Yield: 0.17 g, 72 % 
m.p: 71.4-72.4 °C (Lit: 74-76 °C [262]) 
m/z (ESI): 470.19 ([M+Na]+, 100%), 448.21 ([M+H]+, 21%). 
HRMS (ESI): Calc. for C27H30NO5= 448.2118. Found [M+H]
+ 448.2111, mean 
error= 1.8 ppm. Calc. for C27H29NaNO5= 470.1938. Found [M+Na]
+ 
470.1944, mean error= -0.3 ppm. 
1H NMR (400 MHz, CDCl3): δH  8.01 (1H, t, 
3JH-H = 5.2 Hz H), 7.74 (1H, m, 
H6) 7.36-7.49 (10H, m, Ar C-H, H, 10-14, 17-21), 7.15-7.17 (2H, m, Ar C-H, 
H4, 5), 5.16 (2H, s, CH2, H8/15), 5.09 (2H, s, CH2C6H5, H8/15), 3.26-3.30 
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(2H, m, CH2, H22) 2.27 (2H, t, 
3JH-H=7.6 Hz , H26), 1.56 (2H, qn, 
3JH-H, 7.6 
Hz, CH2, H24),  1.31-1.38 (2H, m, H23), 1.21-1.28 (2H, m, H25) 
13C NMR (100 MHz, CDCl3): δC 179.31 (C=O, C27), 165.58 (C=O, C7), 
152.01 (ipso-Ar, C-O, C3), 147.08 (ipso-Ar C-O, C2), 136.65 (ipso-Ar C-C, 
C9, 16), 128.95- 127.88 (Ar C-H, C10-14, 17-21) 127.37 (ipso-Ar C-C, C1), 
124.66 (Ar C-H, C5), 123.522 (Ar C-H, C6), 117.07 (Ar C-H, C4). 76.33 (CH2, 
C8/15), 71.17 (CH2, C8/15), 39.26 (CH2, C22) 33.51 (CH2, C26), 28.55 (CH2, 
C25), 26.10 (CH2, C23), 23.98 (CH2, C24) 
IR (KBr, cm-1): 3340.7 (N-H), 1732.7 (C=O), 1616.5 (C=O), 1236.7 (C-O) 
Spectroscopic data is consistent with literature values [262]. 
7.2.2.11. 5-[4-[1-cyclopropyl-6-fluoro-3-(methoxycarbonyl)-4-oxo-1,4-
dihydroquinolin-7-yl]piperazine-1-yl]5oxopentanoic acid (3-78) 
 
Molecular Formula: C23H26FN3O6 
Molecular Weight: 459.468 g mol
-1  
 
Methyl-1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-
carboxylate 2-20 (1.00 g, 2.9 mmol) was dissolved in CHCl3 (30 mL). Glutaric 
anhydride 3-80 (0.37 g, 3.2 mmol) was added. The flask was purged with N2 
and the solution left to stir under N2 overnight. 
After 18 hours stirring a white precipitate was observed. The precipitate was 
isolated by filtration with suction. The isolated solid was then further dried in 
vacuo yielding the product as a white crystalline solid 
Yield: 1.32 g, 99% 
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m.p: 220-221 °C 
Rf (9:1:1, CHCl3: MeOH: HCOOH): 0.23 
m/z (ESI): 482.17 ([M+Na]+, 8%), 460.18 ([M+H]+, 100%). 
HRMS (ESI): Calc. for C23H26N2FO5= 460.1878. Found [M+H]
+ 460.1872, 
mean error= 1.6 ppm. Calc. for C23H25NaN2FO5= 482.1698, found [M+H]
+ 
482.1698, mean error= -0.4 ppm. 
1H NMR (400 MHz, d6-DMSO): δH 8.42 (1H, s, H4), 7.73 (1H, d, 
3JH-F = 13.4 
Hz, H8), 7.43 (1H, d, 4JH-F = 7.3 Hz, H11), 3.72 (3H, s, CH3, H18), 3.65 (5H, 
m, CH2, H14/15 & CH, H3), 3.19-3.24 (4H, m, CH2, H13/16), 2.39 (2H, t, 
3JH-H 
= 7.3 Hz, CH2, H22), 2.27 (2H, t, 
3JH-H = 7.3 Hz, CH2, H20), 1.68-1.77 (2H, m, 
CH2, H21), 1.22-1.27 (2H, m, CH2 H1/2), 1.08-1.10 (2H, m, CH2, H1/2) 
13C NMR (100 MHz, d6-DMSO): δC 174.39 (C=O, C23), 171.59 (C=O, C6), 
170.37 (C=O, C19), 164.98 (C=O, C17), 152.6 (ipso-Ar, 1JH-F =245.8 Hz, C9), 
148.39 (C-H, C4), 143.67 (ipso-Ar, d, 2JC-F = 10.6 Hz, C9), 138.04 (ipso-Ar, 
C12), 122.1(ipso-Ar, d, 3JC-F = 6.90 Hz, C7), 111.58 (C-H, d, 
2JC-F = 22 Hz, 
C8), 108.95 (ipso-Ar, C5), 106.67( C-H, C11), 51.34 (CH3, C18), 49.69 (CH2, 
C16/13), 44.70 (CH2, C14/15), 40.74 (CH2, C14/15),  34.83 (CH, C3), 33.04 
(CH2, C20), 31.48 (CH2, C22), 20.28 (CH2, C21), 7.60 (CH2, C1, C2). 
19F NMR (376 MHz, CDCl3) δF -124.43 (m, F-9) 
IR (KBR, cm-1): 3512.7 (C-O), 1716.3 (C=O), 1627.1 (C=O) 
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7.2.2.12. 2,3-Bis(benzyloxy)-N-[4-
([[2,3bis(benzyloxy)phenyl]methylidene]amino)butyl]benzamide (3-
81) 
 
Molecular Formula: C46H44N2O5 
Molecular Weight: 704.325 g mol
-1  
 
N-(4-aminobutyl)-2,3-bis(benzyloxy)benzamide hydrochloride 2-40 (0.50 g, 
1.10 mmol) and 2,3-bis(benzyloxy) benzaldehyde 2-25 (0.35 g, 1.1 mmol) 
was suspended in anhydrous EtOH (25 ml). DIPEA (0.38 mL, 2.20 mmol) 
was added by syringe. The reaction was left to stir for 18 hours. After 18 
hours a white precipitate had formed. This was isolated by fi ltration and 
retained as the product. 
Yield: 0.65g, 84% 
m.p:111.4-112.3 °C 
Rf: N/A, decomposes during TLC 
m/z (ESI): 727.31 ([M+Na]+, 8.3%), 705.33 ([M+H]+, 100%). 
HRMS (ESI): Calc. for C46H45N2O5= 705.3323 Found [M+H]
+ 705.3308, mean 
error= 2.7 ppm, Calc. for C46H44N2NaO5= 727.3142 Found [M+Na]
+ 727.3125 
, mean error= 2.5 ppm. 
1H NMR (400 MHz, CDCl3): δH 8.47 (1H, s, CH, H26), 7.94 (1H, m, NH) 7.77 
(1H, dd, 3JH-H = 3.2 Hz, Ar, C-H, H6), 7.29-7.55 (21H, m, Ar, C-H, H9-13, 16-
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20, 32, 35-39, 42-46), 7.15-7.16 (2H, m, Ar, C-H, H4, 5), 7.06-7.07 (2H, m, 
Ar, C-H, H30, 31), 5.16-5.17 (4H, m, CH2, H7/14, 33/40), 5.09 (2H, s, CH2, 
H7/14, 33/40), 3.42-3.45 (2H, m, CH2, H25), 3.29-3.34 (2H, m, CH2 H22), 
1.55-1.62 (2H, m, CH2, H24), 1.36-1.44 (2H, m, CH2, H23). 
13C NMR (100 MHz, CDCl3): δC 165.41 (C=O, C21), 157.55 (CH, C26), 
152.27 (ipso-Ar, C-O, C2), 152.04 (ipso-Ar, C-O, C3), 148.38 (ipso-Ar, C-O, 
C28), 146.86 (ipso-Ar, C-O, C29), 136.93 (m, ipso-Ar, C-C, C8, 15, 34, 41), 
130.71 (ipso-Ar, C-C, C1, 27), 128.81-127.55 (Ar C-H, C9-13, 16-20, 35-39, 
42-46), 124.50 (Ar, C-H, C5), 124.42 (Ar, C-H, C31), 123.53 (Ar, C-H, C6) 
119.41 (Ar, C-H, H32), 117.01(Ar, C-H, C4), 116.23 (Ar, C-H, C30), 76.49 
(CH2, C7/33), 76.11 (CH2, C7/33),  71.38 (CH2, C14/40), 71.10 (CH2, 
C14/40), 61.42 (CH2, C25) 39.64 (CH2, C22), 28.43 (CH2, C24), 27.19 (CH2, 
C23) 
IR (KBr, cm-1): 1660.0 (C=N), 1655.0 (C=O) 1268.2(C-O) 
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7.2.3. Synthesis of bis-catecholate ligands  
7.2.3.1. N-(4-[[(2,3-dihydroxyphenyl)methyl]amino]butyl)-2,3-
dihydroxybenzamide (4-24) 
 
Molecular Formula: C18H22N2O5 
Molecular Weight: 346.378 g mol
-1  
 
2,3-Bis(benzyloxy)-N-[4-
([[2,3bis(benzyloxy)phenyl]methylidene]amino)butyl]benzamide 3-80 (0.50 g 
0.71 mmol), was suspended in 2:1 EtOH: Toluene (60 mL). A catalytic 
amount of Pd black was added to the solution. The mixture was stirred under 
hydrogen at 50 bar.  
The reaction was monitored by TLC and ESI mass spectrometry. Once both 
techniques confirmed the completion of the reaction, the solution was passed 
through a glass filter to remove the Pd catalyst and the solution was 
concentrated in vacuo to yield a yellow residue. This was resuspended in 
anhydrous MeOH (10 mL) and passed through a micro-fi lter to remove any 
remaining Pd. The solution was concentrated in vacuo to yield the product: 
Yield: 0.19 g, 79% 
m.p: 92.6-93 °C 
m/z(ESI): 347.16 ([M+H]+, 100%).  
HRMS (ESI): Calc. for C18H23N2O5= 347.1601. Found [M+H]
+ 347.1589 , 
mean error= 3.1ppm.  
1H NMR (400 MHz, d6-DMSO): δH 7.25 ( 1H, m, Ar, C-H H6 ), 6.85 (1H, m, 
Ar, C-H, H4 ), 6.64 (1H, m, Ar, C-H, H18), 6.58 (1H, t, 3JH-H=8.0 Hz, Ar, C-H, 
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H5), 6.52-6.53 (2H, m, Ar, C-H, H16, 17), 3.83 (2H, s, CH2, H12), 3.26-3.29 
(2H, m, CH2, H11), 2.57-2.60 (2H, m, CH2, H8), 1.54-1.55 (4H, m, CH2, 
H9,10)  
13C NMR (100 MHz, d6-DMSO): δC 169.59 (C=O, C7), 151.06 (ipso-Ar, C-O, 
C2) 148.54 (ipso-Ar, C-O, C3), 146.70 (ipso-Ar, C-O, C14), 146.2409 (ipso-
Ar, C-O, C15), 123.21 (ipso-Ar, C-C, C13), 119.08-116.58 (Ar, C-H, C4, 5, 6, 
16, 17), 115.03 (ipso-Ar, C-C, C1) 114.54 (Ar, C-H, C18), 50.36 (CH2, C12) 
47.63 (CH2, C11), 39.58(CH2, C8), 27.89 (CH2, C10), 25.75 (CH2, C9). 
IR (KBr, cm-1): 3384.3 (N-H), 1265.7 (C-O), 1224.3(C-O). 
7.2.3.2. General procedure for the synthesis of bis-imine ligands [220] 
2,3-Dihydroxybenzaldehyde 2-18 (1.00 g, 7.24 mmol) was dissolved in 10 mL 
anhydrous MeOH (10 mL). The appropriate amine (3.62 mmol) was added by 
syringe. After 5 minutes stirring an orange/yellow (depending on the diamine) 
precipitate was formed. The mixture was allowed to stand for 30 minutes. 
The precipitate was isolated by filtration. The recovered  solid was then stirred 
in ice cold MeOH and filtered to yield the product as an orange/yellow 
powder. 
7.2.3.3. 3‐[(1E)‐((2‐[(E)‐[(2,3‐dihydroxyphenyl)methylidene]amino]ethyl)imino)
methyl]benzene‐1,2‐diol (4-30) 
 
Molecular Formula: C16H16N2O4 
Molecular Weight: 300.309 g mol
-1  
 
Yield: 0.97 g, 89% 
m.p: Decomposed at 188-189 °C 
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Rf: N/A, decomposes during TLC  
m/z (ESI): 299.10 ([M-H]-,100%). 
HRMS (ESI): Calc. for C16H15N2O4= 299.1037, found [M-H]
- 299.1039, Mean 
error= -0.6 ppm 
1H NMR (400 MHz, d6-DMSO): δH 8.54 (2H, s, CH, H7, 10), 6.83-6.86 (4H, 
m, Ar, C-H, H4, 6, 14, 16), 6.64-6.68 (2H, m, Ar, C-H, H5, 15), 3.92 (4H, s, 
CH2, H8, 9),  
13C NMR (100 MHz, d6-DMSO): δC 167.90 (CH, C7, 10), 151.76 (ipso-Ar, C-
O, C3, 13), 146.46 ( ipso-Ar, C-O, C2, 12), 122.35 (Ar-C, C-H, C4, 14), 
118.57 (ipso-Ar, C-C, C1, 11), 118.23 (Ar-C, C-H, C5, 15) 118.14 (Ar-C, C6, 
16), 58.18 (CH2, C8, 9) 
(KBr, cm-1): 3452.44 (O-H), 3388.2 (O-H), 3254.2 (O-H), 1631.6 (C=N), 
1200.1 (C-O) 
7.2.3.4. 3-[(1E)-([3-[(E)-[(2,3-
dihydroxyphenyl)methylidene]amino]propyl]imino)methyl]benzene-
1,2-diol (4-31) 
 
Molecular Formula: C17H18N2O4 
Molecular Weight: 314.336 g mol
-1  
 
Yield: 0.45 g, 90% 
m.p: Decomposed at 156.4-157 °C 
Rf: N/A, decomposes during TLC 
Chapter 7: Experimental 
279 
 
m/z (ESI): 313.12 ([M-H]-, 100%). 
HRMS (ESI): Calc. for C17H17N2O4= 313.1194, found [M-H]
- 313.1198, mean 
error= -1.1 ppm 
1H NMR (400 MHz, d6-DMSO): δH 8.53 (2H, s, CH, H7, 11), 6.85-6.87 (4H, 
m, Ar, C-H, H4, 6, 15, 17), 6.63-6.67 (2H, m, Ar, C-H, H5, 16), 3.66-3.69 (4H, 
m, CH2, H8, 10), 2.01 (2H, qn, 
3JH-H = 6.9 Hz, CH2, H9 
13C NMR (100 MHz, d6-DMSO): δC 167.18 (CH, C7, 11), 152.32 (ipso-Ar, C-
O, C3, 14), 146.59 ( ipso-Ar, C-O, C2, 13), 122.3 (Ar-C, C-H, C4,15), 118.45 
(ipso-Ar, C-C, C1, 12), 118.02 (Ar-C, C-H, C5, 16) 117.92 (Ar-C, C6, 17), 
58.18 (CH2, C8, 10), 31.47 (CH2, C9) 
IR (KBr cm-1): 3309.4 (O-H), 3007.0 (O-H), 1654.1 (C=N), 1224.3 (C-O) 
7.2.3.5. 3-[(1E)-([4-[(E)-[(2,3-
dihydroxyphenyl)methylidene]amino]butyl]imino)methyl]benzene-1,2-
diol (4-32) 
 
Molecular Formula: C18H20N2O4 
Molecular Weight: 328.362g mol
-1  
 
Yield: 0.58 g, 99% 
m.p: Decomposed at 186.9-187.6 °C (lit decomposed at 205 °C [214]) 
Rf: N/A, decomposes during TLC 
m/z (ESI): 327.14 ([M-H]-, 100%).  
HRMS (ESI): Calc. for C18H19N2O4= 327.1350, found [M-H]
- 327.1354, mean 
error= -0.9 ppm 
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1H NMR (400 MHz, d6-DMSO): δH 8.51 (2H, s, CH, H7, 12), 6.81-6.85 (4H, 
m, Ar, C-H, H4, 6, 16, 18), 6.60-6.64 (2H, m, Ar, C-H, H5, 17), 3.63 (4H, br s, 
CH2, H8, 11), 1.71 (4H, br s, CH2, H9, 10) 
13C NMR (100 MHz, d6-DMSO): δC 166.77 (CH, C7, 11), 152.26 (ipso-Ar, C-
O, C3, 15), 146.78 (ipso-Ar, C-O, C2, 14), 122.22 (Ar-C, C-H, C4,16), 118.08 
(ipso-Ar, C-C, C1, 13), 117.74 (Ar-C, C-H, C5, 17) 117.54 (Ar-C, C6, 18), 
58.51 (CH2, C8, 11), 27.88 (CH2, C9, 10) 
IR (KBr, cm-1): 3213.6 (O-H), 1642.8 (C=N), 1236.0 (C-O)  
7.2.3.6. 3-[(1E)-([5-[(E)-[(2,3-
dihydroxyphenyl)methylidene]amino]pentyl]imino)methyl]benzene-
1,2-diol(4-33) 
 
Molecular Formula: C19H22N2O4 
Molecular Weight: 342.389 g mol
-1  
 
Yield: 0.44 g, 72% 
Rf: N/A, decomposes during TLC 
m/z (ESI): 365.15.12 ([M+Na]+ 18%), 343.16 ([M+H]+100%), 172.08 
([M+2H]2+ 89%). 
HRMS (ESI): Calc. for C19H23N2O4= 343.1652, found [M+H]
+ 343.1662, mean 
error= -3.4 ppm, Calc. for C19H12N2NaO4= 365.1742, found [M+Na]
+ 
365.1488, mean error= -4.5 ppm 
1H NMR (400 MHz, d6-DMSO): δH 8.48 (2H, s, CH, H7, 13), 6.80-6.83 (4H, 
m, Ar, C-H, H4, 6, 17, 19), 6.58-6.62 (2H, m, Ar, C-H, H5, 18), 3.59 (4H, t, 
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3JH-H = 6.8 Hz, CH2, H8, 12), 1.69 (4H, qn, 
3JH-H = 7.2 Hz , CH2, H9, 11), 1.38-
1.46 (2H, m, CH2, H10) 
13C NMR (100 MHz, d6-DMSO): δC 165.97 (CH, C7, 13), 152.93(ipso-Ar, C-
O, C3, 16), 146.22 (ipso-Ar, C-O, C2, 15), 121.78 (Ar-C, C-H, C4,17), 117.54 
(ipso-Ar, C-C, C1, 14), 117.18 (Ar-C, C-H, C5, 18) 116.96 (Ar-C, C6, 19), 
56.52 (CH2, C8, 12), 29.97(CH2, C9, 11), 24.03 (CH2, C10) 
IR (KBr cm-1): 3422.6 (O-H), 3299.7 (O-H), 1643.1 (C=N), 1235.2 (C-O)  
7.2.3.7. 3-[(1E)-([6-[(E)-[(2,3-
dihydroxyphenyl)methylidene]amino]hexyl]imino)methyl]benzene-1,2-
diol (4-34) 
 
Molecular Formula: C20H24N2O4 
Molecular Weight: 356.416 g mol
-1  
  
Yield: 0.48, 75% 
m.p: Decomposed at 149.5-150 °C 
Rf: N/A, decomposes during TLC 
m/z (ESI): 379.16 ([M+Na]+ 5%), 357.18 ([M+H]+ 54%), 179.09 ([M+2H]
2+ 
100%). 
HRMS (ESI): Calc. for C19H23N2O4= 357.1809 found [M+H]
+ 357.1802, mean 
error= 1.5 ppm. 
1H NMR (400 MHz, d6-DMSO): δH 8.48 (2H, s, CH, H7, 14), 6.79-6.83 (4H, 
m, Ar, C-H, H4, 6, 18, 20), 6.57-6.61 (2H, m, Ar, C-H, H5, 19), 3.58 (4H, t, 
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3JH-H = 6.8 Hz, CH2, H8, 13), 1.63-1.66 (4H, m, CH2, H9, 12), 1.39 (4H, br s, 
CH2, H10, 11) 
13C NMR (100 MHz, d6-DMSO): δC 165.57 (CH, C7, 14), 153.61 (ipso-Ar, C-
O, C3, 17), 146.79 (ipso-Ar, C-O, C2, 16), 122.20 (Ar-C, C-H, C4,18), 117.91 
(ipso-Ar, C-C, C1, 15), 117.54 (Ar-C, C-H, C5, 19) 117.32 (Ar-C, C6, 20), 
55.56 (CH2, C8, 13), 30.11(CH2, C9, 12), 26.08 (CH2, C10, 11) 
IR (KBr, cm-1): 3421.2 (O-H), 3259.9 (O-H), 1646.0 (C=N), 1208.5 (C-O)  
 
7.2.3.8. 3-[(1E)-([7-[(E)-[(2,3-
dihydroxyphenyl)methylidene]amino]heptyl]imino)methyl]benzene-
1,2-diol (4-35) 
 
Molecular Formula: C21H26N2O4 
Molecular Weight: 370.442 g mol
-1  
 
Yield: 1.34 g, 100% 
Rf: N/A, decomposes during TLC 
m/z (ESI): 393.17([M+Na]+, 100%). 
HRMS (ESI): Calc. for C21H26N2NaO4= 393.1785. Found [M+Na]
+ 393.1774, 
mean error= 3.0 ppm  
1H NMR (400 MHz, d6-DMSO): δH 8.47 (2H, s, CH, H7, 15), 6.79-6.83 (4H, 
m, Ar H, H4, 6, 19, 21), 6.57-6.61 (m, Ar, C-H, H5, 20), 3.57 (4H, t, 3JH-H = 
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6.6 Hz, CH2, H8, 14), 1.60-1.64 (4H, m, CH2, H9, 13), 1.35 (6H, br s, CH2, 
H10, 11, 12) 
13C NMR (100 MHz, d6-DMSO): δC 166.55 (CH, C7, 15), 153.76 (ipso-Ar, C-
O, C3, 18), 146.84 (ipso-Ar, C-O, C2, 17), 122.23 (Ar-C, C-H, C4,19), 117.88 
(ipso-Ar, C-C, C1, 16), 117.55 (Ar, C-H, C5, 20) 117.30 (Ar-C, C6, 21), 55.57 
(CH2, C8, 14), 30.17 (CH2, C9, 13), 28.31 (CH2, C11), 26.39 (CH2, C10, 12) 
IR (KBr cm-1): 3333.5 (O-H), 1645.9 (C=N), 1240.9 (C-O) 
 
7.2.3.9. 3-[(1E)-([12-[(E)-[(2,3-
dihydroxyphenyl)methylidene]amino]dodecyl]imino)methyl]benzene-
1,2-diol(4-36) 
 
Molecular Formula: C26H36N2O4 
Molecular Weight: 440.575 g mol
-1  
 
Yield: 1.28 g, 80% 
Rf: N/A, decomposes during TLC 
m/z (ESI): 463.25 ([M+Na]+, 11%), 441.23 ([M+H]+, 100%). 
HRMS (ESI): Calc. for C26H37N2O4= 441.2748. Found 441.2730, mean error= 
4.1 ppm. Calc. for C26H36N2NaO4= 463.2567. Found 463.2563, mean error= 
1.0 ppm  
1H NMR (400 MHz, d6-DMSO): δH 8.48 (2H, s, CH, H7, 20), 6.78-6.83 (4H, 
m, Ar, C-H, H4, 6, 24, 26), 6.57-6.61 (m, Ar, C-H, H5, 25), 3.57 (4H, t, 3JH-H = 
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6.6 Hz, CH2, H8, 19), 1.61 (4H, qn, 
3JH-H = 6.9 Hz, CH2, H9, 18), 1.24-1.34 
(16H, m, CH2, H10, 11, 12, 13, 14, 15, 16, 17) 
13C NMR (100 MHz, d6-DMSO): δC 166.55 (CH, C7, 20), 153.76 (ipso-Ar, C-
O, C3, 23), 146.84 (ipso-Ar, C-O, C2, 22), 122.23 (Ar-C, C-H, C4,24), 117.88 
(ipso-Ar, C-C, C1, 21), 117.55 (Ar, C-H C5, 25) 117.30 (Ar-C, C6, 26), 55.57 
(CH2, C8, 19), 30.16 (CH2, C9, 18), 28.31 (CH2, C13, 14), 26.39 (CH2, C10-
12, 15-17) 
IR (KBr, cm-1): 3333.5 (O-H), 1650.2 (C=N), 1209.9 (C-O) 
7.2.3.10. General procedure for the synthesis of benzyl protected bis-
imines [220] 
2,3-Bis(benzyloxy)benzaldehyde 2-25 (1.00 g, 3.14 mmol) was 
suspended in anhydrous MeOH (15 mL). The appropriate diamine (1.57 
mmol) was added. The solution was left to stir. After stirring overnight, a 
white precipitate was formed. The precipitate was isolated by filtration as a 
white solid. The solid was stirred in hot MeOH to remove any impurities and 
filtered hot to give the product as a white solid. 
7.2.3.11. (E)-[[2,3-bis(benzyloxy)phenyl]methylidene]([2-[(E)-[[2,3-
bis(benzyloxy)phenyl]methylidene]amino]ethyl])amine (4-37) 
 
Molecular Formula: C44H40N2O4 
Molecular Weight: 660.799 g mol
-1  
 
Yield: 1.03 g, 100% 
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m.p: 138.8-139 °C 
Rf: N/A, decomposes during TLC  
m/z (ESI): 661.30 ([M+H]+, 100%). 
HRMS (ESI): Calc. for C44H40N2O4= 661.3044, found  [M+H]
+ 661.3044, 
mean error= 2.5 ppm 
1H NMR (400 MHz, CDCl3): δH 8.55 (2H, s, CH, H21, 24), 7.54-7.56 (2H, m, 
Ar, C-H, H6, 30), 7.30-7.47 (20H, m, Ar, C-H, H9-13, 17-20, 33-37, 40-43), 
7.00-7.05 (4H, m, Ar, C-H, H4, 5, 28, 29), 5.14 (2H, s, CH2, H7/14, 31/38) 
4.99 (2H, s, CH2, H7/14, 31/38), 3.85 (4H, s, CH2, H22, 23),  
13C NMR (100 MHz, CDCl3): δC 159.07 (CH, C21, 24), 152.28 (ipso-Ar, C-O, 
C3, 27), 148.71 (ipso-Ar, C-O, C2, 26), 137.23 (ipso-Ar, C-C, C8/15, 32/39), 
137.00 (ipso-Ar, C-C, C8/15, 32/39), 130.77 (ipso-Ar, C-C, C1, 25), 128.8 (m, 
Ar, C-H, C9-13, 16-20, 33-37, 40-44), 124.42 (Ar, C-H, C4,28), 119.46 (Ar, C-
H, C6, 30), 116.33 (Ar, C-H C5, 29), 75.95 (CH2, C7/14, 31/38), 70.93 (CH2, 
C7/14, 31/38), 61.89 (CH2, C22, 23)  
IR (KBr, cm-1): 1641.8 (C=N), 1264.9 (C-O) 
7.2.3.12.  (E)-[[2,3-bis(benzyloxy)phenyl]methylidene]([3-[(E)-[[2,3-
bis(benzyloxy)phenyl]methylidene]amino]propyl])amine(4-38) 
 
Molecular Formula: C45H42N2O4 
Molecular Weight: 674.826 g mol
-1  
 
Yield: 0.81 g, 76% 
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m.p: 93.4-93.6 °C 
Rf: N/A, decomposes during TLC 
1H NMR (400 MHz, CDCl3): δH 8.52 (2H, s, CH, H21, 25), 7.56 (2H, m, Ar, C-
H, H6, 31), 7.37 (20H, m, Ar, C-H, H9-13, 16-20, 34-38, 41-45), 7.08 (4H, m, 
Ar, C-H, H4, 5, 29, 30) 5.17 (2H, s, CH2, H7/14, 32/39), 5.09 (2H, s, CH2, 
H7/14, 32/39), 3.52 (4H, m, CH2, H22, 24), 1.65 (2H, m, CH2, H23). 
13C NMR (100 MHz, CDCl3): δC 157.52 (CH, C21, 25), 152.29 (ipso-Ar, C-O, 
C3, 28), 148.59 (ipso-Ar, C-O, C2, 27), 137.32 (ipso-Ar, C-C, C8/15, 33/40), 
137.06 (ipso-Ar, C-C, C8/15, 33/40), 131.01 (ipso-Ar, C-C, C1, 26), 128.31 
(m, Ar, C-H, C9-13, 16-20, 34-38, 41-45), 124.44 (Ar, C-H, C4,29), 119.46 
(Ar, C-H, C6, 31), 116.23 (Ar, C-H C5, 30), 75.96 (CH2, C7/14, 32/39), 70.93 
(CH2, C7/14, 32/39), 61.89 (CH2, C22, 24), 28.40 (CH2, C23). 
IR (KBr cm-1): 1641.6 (C=N), 1269.1 (C-O)  
7.2.3.13.  (E)-[[2,3-bis(benzyloxy)phenyl]methylidene]([4-[(E)-[[2,3-
bis(benzyloxy)phenyl]methylidene]amino]butyl])amine(4-39) 
 
Molecular Formula: C46H44N2O4 
Molecular Weight: 688.853 g mol
-1  
 
Yield: 1.04 g, 96% 
m.p: 129.5-130 °C 
Rf: N/A, decomposes during TLC 
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m/z (ESI): 689.33 ([M+H]+, 100%). 
HRMS (ESI): Calc. for C46H45N2O4= 689.3374, found [M+H]
+ 689.3346, mean 
error= 4.5 ppm 
1H NMR (400 MHz, CDCl3): δH 8.52 (2H, s, CH, H21, 26), 7.55-7.57 (2H, m, 
Ar, C-H, H6, 32), 7.31-7.50 (20H, m, Ar, C-H, H9-13, 16-20, 35-39, 42-46), 
7.06-7.07 (4H, m, Ar, C-H, H4, 5, 30, 31) 5.17 (2H, s, CH2, H7/14, 33/40), 
5.09 (2H, s, CH2, H7/14, 33/40), 3.55-3.56 (4H, m, CH2, H22, 25), 1.68-1.70 
(4H, m, CH2, H23, 24). 
13C NMR (100 MHz, CDCl3): δC 157.51 (CH, C21, 26), 152.29 (ipso-Ar, C-O, 
C3, 29), 148.59 (ipso-Ar, C-O, C2, 28), 137.32 (ipso-Ar, C-C, C8/15, 33/40), 
137.06 (ipso-Ar, C-C, C8/15, 34/41), 131.01 (ipso-Ar, C-C, C1, 27), 128.31 
(m, Ar, C-H, C9-13, 16-20, 35-39, 42-46), 124.44 (Ar, C-H, C4,30), 119.46 
(Ar, C-H, C6, 32), 116.23 (Ar, C-H C5, 31), 75.96 (CH2, C7/14, 33/40), 70.93 
(CH2, C7/14, 33/40), 61.87 (CH2, C22, 25), 28.40 (CH2, C23, 24). 
IR (KBr cm-1): 1644.9 (C=N), 1268.2 (C-O),  
7.2.3.14.  (E)-[[2,3-bis(benzyloxy)phenyl]methylidene]([5-[(E)-[[2,3-
bis(benzyloxy)phenyl]methylidene]amino]pentyl])amine (4-40) 
 
Molecular Formula: C47H46N2O4 
Molecular Weight: 702.879 g mol
-1  
 
Yield: 0.77 g, 70% 
m.p: 83.9-84.7 °C 
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Rf : N/A, decomposes during TLC  
m/z (ESI): 703.35 ([M+H]+, 100%). 
HRMS (ESI): Calc. for C47H47N2O4= 703.3530, found [M+H]
+ 703.3537, mean 
error= -0.4 ppm 
1H NMR (400 MHz, CDCl3): δH 8.52 (2H, s, CH, H21, 27), 7.54-7.58 (2H, m, 
Ar, C-H, H6, 33), 7.32-7.50 (20H, m, Ar, C-H, H9-13, 16-20, 36-40, 43-47), 
7.07-7.08 (4H, m, Ar, C-H, H4, 5, 31, 32) 5.17 (2H, s, CH2, H7/14, 34/41), 
5.09 (2H, s, CH2, H7/14, 34/41), 3.52-3.55 (4H, m, CH2, H22, 26), 1.66-1.73 
(4H, m, CH2, H23, 25), 1.36-1.43 (2H, m, CH2, H24) 
13C NMR (100 MHz, CDCl3): δC 157.51 (CH, C21, 27), 152.29 (ipso-Ar, C-O, 
C3, 30), 148.59 (ipso-Ar, C-O, C2, 29), 137.32 (ipso-Ar, C-C, C8/15, 35/42), 
137.06 (ipso-Ar, C-C, C8/15, 35/42), 131.01 (ipso-Ar, C-C, C1, 29). 128.30 
(m, Ar, C-H, C9-13, 16-20, 37-41, 44-48), 124.46 (Ar, C-H, C4,31), 119.46 
(Ar, C-H, C6, 33), 116.18 (Ar, C-H C5, 32), 75.96 (CH2, C7/14, 34/41), 70.93 
(CH2, C7/14, 34/41), 61.87 (CH2, C22, 26) 30.61 (CH2, C23, 25), 26.93 (CH2, 
C24). 
IR (KBr cm-1): 1645.2 (C=N), 1272.2 (C-O)  
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7.2.3.15.  (E)-[[2,3-bis(benzyloxy)phenyl]methylidene]([6-[(E)-[[2,3-
bis(benzyloxy)phenyl]methylidene]amino]hexyl])amine (4-41) 
 
Molecular Formula: C48H48N2O4 
Molecular Weight: 716.906 g mol
-1  
 
Yield: 0.57 g, 51% 
m.p: 94.0-94.3 °C 
Rf : N/A, decomposes on TLC plate  
m/z (ESI): 717.36 ([M+H]+, 100%). 
HRMS (ESI): Calc. for C48H49N2O4= 717.3687, found 717.3660, mean error= 
3.1 ppm 
1H NMR: (400 MHz, CDCl3): δH 8.52 (2H, s, CH, H21, 28), 7.54-7.58 (2H, m, 
Ar, C-H, H6, 34), 7.32-7.50 (20H, m, Ar, C-H, H9-13, 17-20, 36-40, 43-47), 
7.07-7.09 (4H, m, Ar, C-H, H4, 5, 31, 32) 5.17 (2H, s, CH2, H7/14, 34/41), 
5.09 (2H, s, CH2, H7/14, 34/41), 3.53 (4H, td, 
3JH-H = 7.0 Hz, 
4JH-H = 1.2 Hz, 
CH2, H22, 27), 1.63-1.69 (4H, m, CH2, H23, 26), 1.36-1.39 (4H, m, CH2, H24, 
25) 
13C NMR: (100 MHz, CDCl3) δC 157.34 (CH, C21, 28), 152.29 (ipso-Ar, C-O, 
C3, 31), 148.59 (ipso-Ar, C-O, C2, 30), 137.32 (ipso-Ar, C-C, C8/15, 36/45), 
137.06 (ipso-Ar, C-C, C8/15, 36/45), 131.01 (ipso-Ar, C-C, C1, 29). 128.30 
(m, Ar, C-H, C9-13, 16-20, 37-41, 44-48), 124.46 (Ar, C-H, C4,32), 119.46 
(Ar, C-H, C6, 34), 116.18 (Ar, C-H C5, 33), 75.96 (CH2, C7/14, 40/47), 70.93 
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(CH2, C7/14, 40/47), 61.87 (CH2, C22, 27) 30.61 (CH2, C23, 26), 26.93 (CH2, 
C24, 25). 
IR (KBr cm-1): 1637.8 (C=N), 1269.1 (C-O). 
  
7.2.3.16.  (E)-[[2,3-bis(benzyloxy)phenyl]methylidene]([7-[(E)-[[2,3-
bis(benzyloxy)phenyl]methylidene]amino]heptyl])amine (4-42) 
 
Molecular Formula: C49H50N2O4 
Molecular Weight: 730.932 g mol
-1  
 
Yield: 0.85 g, 74% 
m.p: 85.4-86.2 °C 
Rf: N/A, decomposes during TLC  
m/z (ESI): 731.38 ([M+H]+, 27%), 366.19 ([M+2H]2+, 100%). 
HRMS (ESI): Calc. for C49H52N2O4= 366.1958, found [M+2H]
2+ 366.1951, 
mean error= 2.6 ppm. Calc. for C49H52N2O4= 731.3843, found [M+H]
+ 
731.3831, mean error= 2.0 ppm 
1H NMR: (400 MHz, CDCl3): δH 8.52 (2H, s, CH, H21, 29), 7.54-7.59 (2H, m, 
Ar, C-H, H6, 35), 7.32-7.50 (20H, m, Ar, C-H, H9-13, 17-20, 38-42, 45-49), 
7.06-7.08 (4H, m, Ar, C-H, H4, 5, 33, 34) 5.17 (2H, s, CH2, H7/14, 36/43), 
5.09 (2H, s, CH2, H7/14, 36/43), 3.51-3.54 (4H, m, CH2, H22, 28), 1.64-1.69 
(4H, m, CH2, H23, 27), 1.33-1.37 (6H, m, CH2, H24-26) 
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13C NMR: (100 MHz, CDCl3) δC 157.30 (CH, C21, 29), 152.28 (ipso-Ar, C-O, 
C3, 32), 148.58 (ipso-Ar, C-O, C2, 31), 137.32 (ipso-Ar, C-C, C8/15, 37/44), 
137.05 (ipso-Ar, C-C, C8/15, 37/44), 131.00 (ipso-Ar, C-C, C1, 30), 128.29 
(m, Ar, C-H, C9-13, 16-20, 38-42, 45-49), 124.45 (Ar, C-H, C4, 33), 119.44 
(Ar, C-H, C6, 35), 116.14 (Ar, C-H C5, 34), 75.93 (CH2, C7/14, 41/48), 70.90 
(CH2, C7/14, 41/48), 61.91 (CH2, C22, 28) 30.61 (CH2, C23, 27), 29.03 (CH2, 
C25), 27.02 (CH2, C24, 26) 
IR (KBr cm-1): 1641.1 (C=N), 1270.4 (C-O)  
7.2.3.17. (E)-[[2,3-bis(benzyloxy)phenyl]methylidene]([12-[(E)-[[2,3-
bis(benzyloxy)phenyl]methylidene]amino]dodecyl])amine (4-43) 
 
Molecular Formula: C54H60N2O4 
Molecular Weight: 801.065 g mol
-1  
 
Yield: 0.70 g, 56% 
m.p:89.3-89.9 °C 
Rf : N/A, decomposes on TLC plate  
m/z (ESI): 801.46 ([M+H]+, 11%), 401.23 ([M+2H]2+, 100%). 
HRMS (ESI): Calc. for C54H62N2O4= 401.2349, found [M+2H]
+ 401.2337, 
mean error= 4.9 ppm, Calc. for C54H61N2O4= 801.4626, found [M+H]
+ 
801.4611, mean error= 2.2 ppm 
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1H NMR: (400 MHz, CDCl3): δH 8.53 (2H, s, CH, H21, 34), 7.56-7.58 (2H, m, 
Ar, C-H, H6, 40), 7.33-7.50 (20H, m, Ar, C-H, H9-13, 17-20, 43-47, 50-54), 
7.07-7.09 (4H, m, Ar, C-H, H4, 5, 38, 39) 5.17 (2H, s, CH2, H7/14, 41/48), 
5.09 (2H, s, CH2, H7/14, 41/48), 3.53 (4H, t, 
3JH-H = 6.8 Hz, CH2, H22, 33), 
1.63-1.67 (4H, m, CH2, H23, 32), 1.29-1.33 (16H, m, CH2, H24-31) 
13C NMR: (100 MHz, CDCl3) δC 157.27 (CH, C21, 34), 152.28 (ipso-Ar, C-O, 
C3, 37), 148.56 (ipso-Ar, C-O, C2, 36), 137.32 (ipso-Ar, C-C, C8/15, 42/49), 
137.04 (ipso-Ar, C-C, C8/15, 42/49), 131.02 (ipso-Ar, C-C, C1, 35). 128.29 
(m, Ar, C-H, C9-13, 16-20, 43-47, 50-54), 124.45 (Ar, C-H, C4,38), 119.44 
(Ar, C-H, C6, 40), 116.12 (Ar, C-H C5, 39), 75.95 (CH2, C7/14, 41/48), 70.89 
(CH2, C7/14, 41/48), 61.94 (CH2, C22, 33), 30.62 (CH2, C23, 32) 29.36 (CH2, 
C25-30), 27.06 (CH2, C24, 31) 
IR (KBr, cm-1): 1642.3 (C=N), 1268.2 (C-O)  
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7.3. Biological studies 
7.3.1. Suppliers 
All chemicals, reagents and media used in this project were purchased from: 
Acros Organics, Fermedium, Fischer Scientific, Invitrogen, Melford, New 
England Biolabs, Oxoid and Sigma Aldrich 
7.3.2. Bacterial strains 
See Table 7.1 for details of the bacterial strains used. 
 
Bacterial strain Genotype Source 
BW25113 Wild type Baba et al., 2006 [263] 
JW0588  BW25113 entA::kan Baba et al., 2006 
BW25113  ompF::kan Baba et al., 2006 
BW25113  tonB::kan Baba et al., 2006 
BW25113  galPmglCytfT::Δkan  H. Neves and G.H. 
Thomas, unpublished 
data. 
Table 7.1: List of E. coli strains utilised in biological assays 
7.3.3. Media and antibiotics 
All solutions and media were prepared using MilliQ deionised H2O and 
sterilised by autoclave prior to use 
7.3.3.1. Luria-Bertani (LB) media 
LB media was prepared using 10 g tryptone, 5 g of yeast extract and 10 g 
NaCl per litre. 
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7.3.3.2.  M9 minimal media 
M9 minimal media was prepared using 6 g Na2HPO4, 3 g KH2PO4, 1 g NH4Cl 
and 0.5 g NaCl per litre. After autoclaving, the solution was supplemented 
with a specified amount of carbon source (see individual experiments) and 1 
mM MgSO4
[264]. The antibiotic kanamycin was also added where required. 
7.3.4. Solid media 
7.3.4.1. Nutrient agar 
Nutrient agar was prepared by combining either LB or M9 minimal media with 
1.5% (w/v) technical grade agar. 
7.3.4.2. Top agar 
Top agar was prepared using 0.7% (w/v) of agarose in MilliQ H2O 
7.3.4.3. Antibiotics 
Kanamycin stock solutions were made in H2O MilliQ at a concentration 
of 50 mg/mL and filter sterilized. The kanamycin was added where required 
to liquid cultures in a volume sufficient to give a concentration of 50 µg/mL. 
7.3.5. Buffers and solutions 
7.3.5.1. Agarose gel electrophoresis 
TAE running buffer was prepared using 750 mL of H2O, 48.4 g/L of Tris, 22.8 
mL of glacial acetic acid, 200 mL of 29.2 g/L EDTA. The solution was made 
up to 1 L using H2O. To produce a working concentration of TAE buffer the 
solution was diluted by 1 in 10 in H2O. The agarose gels used were prepared 
using 1% (w/v) agarose in 1 x TAE buffer.  
7.3.5.2. Stop buffer  
The stop buffer for the DNA gyrase assay was prepared using 40% (w/v) of 
sucrose, 12.11 g/L Tris·HCl (pH 7.5), 0.29 g/L EDTA and 0.5 mg/mL of 
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bromophenol blue. This was used to terminate the assay in combination with 
a 24:1 solution of chloroform/ isoamyl alcohol. 
7.3.5.3. DNA Gyrase assay buffer 
The DNA gyrase assay buffer came pre-prepared in a kit from Inspiralis. The 
buffer contained 3.92 g/L Tris·HCl (pH 7.5), 1.79 g/L KCl, 0.38 g/L MgCl2, 0.3 
g/L dithiothreitol, 0.26 g/L spermidine, 0.5 g/L ATP, 6.5% (w/v) glycerol and 
0.1 mg/mL BSA 
7.3.6. Liquid culture assays 
7.3.6.1. O/D650 measurements 
Optical densities were recorded to 3 decimal places using a Jenway 
6305 spectrophotometer in plastic cuvettes with a 1 cm path length, and are 
accurate to ±0.0005. 
7.3.6.2. Determination of growth conditions fluoroquinolone uptake  
Cultures of the wild type and galactose transport mutant strains were 
inoculated into 5 mL of M9 glycerol and incubated with shaking at 37  °C. The 
cultures were centrifuged, the supernatant was discarded and the pellet 
resuspended in M9 glucose and M9 galactose. This process was repeated. 
The O/D650 of the cultures was measured and the cultures diluted into 8 mL 
the appropriate media (one WT in M9 glucose, one WT in M9 galactose, one 
mutant in M9 glucose, one mutant in M9 galactose) in sterilins. The cultures 
were then incubated with shaking at 37 °C. O/D650 measurements were taken 
every hour for six hours, then every two hours after overnight growth.  
7.3.6.3. Antimicrobial evaluation of iron chelators 
Cultures of the required strains were inoculated into 20 mL of LB media 
and incubated overnight with shaking at 37 °C. The cultures were 
centrifuged, the supernatant was discarded and the pellet resuspended in M9 
glucose. This process was repeated. The O/D650 of the cultures was 
measured and the culture diluted into 20 mL of M9 in sterilins to an 
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approximate O/D650 of 0.1. The cultures were inoculated with the compound 
to be evaluated using a range of concentrations from 100−10 µM. In 
experiments where iron was required one molar equivalent of iron was added 
to each culture (1:1 iron: ligand ratio) by adding an appropriate volume of 
aqueous Fe(NO3)3. The cultures were incubated with shaking at 37 °C for 24 
hours with O/D650 measurements taken at 0.5 hours, 3 hours, 6 hours and 24 
hours. 
7.3.7. Zone of inhibition assays 
7.3.7.1. Screening of the Ugi conjugate 3-1 
Zone of inhibition assays were performed on solid media. Screening 
plates were prepared by melting M9 glucose or LB agar and pouring 100 mL 
molten agar into large screening plates. Cultures of E. coli BW25113 were 
pre-grown with shaking overnight 37 °C in LB media. After overnight growth 
the cultures were diluted into the appropriate media (M9 glucose or LB) at an 
O/D650 of 0.100. Cultures diluted into M9 were centrifuged and washed with 
M9 media to remove all traces of LB media. The cultures were grown with 
shaking at 37 °C to mid-log phase (O/D650 = 0.6). The cultures were 
inoculated into molten top agar at a concentration of 4% v/v. The inoculated 
top agar was poured onto the nutrient agar and allowed to set. 3 mM stock 
solutions of ciprofloxacin and the Ugi conjugate 3-1 were prepared in 0.1 M 
acetic acid and DMSO respectively. One in five dilutions series of both 
compounds were prepared using sterile H2O. 3 µL of each concentration of 
each compound was applied to the agar plates using a micropipette and 
allowed to dry. The plates were incubated at 37 °C overnight to allow 
bacterial growth. After overnight growth the plates were examined and the 
zones of inhibition measured. The data was processed using Sigma-plot 
12.0. 
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7.3.7.2. Screening of glycosylated fluoroquinolones 
Zone of inhibition assays on the glycosylated fluoroquinolones were 
performed on solid media. Screening plates were prepared by melting M9 
glucose or galactose and pouring 100 mL molten agar into large screening 
plates. Cultures of E. coli BW25113 were pre-grown with shaking overnight 
37 °C in M9 glycerol. For the mutant studies BW25113 ompf::kan was used 
instead of the wild type. After overnight growth the cultures were diluted into 
the appropriate media (M9 glucose or M9 galactose) at an O/D650 of 0.100. 
The cultures were centrifuged and washed with M9 media to remove all 
traces of the pre-growth media. The cultures were grown with shaking at 37  
°C to mid-log phase (O/D650 = 0.6). The cultures were inoculated into molten 
top agar at a concentration of 4% v/v. The inoculated top agar was poured 
onto the nutrient agar and allowed to set. 3 mM stock solutions of 
ciprofloxacin and the three fluoroquinolone conjugates were prepared in 0.1 
M acetic acid. One in five dilutions series of each compound were prepared  
using sterile H2O. 3 µL of each concentration of each compound was applied 
to the agar plates using a micropipette and allowed to dry. The plates were 
incubated at 37 °C overnight to allow bacterial growth. After overnight growth 
the plates were examined and the zones of inhibition measured. The data 
was processed using Sigma-plot 12.0. 
 
7.3.8. DNA Gyrase assay 
3 mM solutions of ciprofloxacin 1-18, and the Ugi conjugate 3-1 were 
prepared in acetic acid and DMSO respectively. The antimicrobial 
compounds were combined with relaxed pBR322 DNA, DNA gyrase and 
running buffer (6.3.5.3) in H2O at fixed proportions (Table 7.2). For ease of 
preparation a set of dilutions of the antimicrobial solutions were prepared with 
concentrations of 300, 30, 15 and 3 µM. 
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Antimicrobial concentration (µM) 
[Solution concentration used] 
Volume of antimicrobial 
solution (µL) 
Volume of 
H2O (µL) 
Positive control 0 21.5 
Negative control 0 23.5 
200 [300 µM] 20 1.5 
150 [300 µM] 15 6.5 
125 [300 µM] 12.5 9 
100 [300 µM] 10 11.5 
75 [300 µM] 7.5 14 
50 [300 µM] 5 16.5 
40 [300 µM] 4 17.5 
30 [300 µM] 3 18.5 
20 [300 µM] 2 19.5 
10 [300 µM] 1 20.5 
5 [300 µM] 0.5 21 
1 [30 µM] 1 20.5 
0.5 [30 µM] 0.5 21 
0.25 [15 µM] 0.5 21 
0.1 [3 µM] 1 20.5 
Table 7.2: Volumes of antimicrobial solutions and H2O added to each sample for the 
DNA gyrase assay.  
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The solutions were incubated at 37 °C for 30 minutes. The assay was 
stopped by the addition of 30 µL of 24:1 CHCl3: isoamyl alcohol and 18 µL of 
stop buffer. 20 µL of each solution was loaded onto a 1% agarose gel. The 
gel was subjected to electrophoresis for 90 minutes at 80 volts. Upon 
completion of electrophoresis, the gel was stained using ethidium bromide 
overnight and photographed using a gel doc. 
7.3.9. UV analysis of tetradentate ligands 
Stock solutions of the ligands were prepared by dissolving in an 
aqueous buffer solution of Na2HPO4 (6 g/L) and KH2PO4 (3 g/L) at a 
concentration of 16 mM (equivalent to 5 mg/mL of ligand 4-30). Samples 
were prepared by preparing a 1 in 20 dilution of the stock solution in the 
aqueous phosphate solution. A baseline was generated by running a scan of 
the aqueous phosphate buffer solution. Samples were then scanned relative 
to the phosphate buffer from 200-550 nm, and the data processed as 
described in section 7.1.4. 
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Appendix I: UV spectra of bis-catecholate imine ligands 
 
UV/Vis spectrum of the propyl bis-catecholimine ligand 4-30 over a period of 8 hours  
 
 
UV/Vis spectrum of the butyl bis-catecholimine ligand 4-31 over a period of 8 hours 
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UV/Vis spectrum of the pentyl bis-catecholimine ligand 4-32 over a period of 8 hours  
 
 
UV/Vis spectrum of the hexyl bis-catecholimine ligand 4-33 over a period of 8 hours 
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UV/Vis spectrum of the heptyl bis-catecholimine ligand 4-34 over a period of 8 hours  
 
 
General structure of the bis-catecholimine ligands  
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Glossary 
Biological 
ABC ATP Binding Cassette 
ADP Adenosine Diphosphate 
ATP Adenosine Triphosphate 
DNA Deoxyribosenucleic acid 
FDA Food and Drug Administration 
GLUT Glucose Transporter Family 
G6P Glucose 6 Phosphate 
MATE Multi-drug and toxic compound Extrusion 
MDR Multi-drug resistant 
MFS Major Facilitator Superfamily 
MIC Minimum Inhibitory Concentration 
MRSA Multi-drug Resistant Staphylococcus aureus 
NDM-1 New Delhi Metallo-β-lactamase 
NSAID Non-Steroidal Anti-Inflammatory Drug 
OMP Outer Membrane Porin 
PBP Penicillin Binding Protein 
PerBP Periplasmic Binding Protein 
PEP Phosphoenolpyruvate 
PEP-PTS Phosphoenolpyruvate-dependent sugar 
phosphotransferase system 
Pi Inorganic phosphate 
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pmf Proton Motive Force 
PRP Pentapeptide Repeat Protein 
QIDP Qualified Infectious Disease Product 
QNR Quinolone resistance proteins 
RND Resistance Nodulation-Cell Division 
SCOR Short Chain Oxidoreductase 
TMQR Transferable Mechanisms of Quinolone Resistance 
Chemistry 
Acac Acetylacetonate 
Boc tert-Butyloxycarbonyl 
Boc2O Di-tert-butyl Dicarbonate 
Boc-Gly-OH Boc-protected glycine 
CD3OD Deuterated methanol 
CDCL3 Deuterated chloroform 
CHCl3 Chloroform 
Cpf Ciprofloxacin 
D2O Deuterated water 
d6-DMSO Deuterated dimethyl sulfoxide 
DCC N,N’-Dicyclohexylcarbodiimide 
DCE 1,2-Dichloroethane 
DCM Dichloromethane 
DIPEA N,N’-Diisopropylethylamine 
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DMF Dimethylformamide 
DMSO Dimethyl sulfoxide 
DPTA Diethylenetriaminepentaacetic acid 
EDC·HCl 1-Ethyl-3-(3’-dimethylaminopropyl)carbodiimide 
hydrochloride 
Et2O Diethyl ether 
EtOAc Ethyl acetate 
EtOH Ethanol 
Ga(Acac)3 Gallium acetylacetonate 
Ga(NO3)3 Gallium nitrate 
H2SO4 Sulfuric acid 
H3PO4 Phosphoric acid 
HCl Hydrochloric acid 
HOBt·H2O N-Hydroxybenzotriazole hydrate 
KBr Potassium bromide 
LICAM Linear Catechol Amide 
m.p. Melting point 
MCC Multi-component condensation 
MeCN Acetonitrile 
MeOH Methanol 
MeSO3H Methanesulfonic acid 
MgSO4 Magnesium Sulphate 
Na2CO3 Sodium Carbonate 
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NaHCO3 Sodium Hydrogen Carbonate 
NaOH Sodium Hydroxide 
NHS N-Hydroxy Succinimide 
PhMe Toluene 
rt Room Temperature 
SOCl2 Thionyl Chloride 
Spectroscopy 
4°-C Quaternary carbon 
1H Proton 
13C Carbon 
19F Fluorine 
AU Absorbance Units 
Ar Aromatic 
br Broad 
Calc Calculated 
COSY Correlation Spectroscopy 
δ Chemical Shift 
d Doublet 
dd Doublet of doublets 
DEPT Distortionless Enhancement of Polarisation Transfer 
ESI Electrospray Ionisation 
HPLC High-Performance Liquid Chromatography 
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HRMS High Resolution Mass Spectrometry 
HSQC Gradient Heteronuclear Single Quantum Correlation 
IR Infra-red 
J Coupling constant 
LC-MS Liquid Chromatography- Mass Spectrometry 
m Medium 
m Multiplet 
[M+H]+ Protonated molecular ion 
[M+Na]+ Sodiated molecular ion 
[M+NH4]
+ Ammoniated molecular ion 
MS Mass Spectrometry 
m/z Mass to charge ratio 
NMR Nuclear Magnetic Resonance 
ppm Parts per million 
q Quartet 
qn Quintet 
Rf  Retention Factor 
S Sharp 
s Singlet 
t Triplet 
TLC Thin Layer Chromatography 
UV Ultra violet 
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vis Visible 
w Weak 
Units 
Å Angstroms (1 × 10-10 m) 
°C Degrees Centigrade 
µA/ cm2  Microamps per centimetre squared 
µg/L Micrograms per litre 
µg/mL Micrograms per millilitre 
A Amps 
cm-1 Wavenumbers 
Da Daltons 
g Grams 
g mol-1 Grams per mole 
h hours 
Hz Hertz 
K Degrees Kelvin 
L Litres 
M Molar 
mg/L Milligrams per litre 
mg/mL Milligrams per millilitre 
mL Millilitres 
mol Moles 
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w/v Weight by volume 
 310 
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